TY 2022 Form 990

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(1) BETH GALETTI MBA...................................................................... CHAIR	2.00 ................. 0.00	X	X
(2) DAVID KING JD...................................................................... VICE CHAIR	2.00 ................. 0.00	X	X
(3) SANFORD MELZER MD MBA...................................................................... SECRETARY	2.00 ................. 0.00	X	X
(4) BRUCE MCNAMER JD MBA...................................................................... TREASURER	2.00 ................. 0.00	X	X
(5) FREDERICK WERE MD MMED PHD...................................................................... DIRECTOR	2.00 ................. 0.00	X
(6) YEHONG ZHANG PHD MBA...................................................................... DIRECTOR	2.00 ................. 0.00	X
(7) JO ADDY MBA MPA...................................................................... DIRECTOR	2.00 ................. 0.00	X
(8) IREENA VITTAL...................................................................... DIRECTOR (RESIGNED 9/15/22)	2.00 ................. 0.00	X
(9) DEANNA OPPENHEIMER...................................................................... DIRECTOR (RESIGNED 9/15/22)	2.00 ................. 0.00	X
(10) JOHN-ARNE ROTTINGEN MD PHD...................................................................... MSC, MPA--DIRECTOR	2.00 ................. 0.00	X
(11) JOEL HOLSINGER...................................................................... DIRECTOR	2.00 ................. 0.00	X
(12) HELENA WAYTH MSC...................................................................... DIRECTOR	2.00 ................. 0.00	X
(13) ABAYOMI SULE MBBS MBA...................................................................... DIRECTOR	2.00 ................. 0.00	X
(14) LISA ANDERSON...................................................................... DIRECTOR	2.00 ................. 0.00	X
(15) RACHEL SIBANDE MSC...................................................................... DIRECTOR	2.00 ................. 0.00	X
(16) SYLVANA SINHA...................................................................... DIRECTOR	2.00 ................. 0.00	X
(17) LUTZ HEGEMANN MD PHD...................................................................... DIRECTOR	2.00 ................. 0.00	X

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(E) Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)	(F) Estimated amount of other compensation from the organization and related organizations
(18) NIKOLAJ JESTED GILBERT MSC........................................................................ PRESIDENT AND CEO	39.00 .......................1.00	X			587,315	0	46,332
(19) PHILIPPE GUINOT MBA........................................................................ CHIEF OF BUSINESS, FIN. & OPS.	1.00 .......................39.00	X			0	309,656	26,676
(20) JESSICA MILMAN........................................................................ EXEC. DIR., STRATEGY, OPS., & EFFECTIVENESS	39.00 .......................1.00		X		310,143	0	51,153
(21) JEFFREY D BERNSON MPH MPA........................................................................ CHIEF PROGRAMS & INNOVATION OFFICER	40.00 .......................0.00		X		334,378	0	53,907
(22) MEISSA DIAW........................................................................ CHIEF PEOPLE & DIVERSITY OFFICER	40.00 .......................0.00		X		223,533	0	401
(23) MOLLI M BARNES........................................................................ CHIEF PEOPLE OFFICER (UNTIL 1/31/22)	40.00 .......................0.00		X		173,318	0	28,282
(24) CARLA ANNE COSTA SANDINE........................................................................ CHIEF OF EXTERNAL AFFAIRS	40.00 .......................0.00		X		238,350	0	47,936
(25) SABRINA L POWERS JD........................................................................ CHIEF OF LEGAL & RESEARCH AFFAIRS/GC	40.00 .......................0.00		X		282,858	0	46,915
(26) NANTHALILE C MUGALA MD MMED........................................................................ CHIEF OF AFRICA REGION	40.00 .......................0.00		X		300,528	0	108,653
(27) NABEEL A GOHEER PHD........................................................................ CHIEF OF AFRICA	40.00 .......................0.00		X		206,849	0	1,636
(28) DAVID C KASLOW MD........................................................................ CHIEF SCIENTIFIC OFF. (UNTIL 10/8/22)	40.00 .......................0.00		X		356,341	0	64,013
(29) TRAD M HATTON MA MHS........................................................................ DIR., CEN. AFRICA HUB & DRC COUNTRY PRO.	40.00 .......................0.00			X	360,453	0	53,782
(30) ASHLEY J BIRKETT PHD........................................................................ GLOBAL HEAD, MALARIA VACCINES	40.00 .......................0.00			X	340,464	0	63,199
(31) BRUCE LAMONT INNIS MD FIDSA........................................................................ GLOBAL HEAD, RESPIRATORY INFECTIONS	40.00 .......................0.00			X	351,046	0	34,748
(32) JOHN O KONZ PHD........................................................................ GLOBAL HEAD OF POLIO	40.00 .......................0.00			X	360,406	0	69,154
(33) KIMBERLY GREEN PHD........................................................................ DIRECTOR, PRIMARY HEALTH CARE	40.00 .......................0.00			X	332,684	0	70,010

(A) Name and business address	(B) Description of services	(C) Compensation
RANDSTAD INDIA PVT LTD SUITE NO 001 002 COPIA NEW DELHI 110025 IN	STAFFING SERVICES	2,359,826
WMBE PAYROLLING DBA TARGETCW 9475 CHESAPEAKE DRIVE SAN DIEGO,CA92123	GENERAL CONTRACTOR	835,922
PIVOTAL CONSULTING LLC 1631 15TH AVE W 118 SEATTLE,WA98119	CONSULTING	758,295
GLOBALIZATION PARTNERS INC 175 FEDERAL ST 17TH FL BOSTON,MA02110	STAFFING SERVICES	670,108
SAFEGUARD WORLD INT'L BLDG 2 CAMPION PARK HOLMES CHAPEL CREWE CW4 8AX UK	GENERAL CONTRACTOR	595,667
2 Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization 60

- TIN:

SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow

Attach to Form 990 or Form 990-EZ.
right arrow

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Part I

Reason for Public Charity Status (All organizations must complete this part.) See instructions.

The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)

A church, convention of churches, or association of churches described in section 170(b)(1)(A)(i).

A school described in section 170(b)(1)(A)(ii). (Attach Schedule E (Form 990).)

A hospital or a cooperative hospital service organization described in section 170(b)(1)(A)(iii).

A medical research organization operated in conjunction with a hospital described in section 170(b)(1)(A)(iii). Enter the hospital's name, city, and state:

An organization operated for the benefit of a college or university owned or operated by a governmental unit described in section 170(b)(1)(A)(iv). (Complete Part II.)

A federal, state, or local government or governmental unit described in section 170(b)(1)(A)(v).

An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in section 170(b)(1)(A)(vi). (Complete Part II.)

A community trust described in section 170(b)(1)(A)(vi). (Complete Part II.)

An agricultural research organization described in 170(b)(1)(A)(ix) operated in conjunction with a land-grant college or university or a non-land grant college of agriculture. See instructions. Enter the name, city, and state of the college or university:

An organization that normally receives: (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975. See section 509(a)(2). (Complete Part III.)

An organization organized and operated exclusively to test for public safety. See section 509(a)(4).

An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2). See section 509(a)(3). Check the box on lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g.

Type I. A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization. You must complete Part IV, Sections A and B.

Type II. A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s). You must complete Part IV, Sections A and C.

Type III functionally integrated. A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions). You must complete Part IV, Sections A, D, and E.

Type III non-functionally integrated. A supporting organization operated in connection with its supported organization(s) that is not functionally integrated. The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions). You must complete Part IV, Sections A and D, and Part V.

Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization.

Enter the number of supported organizations ...............................

Provide the following information about the supported organization(s).

(i) Name of supported organization	(ii) EIN	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
(i) Name of supported organization	(ii) EIN	Yes	No	(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)


Total

For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.

Cat. No. 11285F

Schedule A (Form 990) 2022

Page 2

Part II

Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") ..	305,316,107	286,808,545	287,454,383	333,068,959	347,720,581	1,560,368,575
2	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....
3	The value of services or facilities furnished by a governmental unit to the organization without charge..
4	Total. Add lines 1 through 3	305,316,107	286,808,545	287,454,383	333,068,959	347,720,581	1,560,368,575
5	The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) ..						702,888,681
6	Public support. Subtract line 5 from line 4.						857,479,894

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
7	Amounts from line 4..	305,316,107	286,808,545	287,454,383	333,068,959	347,720,581	1,560,368,575
8	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources...	2,963,587	6,310,221	12,207,084	8,920,472	4,050,778	34,452,142
9	Net income from unrelated business activities, whether or not the business is regularly carried on..
10	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.)..	980,560	836,870	1,030,112	843,270	869,980	4,560,792
11	Total support. Add lines 7 through 10						1,599,381,509

Gross receipts from related activities, etc. (see instructions) ..................

3,538

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................ right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 6, column (f) divided by line 11, column (f)) .........

53.610 %

Public support percentage for 2020 Schedule A, Part II, line 14 ...............

52.640 %

16a

33 1/3% support test—2022. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box
and stop here. The organization qualifies as a publicly supported organization ....................... right arrow

33 1/3% support test—2021. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this
box and stop here. The organization qualifies as a publicly supported organization ..................... right arrow

17a

10%-facts-and-circumstances test—2022. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

10%-facts-and-circumstances test—2021. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization ............ right arrow

Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow

Schedule A (Form 990) 2022

Page 3

Part III

Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
1	Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .
2	Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose
3	Gross receipts from activities that are not an unrelated trade or business under section 513 .....
4	Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...
5	The value of services or facilities furnished by a governmental unit to the organization without charge
6	Total. Add lines 1 through 5
7a	Amounts included on lines 1, 2, and 3 received from disqualified persons
b	Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.
c	Add lines 7a and 7b..
8	Public support. (Subtract line 7c from line 6.)

Section B. Total Support

Calendar year (or fiscal year beginning in)		(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) 2022	(f) Total
9	Amounts from line 6...
10a	Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..
b	Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.
c	Add lines 10a and 10b.
11	Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.
12	Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..
13	Total support. (Add lines 9, 10c, 11, and 12.)..

First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here................................................. right arrow

Section C. Computation of Public Support Percentage

Public support percentage for 2022 (line 8, column (f) divided by line 13, column (f)) .........

Public support percentage from 2021 Schedule A, Part III, line 15 ...............

Section D. Computation of Investment Income Percentage

Investment income percentage for 2022 (line 10c, column (f) divided by line 13, column (f)) ......

Investment income percentage from 2021 Schedule A, Part III, line 17 .............

19a

33 1/3% support tests-2022. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ....... right arrow

33 1/3% support tests—2021. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization ..... right arrow

Private foundation. If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions .... right arrow

Schedule A (Form 990) 2022

Page 4

Part IV

Supporting Organizations

(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)

Section A. All Supporting Organizations

Yes

Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.

Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).

Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.

Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.

Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.

Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.

Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.

Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.

Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).

Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?

Substitutions only. Was the substitution the result of an event beyond the organization's control?

Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.

Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .

Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).

Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.

Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.

Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.

10a

Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.

10a

Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).

10b

Schedule A (Form 990) 2022

Page 5

Part IV

Supporting Organizations (continued)

Yes

Has the organization accepted a gift or contribution from any of the following persons?

A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?

11a

A family member of a person described on 11a above?

11b

A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.

11c

Section B. Type I Supporting Organizations

Yes

Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.

Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.

Section C. Type II Supporting Organizations

Yes

Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).

Section D. All Type III Supporting Organizations

Yes

Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?

Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).

By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.

Section E. Type III Functionally-Integrated Supporting Organizations

Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):

The organization satisfied the Activities Test. Complete line 2 below.

The organization is the parent of each of its supported organizations. Complete line 3 below.

The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions)

Activities Test. Answer lines 2a and 2b below.

Yes

Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.

Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.

Parent of Supported Organizations. Answer lines 3a and 3b below.

Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.

Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.

Schedule A (Form 990) 2022

Page 6

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

	Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1
2	Recoveries of prior-year distributions	2
3	Other gross income (see instructions)	3
4	Add lines 1 through 3	4
5	Depreciation and depletion	5
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6
7	Other expenses (see instructions)	7
8	Adjusted Net Income (subtract lines 5, 6 and 7 from line 4)	8

	Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year):	1
a	Average monthly value of securities	1a
b	Average monthly cash balances	1b
c	Fair market value of other non-exempt-use assets	1c
d	Total (add lines 1a, 1b, and 1c)	1d
e	Discount claimed for blockage or other factors (explain in detail in Part VI):
2	Acquisition indebtedness applicable to non-exempt use assets	2
3	Subtract line 2 from line 1d	3
4	Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions).	4
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5
6	Multiply line 5 by 0.035	6
7	Recoveries of prior-year distributions	7
8	Minimum Asset Amount (add line 7 to line 6)	8

	Section C - Distributable Amount		Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1
2	Enter 85% of line 1	2
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3
4	Enter greater of line 2 or line 3	4
5	Income tax imposed in prior year	5
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6

Check here if the current year is the organization's first as a non-functionally-integrated Type III supporting organization (see instructions)

Schedule A (Form 990) 2022

Page 7

Part V

Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)

Section D - Distributions		Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes	1
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity	2
3 Administrative expenses paid to accomplish exempt purposes of supported organizations	3
4 Amounts paid to acquire exempt-use assets	4
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI)	5
6 Other distributions (describe in Part VI). See instructions	6
7Total annual distributions. Add lines 1 through 6.	7
8 Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions	8
9 Distributable amount for 2022 from Section C, line 6	9
10 Line 8 amount divided by Line 9 amount	10

Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2022	(iii) Distributable Amount for 2022
1 Distributable amount for 2022 from Section C, line 6
2 Underdistributions, if any, for years prior to 2022 (reasonable cause required-- explain in Part VI). See instructions.
3 Excess distributions carryover, if any, to 2022:
a From 2017.......
b From 2018.......
c From 2019.......
d From 2020.......
e From 2021.......
fTotal of lines 3a through e
g Applied to underdistributions of prior years
h Applied to 2022 distributable amount
i Carryover from 2017 not applied (see instructions)
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.
4Distributions for 2022 from Section D, line 7:
$
a Applied to underdistributions of prior years
b Applied to 2022 distributable amount
c Remainder. Subtract lines 4a and 4b from line 4.
5 Remaining underdistributions for years prior to 2022, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions.
6 Remaining underdistributions for 2022. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions.
7 Excess distributions carryover to 2023. Add lines 3j and 4c.
8 Breakdown of line 7:
a Excess from 2018.....
b Excess from 2019.....
c Excess from 2020.....
d Excess from 2021.....
e Excess from 2022.....

Schedule A (Form 990) (2022)

Schedule A (Form 990) 2022

Page 8

Part VI

Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).

Facts And Circumstances Test

Return Reference	Explanation

Schedule A (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Schedule B
(Form 990)

Department of the Treasury
Internal Revenue Service

Schedule of Contributors

Attach to Form 990, 990-EZ, or 990-PF.

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Name of the organization

PATH

Employer identification number

91-1157127

Organization type (check one):

Filers of:

Section:

Form 990 or 990-EZ

501(c)( ) (enter number) organization

4947(a)(1) nonexempt charitable trust not treated as a private foundation

527 political organization

Form 990-PF

501(c)(3) exempt private foundation

4947(a)(1) nonexempt charitable trust treated as a private foundation

501(c)(3) taxable private foundation

Check if your organization is covered by the General Rule or a Special Rule.
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.

General Rule

For an organization filing Form 990, 990-EZ, or 990-PF that received, during the year, contributions totaling $5,000 or more (in money or other property) from any one contributor. Complete Parts I and II. See instructions for determining a contributor's total contributions.

Special Rules

For an organization described in section 501(c)(3) filing Form 990 or 990-EZ that met the 33¹/3% support test of the regulations
under sections 509(a)(1) and 170(b)(1)(A)(vi), that checked Schedule A (Form 990 or 990-EZ), Part II, line 13, 16a, or 16b, and that received from any one contributor, during the year, total contributions of the greater of (1) $5,000 or (2) 2% of the amount on (i) Form 990, Part VIII, line 1h, or (ii) Form 990-EZ, line 1. Complete Parts I and II.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, total contributions of more than $1,000 exclusively for religious, charitable, scientific, literary, or educational purposes, or for the prevention of cruelty to children or animals. Complete Parts I, II, and III.

For an organization described in section 501(c)(7), (8), or (10) filing Form 990 or 990-EZ that received from any one contributor,
during the year, contributions exclusively for religious, charitable, etc., purposes, but no such contributions totaled more than $1,000. If this box is checked, enter here the total contributions that were received during the year for an exclusively religious, charitable, etc., purpose. Don't complete any of the parts unless the General Rule applies to this organization because it received nonexclusively religious, charitable, etc., contributions totaling $5,000 or more during the year ......... Arrow Bullet

Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).

For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.

Cat. No. 30613XSchedule B (Form 990) (2022)

Schedule B (Form 990) (2022) Page 2

Name of organization PATH

Part I Contributors	Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
RESTRICTED	,	$ RESTRICTED	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
(a) No.	(b) Name, address, and ZIP + 4	(c) Total contributions	(d) Type of contribution
		$	Person Payroll Noncash (Complete Part II for noncash contributions.)
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 3

Name of organization PATH		Employer identification number 91-1157127

Part II	Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
(a) No. from Part I	(b) Description of noncash property given	(c) FMV (or estimate) (See instructions)	(d) Date received
		$
Schedule B (Form 990) (2022)

Schedule B (Form 990) (2022)

Page 4


Name of organization PATH			Employer identification number 91-1157127
Part III Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) $ Use duplicate copies of Part III if additional space is needed.

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a)
No. from Part I

(b) Purpose of gift

(d) Description of how gift is held

(e) Transfer of gift
Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Schedule B (Form 990) (2022)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service

Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

SchCMd Bullet

Complete if the organization is described below. SchCMd Bullet

Attach to Form 990 or Form 990-EZ.
SchCMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet

Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet

Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet

Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet

Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet

Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then
Round Bullet

Section 501(c)(4), (5), or (6) organizations: Complete Part III.

Name of the organization

PATH

Employer identification number

91-1157127

Part I-A

Complete if the organization is exempt under section 501(c) or is a section 527 organization.

Provide a description of the organization’s direct and indirect political campaign activities in Part IV. See instructions for definition of “political campaign activities."

Political campaign activity expenditures. See instructions .................................................................... SchCMd Bullet

Volunteer hours for political campaign activities. See instructions ..................................................................

Part I-B

Complete if the organization is exempt under section 501(c)(3).

Enter the amount of any excise tax incurred by the organization under section 4955 ................................ SchCMd Bullet

Enter the amount of any excise tax incurred by organization managers under section 4955 ....................... SchCMd Bullet

If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .........................................

Yes No

Was a correction made? ......................................................................................................................

Yes No

If "Yes," describe in Part IV.

Part I-C

Complete if the organization is exempt under section 501(c), except section 501(c)(3).

Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... SchCMd Bullet

Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ............................................................................................................................ SchCMd Bullet

Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b........... SchCMd Bullet

Did the filing organization file Form 1120-POL for this year? ...................................................................

Yes No

Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.

(a) Name	(b) Address	(c) EIN	(d) Amount paid from filing organization's funds. If none, enter -0-.	(e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1
2
3
4
5
6

For Paperwork Reduction Act Notice, see the instructions for Form 990.

Cat. No. 50084S

Schedule C (Form 990) 2021

Page 2

Part II-A

Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).

A Check SchCMd Bullet

if the filing organization belongs to an affiliated group (and list in Part IV each affiliated group member's name, address, EIN, expenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet

if the filing organization checked box A and "limited control" provisions apply.

Limits on Lobbying Expenditures (The term "expenditures" means amounts paid or incurred.)		(a) Filing organization's totals	(b) Affiliated group totals
1a	Total lobbying expenditures to influence public opinion (grass roots lobbying) ......................
b	Total lobbying expenditures to influence a legislative body (direct lobbying) ........................	198,070
c	Total lobbying expenditures (add lines 1a and 1b) ............................................................	198,070
d	Other exempt purpose expenditures ...............................................................................	346,106,542
e	Total exempt purpose expenditures (add lines 1c and 1d) ..................................................	346,304,612
f	Lobbying nontaxable amount. Enter the amount from the following table in both columns.	1,000,000
	If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
	Not over $500,00020% of the amount on line 1e.
	Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
	Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
	Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
	Over $17,000,000$1,000,000.

g	Grassroots nontaxable amount (enter 25% of line 1f) .................................................	250,000
h	Subtract line 1g from line 1a. If zero or less, enter -0-. ................................................	0
i	Subtract line 1f from line 1c. If zero or less, enter -0-. ................................................	0
j	If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting section 4911 tax for this year? ...................................................................................................................		Yes No

4-Year Averaging Period Under Section 501(h) (Some organizations that made a section 501(h) election do not have to complete all of the five columns below. See the separate instructions for lines 2a through 2f.)
Lobbying Expenditures During 4-Year Averaging Period
	Calendar year (or fiscal year beginning in)	(a) 2018	(b) 2019	(c) 2020	(d) 2021	(e) Total

2a	Lobbying nontaxable amount	1,000,000	1,000,000	1,000,000	1,000,000	4,000,000

b	Lobbying ceiling amount (150% of line 2a, column(e))					6,000,000

c	Total lobbying expenditures	163,912	135,193	207,166	198,070	704,341

d	Grassroots nontaxable amount	250,000	250,000	250,000	250,000	1,000,000

e	Grassroots ceiling amount (150% of line 2d, column (e))					1,500,000

f	Grassroots lobbying expenditures		405	29,340		29,745

Schedule C (Form 990) 2021

Page 3

Part II-B

Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).

For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.

(a)

Yes|No

(b)

Amount

During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:

Volunteers? ...........................................................................................................

Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ........

Media advertisements? ...................................................................................................

Mailings to members, legislators, or the public? .............................................................................

Publications, or published or broadcast statements? ...........................................................

Grants to other organizations for lobbying purposes? ..........................................................

Direct contact with legislators, their staffs, government officials, or a legislative body? .......................

Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ..................

Other activities? ...................................................................................................................

Total. Add lines 1c through 1i ....................................................................................................

Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....

If "Yes," enter the amount of any tax incurred under section 4912 ...........................................

If "Yes," enter the amount of any tax incurred by organization managers under section 4912 ...................

If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? ........................

Part III-A

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).

Yes

Were substantially all (90% or more) dues received nondeductible by members? ...............................................

Did the organization make only in-house lobbying expenditures of $2,000 or less? ............................................

Did the organization agree to carry over lobbying and political expenditures from the prior year? .................................

Part III-B

Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."

Dues, assessments and similar amounts from members ......................................................................

Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).

Current year .............................................................................................................................

Carryover from last year ............................................................................................................

Total ...........................................................................................................................................

Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .

If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ......................................................................................................................

Taxable amount of lobbying and political expenditures. See Instructions .........................................

Part IV

Supplemental Information

Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part ll-B, line 1. Also, complete this part for any additional information.

Return Reference	Explanation

Schedule C (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE D
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet

Attach to Form 990.
SchDMd Bullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Part I

Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year .........
2	Aggregate value of contributions to (during year)
3	Aggregate value of grants from (during year)
4	Aggregate value at end of year ........

Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............

Yes No

Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................

Yes No

Part II

Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.

Purpose(s) of conservation easements held by the organization (check all that apply).

Preservation of land for public use (e.g., recreation or education) Preservation of an historically important land area

Protection of natural habitat Preservation of a certified historic structure

Preservation of open space

Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.


a	Total number of conservation easements ......................	2a
b	Total acreage restricted by conservation easements ....................	2b
c	Number of conservation easements on a certified historic structure included in (a) .....	2c
d	Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ...	2d

Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet

Number of states where property subject to conservation easement is located SchDMd Bullet

Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............

Yes No

Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet

Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................

Yes No

In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.

If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.

If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:

(i)

Revenue included on Form 990, Part VIII, line 1 ......................... SchDMd Bullet

(ii)

Assets included in Form 990, Part X ............................... SchDMd Bullet

If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:

Revenue included on Form 990, Part VIII, line 1 .......................... SchDMd Bullet

Assets included in Form 990, Part X ............................... SchDMd Bullet

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 52283D

Schedule D (Form 990) 2021

Page 2

Part III

Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):

Public exhibition

Loan or exchange programs

Scholarly research

Other

Preservation for future generations

Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.

During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...

Yes No

Part IV

Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................

Yes No


b	If "Yes," explain the arrangement in Part XIII and complete the following table:		Amount
c	Beginning balance .............................	1c
d	Additions during the year ............................	1d
e	Distributions during the year ..........................	1e
f	Ending balance ................................	1f

Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...

Yes No

If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....

Part V

Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

		(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back

1a	Beginning of year balance ....	11,742,214	10,930,723	10,287,113	9,095,917	10,056,545
b	Contributions ...		2,500	2,745	2,100	1,240
c	Net investment earnings, gains, and losses	-1,762,177	1,323,367	1,095,576	1,691,617	-494,491
d	Grants or scholarships ...
e	Other expenditures for facilities and programs ...	546,557	514,376	454,711	502,521	467,377
f	Administrative expenses ....
g	End of year balance ......	9,433,480	11,742,214	10,930,723	10,287,113	9,095,917

Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:

Board designated or quasi-endowment SchDMd Bullet

36.000 %

Permanent endowment SchDMd Bullet

36.000 %

Term endowment SchDMd Bullet

28.000 %

The percentages on lines 2a, 2b, and 2c should equal 100%.

Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes

(i) Unrelated organizations .................

3a(i)

(ii) Related organizations .................

3a(ii)

If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........

Describe in Part XIII the intended uses of the organization's endowment funds.

Part VI

Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.

Description of property		(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value

1a	Land .....
b	Buildings ....
c	Leasehold improvements	23,293,061	18,151,573	5,141,488
d	Equipment ....	8,100,458	7,256,015	844,443
e	Other .....	5,804,688	5,217,886	586,802
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..				6,572,733

Schedule D (Form 990) 2021

Page 3

Part VII

Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation: Cost or end-of-year market value
(1) Financial derivatives.........
(2) Closely-held equity interests........
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)

Part VIII

Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation: Cost or end-of-year market value

(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)

Part IX

Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.

(a) Description				(b) Book value
(1)RIGHT-OF-USE ASSET				33,353,888
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........				33,353,888

Part X

Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.

1.(a) Description of liability	(b) Book value
(1) Federal income taxes
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)	42,345,583
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII

Schedule D (Form 990) 2021

Page 4

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total revenue, gains, and other support per audited financial statements .......		1
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a	Net unrealized gains (losses) on investments ....	2a
b	Donated services and use of facilities .........	2b
c	Recoveries of prior year grants ...........	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d .....................		2e
3	Subtract line 2e from line 1..................		3
4	Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b .	4a
b	Other (Describe in Part XIII.) ...........	4b
c	Add lines 4a and 4b....................		4c
5	Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ......		5

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1	Total expenses and losses per audited financial statements ...........		1
2	Amounts included on line 1 but not on Form 990, Part IX, line 25:
a	Donated services and use of facilities .........	2a
b	Prior year adjustments ............	2b
c	Other losses ................	2c
d	Other (Describe in Part XIII.) ............	2d
e	Add lines 2a through 2d....................		2e
3	Subtract line 2e from line 1...................		3
4	Amounts included on Form 990, Part IX, line 25, but not on line 1:
a	Investment expenses not included on Form 990, Part VIII, line 7b ..	4a
b	Other (Describe in Part XIII.) ............	4b
c	Add lines 4a and 4b.....................		4c
5	Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ......		5

Part XIII

Supplemental Information

Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.

Return Reference	Explanation
PART V, LINE 4:	PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY.

Schedule D (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE F(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16. Right pointing arrow large image

Attach to Form 990. Right pointing arrow large image

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization
PATH

Employer identification number

91-1157127

Part I

General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.

For grantmakers. Does the organization maintain records to substantiate the amount of its grants and

other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used

to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .

Yes

For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.

Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)

(a) Region		(b) Number of offices in the region	(c) Number of employees, agents, and independent contractors in the region	(d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region)	(e) If activity listed in (d) is a program service, describe specific type of service(s) in the region	(f) Total expenditures for and investments in the region
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AFRICA	1,749,841
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	AMEE	1,411,495
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	BID & PROPOSAL	BID & PROPOSAL	87,939
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	996,160
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	FUNDRAISING	FUNDRAISING	380,879
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	996,077
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	OTHER	158,672
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	3,521,948
	CENTRAL AMERICA AND THE CARIBBEAN	0	0	GRANTMAKING		218,299
	EAST ASIA AND THE PACIFIC	7	133	PROGRAM SERVICES	AMEE	8,570,990
	EAST ASIA AND THE PACIFIC	0	0	BID & PROPOSAL	BID & PROPOSAL	49,051
	EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	5,627,949
	EAST ASIA AND THE PACIFIC	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	1,580,273
	EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	OTHER	778
	EAST ASIA AND THE PACIFIC	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	3,253,896
	EAST ASIA AND THE PACIFIC	0	0	GRANTMAKING		8,668,881
	EUROPE	2	10	PROGRAM SERVICES	AFRICA	27,178
	EUROPE	0	0	PROGRAM SERVICES	AMEE	788,225
	EUROPE	0	0	BID & PROPOSAL	BID & PROPOSAL	8,679
	EUROPE	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	14,319,496
	EUROPE	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	2,614,548
	EUROPE	0	0	PROGRAM SERVICES	OTHER	86,426
	EUROPE	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	11,000,614
	EUROPE	0	0	GRANTMAKING		30,297,004
	MIDDLE EAST AND NORTH AFRICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	17,614
	MIDDLE EAST AND NORTH AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	23,500
	MIDDLE EAST AND NORTH AFRICA	0	0	GRANTMAKING		14,000
	NORTH AMERICA	0	0	PROGRAM SERVICES	AMEE	94,536
	NORTH AMERICA	0	0	BID & PROPOSAL	BID & PROPOSAL	4,574
	NORTH AMERICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	515,407
	NORTH AMERICA	0	0	FUNDRAISING	FUNDRAISING	6,824
	NORTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	91,368
	NORTH AMERICA	0	0	PROGRAM SERVICES	OTHER	5,455
	NORTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	370,768
	NORTH AMERICA	0	0	GRANTMAKING		305,790
	RUSSIA AND NEIGHBORING STATES	1	29	PROGRAM SERVICES	AMEE	5,632,432
	RUSSIA AND NEIGHBORING STATES	0	0	BID & PROPOSAL	BID & PROPOSAL	8,363
	RUSSIA AND NEIGHBORING STATES	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	723,459
	RUSSIA AND NEIGHBORING STATES	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	117,906
	RUSSIA AND NEIGHBORING STATES	0	0	GRANTMAKING		1,586,535
	SOUTH AMERICA	1	5	PROGRAM SERVICES	ESSENTIAL MEDICINE	300,315
	SOUTH AMERICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	54,372
	SOUTH AMERICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	1,054,562
	SOUTH AMERICA	0	0	GRANTMAKING		806,292
	SOUTH ASIA	4	222	PROGRAM SERVICES	AFRICA	26,277
	SOUTH ASIA	0	0	PROGRAM SERVICES	AMEE	13,526,599
	SOUTH ASIA	0	0	BID & PROPOSAL	BID & PROPOSAL	186,511
	SOUTH ASIA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	5,043,332
	SOUTH ASIA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	2,653,797
	SOUTH ASIA	0	0	PROGRAM SERVICES	OTHER	45,474
	SOUTH ASIA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	1,422,691
	SOUTH ASIA	0	0	GRANTMAKING		5,092,495
	SUB-SAHARAN AFRICA	25	651	PROGRAM SERVICES	AFRICA	30,452,212
	SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	AMEE	26,415
	SUB-SAHARAN AFRICA	0	0	BID & PROPOSAL	BID & PROPOSAL	269,910
	SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	ESSENTIAL MEDICINE	9,855,670
	SUB-SAHARAN AFRICA	0	0	FUNDRAISING	FUNDRAISING	9,273
	SUB-SAHARAN AFRICA	0	0	MANAGEMENT & GENERAL	MANAGEMENT & GENERAL	15,391,312
	SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	OTHER	1,239,879
	SUB-SAHARAN AFRICA	0	0	PROGRAM SERVICES	PROGRAM INNOVATION	26,516,790
	SUB-SAHARAN AFRICA	0	0	GRANTMAKING		13,134,829
3a	Sub-total ....	0	0			9,303,011
b	Total from continuation sheets to Part I ...	40	1,050			223,739,825
c	Totals (add lines 3a and 3b)	40	1,050			233,042,836

For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2022

Schedule F (Form 990) 2022

Page 2

Part II

Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.

(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement
CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	115,999	CHECK/WIRE
CENTRAL AMERICA AND THE CARIBBEAN	PROGRAM INNOVATION	102,300	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	142,553	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	129,250	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	39,000	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	11,141	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	37,125	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	78,015	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	700,000	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	99,832	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	44,751	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	125,304	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	19,007	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	13,785	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	19,492	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	8,488	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	19,523	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	116,121	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	230,241	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	130,148	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	9,028	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	200,530	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	177,521	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	174,859	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	525,853	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	220,523	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	29,062	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	273,607	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE & PROGRAM INNOVATION	1,938,449	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	11,298	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	134,828	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	8,804	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	1,125,669	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	36,376	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	155,000	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	150,000	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	952,229	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	101,818	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	235,633	CHECK/WIRE
EAST ASIA AND THE PACIFIC	PROGRAM INNOVATION	45,166	CHECK/WIRE
EAST ASIA AND THE PACIFIC	ESSENTIAL MEDICINE	44,100	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	97,943	CHECK/WIRE
EAST ASIA AND THE PACIFIC	AMEE	56,811	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	507,431	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	56,927	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	20,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	490,000	CHECK/WIRE
EUROPE	AFRICA	148,878	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	972,084	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	491,837	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	71,243	CHECK/WIRE
EUROPE	OTHER	64,838	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	65,000	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	8,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	118,501	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	3,610,913	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	881,119	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	56,173	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	540,754	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	39,227	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	21,800	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	65,000	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	1,837,323	CHECK/WIRE
EUROPE	AFRICA & PROGRAM INNOVATION	1,174,052	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	15,856	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	1,930,000	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	1,311,826	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE & PROGRAM INNOVATION	337,574	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	52,844	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	45,500	CHECK/WIRE
EUROPE	PROGRAM INNOVATION	19,452	CHECK/WIRE
EUROPE	ESSENTIAL MEDICINE	710,062	CHECK/WIRE
EUROPE	AFRICA, AMEE, ESSENTIAL MEDICINE, OTHER, & PROGRAM INNOVATION	9,001,439	CHECK/WIRE
EUROPE	AFRICA, AMEE, ESSENTIAL MEDICINE, OTHER, & PROGRAM INNOVATION	5,631,350	CHECK/WIRE
MIDDLE EAST & NORTH AFRICA	PROGRAM INNOVATION	14,000	CHECK/WIRE
NORTH AMERICA	ESSENTIAL MEDICINE	10,560	CHECK/WIRE
NORTH AMERICA	ESSENTIAL MEDICINE	200,000	CHECK/WIRE
NORTH AMERICA	PROGRAM INNOVATION	60,525	CHECK/WIRE
NORTH AMERICA	PROGRAM INNOVATION	34,704	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	23,990	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	33,297	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	94,947	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	17,448	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	40,544	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	14,465	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	53,731	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	34,852	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	47,176	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	39,082	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	127,064	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	186,332	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	9,689	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	9,750	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	22,763	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	48,650	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	36,137	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE & PROGRAM INNOVATION	177,722	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	18,617	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	17,167	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	60,295	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	88,198	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	40,334	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	186,800	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	59,374	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	55,267	CHECK/WIRE
RUSSIA AND NEIGHBORING STATES	AMEE	39,536	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	100,000	CHECK/WIRE
SOUTH AMERICA	AMEE	10,000	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	61,000	CHECK/WIRE
SOUTH AMERICA	ESSENTIAL MEDICINE	46,903	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	233,991	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	32,588	CHECK/WIRE
SOUTH AMERICA	ESSENTIAL MEDICINE	248,854	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	50,604	CHECK/WIRE
SOUTH AMERICA	PROGRAM INNOVATION	19,821	CHECK/WIRE
SOUTH ASIA	AMEE	67,629	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE & PROGRAM INNOVATION	62,432	CHECK/WIRE
SOUTH ASIA	AMEE	29,359	CHECK/WIRE
SOUTH ASIA	AMEE	102,895	CHECK/WIRE
SOUTH ASIA	AMEE	21,668	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	125,465	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	868,742	CHECK/WIRE
SOUTH ASIA	PROGRAM INNOVATION	381,744	CHECK/WIRE
SOUTH ASIA	PROGRAM INNOVATION	389,157	CHECK/WIRE
SOUTH ASIA	AMEE	29,337	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	20,000	CHECK/WIRE
SOUTH ASIA	AMEE	342,351	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	570,398	CHECK/WIRE
SOUTH ASIA	ESSENTIAL MEDICINE	420,108	CHECK/WIRE
SOUTH ASIA	AMEE	188,142	CHECK/WIRE
SOUTH ASIA	AMEE	147,113	CHECK/WIRE
SOUTH ASIA	AMEE	57,257	CHECK/WIRE
SOUTH ASIA	AMEE	10,026	CHECK/WIRE
SOUTH ASIA	AMEE	140,995	CHECK/WIRE
SOUTH ASIA	PROGRAM INNOVATION	16,187	CHECK/WIRE
SOUTH ASIA	AMEE	146,185	CHECK/WIRE
SOUTH ASIA	PROGRAM INNOVATION	37,760	CHECK/WIRE
SOUTH ASIA	AMEE	917,546	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	13,346	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	7,713	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	57,842	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	48,000	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	33,000	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	10,877	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	19,274	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	125,000	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	14,406	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	188,500	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	17,844	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	21,977	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	8,496	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	14,340	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	92,442	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	151,572	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	43,666	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	1,424,371	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	41,555	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	106,498	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	129,659	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	149,121	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	69,598	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	131,261	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	35,303	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	144,141	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	17,678	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	43,761	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	17,402	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	76,283	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	113,085	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	11,028	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	53,266	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	49,843	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	20,213	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	60,936	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	44,285	CHECK/WIRE
SUB-SAHARAN AFRICA	OTHER	20,761	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	26,101	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	1,074,907	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	1,025,881	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	71,112	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	288,932	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	5,583	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	61,349	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	99,884	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	23,221	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	30,000	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	23,201	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	79,218	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	168,967	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	228,000	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & OTHER	22,905	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	36,038	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	213,737	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	11,523	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	36,434	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	790,000	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	38,199	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	67,927	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	42,670	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	9,611	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	37,894	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	69,592	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	38,936	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	540,034	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	29,980	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	14,938	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	311,517	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA & PROGRAM INNOVATION	409,920	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	339,204	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	1,448,986	CHECK/WIRE
SUB-SAHARAN AFRICA	ESSENTIAL MEDICINE	1,415,829	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	76,289	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	35,251	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	148,787	CHECK/WIRE
SUB-SAHARAN AFRICA	AFRICA	30,544	CHECK/WIRE
SUB-SAHARAN AFRICA	PROGRAM INNOVATION	30,000	CHECK/WIRE

2	Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......	163
3	Enter total number of other organizations or entities .......................	53

Schedule F (Form 990) 2022

Schedule F (Form 990) 2022Page 3

Part III

Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.

Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance		(b) Region	(c) Number of recipients	(d) Amount of cash grant	(e) Manner of cash disbursement	(f) Amount of noncash assistance	(g) Description of noncash assistance	(h) Method of valuation (book, FMV, appraisal, other)

Schedule F (Form 990) 2022

Page 4

Part IV

Foreign Forms

Schedule F (Form 990) 2022

Page 5

Part V

Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.

ReturnReference	Explanation
PART I, LINE 2:	PATH HAS ROBUST POLICIES, PROCEDURES, AND GUIDELINES, INCLUDING SUBRECIPIENT POLICY AND PROCEDURES, IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING (FINANCIAL AND TECHNICAL), SITE VISITS, REGULAR CONTACT, ANNUAL AUDITS, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS/DONORS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. THE AUDIT IS CONDUCTED FOR THE COUNTRY PROGRAMS AND IS EXTENDED TO THE SUBRECIPIENTS.
PART III ACCOUNTING METHOD:

Schedule F (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)

Department of the Treasury
Internal Revenue Service

Grants and Other Assistance to Organizations,
Governments and Individuals in the United States

Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
lBullet

Attach to Form 990.
lBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public
Inspection

Name of the organization
PATH

Employer identification number
91-1157127

Part I

General Information on Grants and Assistance

Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................

Yes No

Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.

Part II

Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient

that received more than $5,000. Part II can be duplicated if additional space is needed.

(a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(h) Purpose of grant or assistance
(1) AKROS INC PO BOX 457 LARAMIE,WY82073	26-3668995	OTHER	176,590	PROGRAM INNOVATION
(2) BAGAMIAN SCIENTIFIC CONSULTING 222 NW 3RD AVE GAINESVILLE,FL32601	82-1347380	OTHER	62,465	ESSENTIAL MEDICINES
(3) BAYLOR COLLEGE OF MEDICINE 1 BAYLOR PLAZA SAN FRANCISCO,CA94612	74-1613878	501(C)(3)	157,111	ESSENTIAL MEDICINES
(4) BUILD HEALTH INTERNATIONAL INC 100 CUMMINGS CENTER SUITE 120 B BEVERLY,MA01915	46-4300024	501(C)(3)	14,770	PROGRAM INNOVATION
(5) CASE WESTERN RESERVE UNIVERSITY 10900 EUCLID AVE CLEVELAND,OH44106	34-1018992	501(C)(3)	27,322	PROGRAM INNOVATION
(6) CHILDREN'S HOSPITAL BOSTON RESEARCH FINANCE PO BOX 414413 BOSTON,MA022414413	04-2774441	501(C)(3)	526,516	ESSENTIAL MEDICINES
(7) CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVE ML 6014 CINCINNATI,OH452293039	31-0833936	501(C)(3)	230,000	ESSENTIAL MEDICINES
(8) CLINTON HEALTH ACCESS INITIATIVE 383 DORCHESTER AVE SUITE 400 BOSTON,MA02127	27-1414646	501(C)(3)	1,778,126	PROGRAM INNOVATION
(9) COOPERSMITH 4206 RIVER RD NW WASHINGTON,DC20016	47-2387850	OTHER	201,210	PROGRAM INNOVATION
(10) DARTMOUTH-HITCHCOCK CLINIC ONE MEDICAL CENTER DR LEBANON,NH03756	22-2715483	501(C)(3)	310,257	ESSENTIAL MEDICINES
(11) DIMAGI INC 585 MASSACHUSETTS AVE SUITE 4 CAMBRIDGE,MA02139	83-0343298	501(C)(3)	191,827	PROGRAM INNOVATION
(12) DKT INTERNATIONAL INC 1001 CONNECTICUT AVE NW SUITE 800 WASHINGTON,DC20036	58-1593137	501(C)(3)	28,749	PROGRAM INNOVATION
(13) FOOD AND DRUG ADMINISTRATION 5600 FISHERS LANEHFA-140 ROOM 11-40 ROCKVILLE,MD20857	53-0196965	GOV	135,200	ESSENTIAL MEDICINES
(14) GET ODK INC 3288 ADAMS AVE 16043 SAN DIEGO,CA92176	45-4561037	OTHER	25,250	PROGRAM INNOVATION
(15) GLOBAL CONNECT DEVELOPMENT GROUP LLC 480 BEACH ST BOSTON,MA02131	82-3433604	OTHER	346,390	PROGRAM INNOVATION
(16) GLOBAL HEALTH CORPS 318 WEST 39TH STREET ROOM 9L NEW YORK,NY10018	80-0512336	501(C)(3)	8,900	PROGRAM INNOVATION
(17) GLOBAL HEALTH STRATEGIES LLC 27 WEST 24TH STREET SUITE 900 NEW YORK,NY10010	27-2494697	501(C)(3)	665,772	PROGRAM INNOVATION
(18) GUARALDI SYSTEMS LLC 97 ALGER BROOK RD SOUTH STAFFORD,VT05070	85-1148274	OTHER	278,812	PROGRAM INNOVATION
(19) HARVARD SCHOOL OF PUBLIC HEALTH 677 HUNTINGTON AVENUE BOSTON,MA02215	04-2103580	501(C)(3)	689,291	ESSENTIAL MEDICINES & PROGRAM INNOVATION
(20) HISP US LLC 31 ANCONA AVE OCEAN PARK,ME04063	85-0894858	OTHER	341,904	PROGRAM INNOVATION
(21) HJF MEDICAL RESEARCH INTERNATIONAL INC 6720A ROCKLEDGE DRIVE SUITE 100 BETHESDA,MD20817	52-2322791	501(C)(3)	3,381,337	ESSENTIAL MEDICINES
(22) ICF MACRO INC 9300 LEE HIGHWAY FAIRFAX,VA22031	22-3661438	OTHER	2,143,241	PROGRAM INNOVATION
(23) INDIANA UNIVERSITY 107 S INDIAN AVE BLOOMINGTON,IN47405	35-6001673	GOV	158,255	PROGRAM INNOVATION
(24) INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI) 1201 EYE STREET NW WASHINGTON,DC20005	52-1041632	501(C)(3)	40,619	PROGRAM INNOVATION
(25) INTRAHEALTH INTERNATIONAL INC 6340 QUADRANGLE DRIVE SUITE 200 CHAPEL HILL,NC27517	55-0825466	501(C)(3)	531,142	AFRICA & PROGRAM INNOVATION
(26) JHPIEGO 1615 THAMES STREET SUITE 200 BALTIMORE,MD212313447	23-7424444	501(C)(3)	773,622	AFRICA & AMEE
(27) JSI RESEARCH AND TRAINING INSTITUTE INC 1616 NORTH FORT MYER DR 16TH FLOOR ARLINGTON,VA222093100	04-2679824	501(C)(3)	991,582	PROGRAM INNOVATION
(28) KINDEVA DRUG DELIVERY LP 11200 HUDSON RD WOODBURY,MN55129	84-4392783	OTHER	476,030	PROGRAM INNOVATION
(29) LAST MILE HEALTH 24 SCHOOL STREET 5TH FLOOR BOSTON,MA02108	26-1401736	501(C)(3)	40,000	PROGRAM INNOVATION
(30) LIVING GOODS 1423 BROADWAY SAN FRANCISCO,CA94612	20-5010527	501(C)(3)	49,886	PROGRAM INNOVATION
(31) MANAGEMENT SCIENCES FOR HEALTH INC 200 RIVERS EDGE DRIVE SUITE 320 MEDFORD,MA02155	04-2482188	501(C)(3)	16,928	PROGRAM INNOVATION
(32) MASS DESIGN GROUP LTD 334 BOYLSTON ST STE 400 BOSTON,MA02116	61-1659704	501(C)(3)	35,000	PROGRAM INNOVATION
(33) MASSACHUSETTS GENERAL HOSPITAL DEPT OF EMERGENCY MEDICINE ZERO EMERSON PL 104 BOSTON,MA02114	04-1564655	501(C)(3)	46,000	ESSENTIAL MEDICINES
(34) MEDIC MOBILE INC 3254 19TH STREET FLOOR 2 SAN FRANCISCO,CA94110	27-5104203	501(C)(3)	677,641	PROGRAM INNOVATION
(35) MICHIGAN STATE UNIVERSITY 3900 COLLINS RD SUITE 1044 LANSING,MI48910	38-6005984	501(C)(3)	334,616	PROGRAM INNOVATION
(36) MICRON BIOMEDICAL INC 311 FERST DRIVE NW SUITE L1309 ATLANTA,GA30332	47-1692844	OTHER	181,474	PROGRAM INNOVATION
(37) NAT'L INST OF ALLERGY & INFECTIOUS DISEASES (NIAID) 6610 ROCKLEDGE DR ROOM 2800 BETHESDA,MD208926606	52-0858115	GOV	265,800	ESSENTIAL MEDICINES
(38) NICHOLAS INSTITUTE FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY 2117 CAMPUS DRIVE PO BOX 90335 DURHAM,NC27708	56-0532129	501(C)(3)	49,618	PROGRAM INNOVATION
(39) ONA SYSTEMS INC 126 E 12TH ST SUITE 4A NEW YORK,NY100035320	38-3940780	OTHER	343,787	PROGRAM INNOVATION
(40) OPEN FUNCTION GROUP INC 66 EUCLID AVE HASTINGS ON HUDSON,NY10706	81-1412952	OTHER	51,750	PROGRAM INNOVATION
(41) OPENMRS INC 10425 COMMERCE DR STE 110 CARMEL,IN460327643	45-5316647	501(C)(3)	430,364	PROGRAM INNOVATION
(42) PARTNERS IN HEALTH A NONPROFIT CORPORATION 800 BOYLSTON ST SUITE 300 BOSTON,MA02199	04-3567502	501(C)(3)	72,703	PROGRAM INNOVATION
(43) PHARMARON CPC INC 800 W BALTIMORE STREET 5TH FLOOR BALTIMORE,MD21201	20-8419781	OTHER	765,054	ESSENTIAL MEDICINES
(44) POPULATION COUNCIL ONE DAG HAMMERKJOLD PLAZA NEW YORK,NY10017	13-1687001	501(C)(3)	38,900	PROGRAM INNOVATION
(45) POPULATION SERVICES INTERNATIONAL INC 1120 19TH ST NW STE 600 WASHINGTON,DC20036	56-0942853	501(C)(3)	482,718	PROGRAM INNOVATION
(46) REGENSTRIEF INSTITUTE INC 1101 W 10TH ST INDIANAPOLIS,IN46202	30-0007730	501(C)(3)	1,242,154	PROGRAM INNOVATION
(47) RTI INTERNATIONAL PO BOX 12106 DURHAM,NC277092106	56-0686338	501(C)(3)	248,661	PROGRAM INNOVATION
(48) SYSTEMONE LLC 5 BRIDGE STREET SHELBURNE FALLS,MA01370	46-1066795	OTHER	46,966	AMEE
(49) TECHCHANGE INC 2001 13TH ST NW 2ND FLOOR WASHINGTON,DC20009	27-3358772	OTHER	495,812	PROGRAM INNOVATION
(50) THE ALBERT B SABIN VACCINE INSTITUTE INC 2175 K STREET NW SUITE 400 WASHINGTON,DC20037	06-1389829	501(C)(3)	2,211,718	ESSENTIAL MEDICINES
(51) THE NATURE CONSERVANCY 4245 FAIRFAX DRIVE ARLINGTON,VA22203	53-0242652	501(C)(3)	8,926	PROGRAM INNOVATION
(52) THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO UCSF OFFICE OF SPONSORED RES 3333 CALIFORNIA ST STE 315 SAN FRANCISCO,CA94118	94-6036493	501(C)(3)	196,237	PROGRAM INNOVATION
(53) TULANE UNIVERSITY 6823 ST CHARLES AVE NEW ORLEANS,LA70112	72-0423889	501(C)(3)	573,668	ESSENTIAL MEDICINES & PROGRAM INNOVATION
(54) UNITED NATIONS FOUNDATION INC 1750 PENNSYLVANIA AVE NW SUITE 300 WASHINGTON,DC20006	58-2368165	501(C)(3)	146,098	PROGRAM INNOVATION
(55) UNIVERSITY OF CALIFORNIA LOS ANGELES ( UCLA ) 10889 WILSHIRE BLVD SUITE 700 LOS ANGELES,CA90095	95-6006143	GOV	213,374	AFRICA
(56) UNIVERSITY OF MARYLAND BALTIMORE BALTIMORE PO BOX 41428 BALTIMORE,MD212036428	52-6002033	GOV	69,793	ESSENTIAL MEDICINES
(57) UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER,MA01655	04-3167352	GOV	236,395	PROGRAM INNOVATION
(58) UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL CENTER FOR INFECTIOUS DISEASES CHAPEL HILL,NC275993368	56-6001393	501(C)(3)	528,440	ESSENTIAL MEDICINES & PROGRAM INNOVATION
(59) UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE AGRICULTURAL COLLEGE 85 SOUTH PROSPECT STREET BURLINGTON,VT05405	03-0179440	501(C)(3)	457,533	ESSENTIAL MEDICINES
(60) UNIVERSITY OF WASHINGTON ( UW ) GRANT CONTRACT ACCOUNTING 12455 COLLECTIONS DRIVE CHICAGO,IL60693	91-6001537	501(C)(3)	1,942,884	ESSENTIAL MEDICINES & PROGRAM INNOVATION
(61) VILLAGEREACH 2900 EASTLAKE AVE E SUITE 230 SEATTLE,WA981023012	91-2088484	501(C)(3)	94,775	AFRICA & PROGRAM INNOVATION
(62) VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY 300 TURNER ST NW SUITE 4200 BLACKSBURG,VA24061	54-6001805	GOV	17,267	ESSENTIAL MEDICINES
(63) VITAL STRATEGIES INC 100 BROADWAY 4TH FLOOR NEW YORK,NY10005	22-3419667	501(C)(3)	62,898	PROGRAM INNOVATION
(64) VITAL WAVE INC 555 BRYANT STREET 226 PALO ALTO,CA94301	20-3208079	OTHER	1,315,199	PROGRAM INNOVATION
(65) WALTER REED ARMY INSTITUTE OF RESEARCH US TREASURY 503 ROBERT GRANT AVE SILVER SPRING,MD20910	52-0664528	GOV	1,755,399	ESSENTIAL MEDICINES

Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image

Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50055P

Schedule I (Form 990) 2022

Page 2

Part III

Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.

(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of noncash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of noncash assistance

(1)
(2)
(3)
(4)
(5)
(6)
(7)

Part IV

Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.

Return Reference

Explanation

PART I, LINE 2:

PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, ANNUAL AUDITS, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS/DONORS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.

Schedule I (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

Schedule J
(Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet

Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet

Attach to Form 990.
SchJMediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Part I

Questions Regarding Compensation

Yes

Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.

First-class or charter travel Housing allowance or residence for personal use

Travel for companions Payments for business use of personal residence

Tax idemnification and gross-up payments Health or social club dues or initiation fees

Discretionary spending account Personal services (e.g., maid, chauffeur, chef)

If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....

Yes

Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....

Yes

Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.

Compensation committee Written employment contract

Independent compensation consultant Compensation survey or study

Form 990 of other organizations Approval by the board or compensation committee

During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:

Receive a severance payment or change-of-control payment? .............

Yes

Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........

Participate in, or receive payment from, an equity-based compensation arrangement? .........

If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.

Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:

The organization? ....................

Any related organization? .......................

If "Yes," on line 5a or 5b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:

The organization? ..................

Any related organization? ......................

If "Yes," on line 6a or 6b, describe in Part III.

For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............

Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................

If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50053T

Schedule J (Form 990) 2022

Page 2

Part II

Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.

For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.

(A) Name and Title		(B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC			(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation in column (B) reported as deferred on prior Form 990
(A) Name and Title		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other reportable compensation	(C) Retirement and other deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)
1NIKOLAJ JESTED GILBERT MSC PRESIDENT AND CEO	(i) (ii)	586,653 ------------- 0	0 ------------- 0	662 ------------- 0	35,800 ------------- 0	10,532 ------------- 0	633,647 ------------- 0	0 ------------- 0
2JOHN O KONZ PHD GLOBAL HEAD OF POLIO	(i) (ii)	342,306 ------------- 0	0 ------------- 0	18,100 ------------- 0	35,800 ------------- 0	33,354 ------------- 0	429,560 ------------- 0	0 ------------- 0
3DAVID C KASLOW MD CHIEF SCIENTIFIC OFF. (UNTIL 10/8/22	(i) (ii)	322,702 ------------- 0	0 ------------- 0	33,639 ------------- 0	35,800 ------------- 0	28,213 ------------- 0	420,354 ------------- 0	0 ------------- 0
4TRAD M HATTON MA MHS DIR., CEN. AFRICA HUB & DRC COUNTRY	(i) (ii)	150,306 ------------- 0	0 ------------- 0	210,147 ------------- 0	18,325 ------------- 0	35,457 ------------- 0	414,235 ------------- 0	0 ------------- 0
5NANTHALILE C MUGALA MD MMED CHIEF OF AFRICA REGION	(i) (ii)	212,753 ------------- 0	0 ------------- 0	87,775 ------------- 0	108,653 ------------- 0	0 ------------- 0	409,181 ------------- 0	0 ------------- 0
6ASHLEY J BIRKETT PHD GLOBAL HEAD, MALARIA VACCINES	(i) (ii)	339,564 ------------- 0	0 ------------- 0	900 ------------- 0	31,367 ------------- 0	31,832 ------------- 0	403,663 ------------- 0	0 ------------- 0
7KIMBERLY GREEN PHD DIRECTOR, PRIMARY HEALTH CARE	(i) (ii)	278,794 ------------- 0	0 ------------- 0	53,890 ------------- 0	24,428 ------------- 0	45,582 ------------- 0	402,694 ------------- 0	0 ------------- 0
8JEFFREY D BERNSON MPH MPA CHIEF PROGRAMS & INNOVATION OFFICER	(i) (ii)	333,778 ------------- 0	0 ------------- 0	600 ------------- 0	33,630 ------------- 0	20,277 ------------- 0	388,285 ------------- 0	0 ------------- 0
9BRUCE LAMONT INNIS MD FIDSA GLOBAL HEAD, RESPIRATORY INFECTIONS	(i) (ii)	350,446 ------------- 0	0 ------------- 0	600 ------------- 0	34,854 ------------- 0	-106 ------------- 0	385,794 ------------- 0	0 ------------- 0
10JESSICA MILMAN EXEC. DIR., STRATEGY, OPS., & EFFECT	(i) (ii)	292,043 ------------- 0	0 ------------- 0	18,100 ------------- 0	30,064 ------------- 0	21,089 ------------- 0	361,296 ------------- 0	0 ------------- 0
11PHILIPPE GUINOT MBA CHIEF OF BUSINESS, FIN. & OPS.	(i) (ii)	0 ------------- 303,679	0 ------------- 0	0 ------------- 5,977	0 ------------- 26,046	0 ------------- 630	0 ------------- 336,332	0 ------------- 0
12SABRINA L POWERS JD CHIEF OF LEGAL & RESEARCH AFFAIRS/GC	(i) (ii)	281,958 ------------- 0	0 ------------- 0	900 ------------- 0	33,808 ------------- 0	13,107 ------------- 0	329,773 ------------- 0	0 ------------- 0
13CARLA ANNE COSTA SANDINE CHIEF OF EXTERNAL AFFAIRS	(i) (ii)	237,750 ------------- 0	0 ------------- 0	600 ------------- 0	27,879 ------------- 0	20,057 ------------- 0	286,286 ------------- 0	0 ------------- 0
14MEISSA DIAW CHIEF PEOPLE & DIVERSITY OFFICER	(i) (ii)	200,760 ------------- 0	0 ------------- 0	22,773 ------------- 0	0 ------------- 0	401 ------------- 0	223,934 ------------- 0	0 ------------- 0
15NABEEL A GOHEER PHD CHIEF OF AFRICA	(i) (ii)	206,069 ------------- 0	0 ------------- 0	780 ------------- 0	1,636 ------------- 0	0 ------------- 0	208,485 ------------- 0	0 ------------- 0
16MOLLI M BARNES CHIEF PEOPLE OFFICER (UNTIL 1/31/22)	(i) (ii)	22,846 ------------- 0	0 ------------- 0	150,472 ------------- 0	4,769 ------------- 0	23,513 ------------- 0	201,600 ------------- 0	0 ------------- 0

Schedule J (Form 990) 2022

Page 3

Part III

Supplemental Information

Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.

Return Reference	Explanation
PART I, LINE 1A	HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT.
PART I, LINE 4A	LIST OF PERSONS IN FORM 990, PART VII, SECTION A WHO RECEIVED SEVERANCE PAYMENTS IN 2022: - MOLLI M. BARNES $133,674

Schedule J (Form 990) 2022

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE M
(Form 990)

Department of the Treasury

Internal Revenue Service

Noncash Contributions

Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image

Attach to Form 990.
Right pointing arrow large image

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2022

Open to Public Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Part I

Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art—Works of art ....
2 Art—Historical treasures .
3 Art—Fractional interests ..
4 Books and publications ..
5 Clothing and household goods .......
6 Cars and other vehicles ..
7 Boats and planes ....
8 Intellectual property ...
9 Securities—Publicly traded .	X	14	58,935	FMV
10 Securities—Closely held stock .
11 Securities—Partnership, LLC, or trust interests ....
12 Securities—Miscellaneous ..
13 Qualified conservation contribution—Historic structures .....
14 Qualified conservation contribution—Other ...
15 Real estate—Residential .
16 Real estate—Commercial ..
17 Real estate—Other ...
18 Collectibles .....
19 Food inventory ...
20 Drugs and medical supplies .
21 Taxidermy ......
22 Historical artifacts ....
23 Scientific specimens ..
24 Archeological artifacts ...
25 Other ( SOFTWARE/SUPP. )	X	5	758,781	COST
26 Other ( )
27 Other ( )
28 Other ( )

Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement

Yes

30a

During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................

30a

If "Yes," describe the arrangement in Part II.

Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?

Yes

32a

Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash

contributions? ..........................

32a

If "Yes," describe in Part II.

If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,

describe in Part II.

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 51227J

Schedule M (Form 990) (2022)

Page 2

Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

Return Reference	Explanation
PART I, COLUMN (B):	THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS.

Schedule M (Form 990) (2022)

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet

Attach to Form 990 or 990-EZ.
MediumBullet

Go to www.irs.gov/Form990 for the latest information.

OMB No. 1545-0047

2021

Open to Public
Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Return Reference	Explanation
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION:	PATH IS A GLOBAL NONPROFIT DEDICATED TO ACHIEVING HEALTH EQUITY. WITH MORE THAN 40 YEARS OF EXPERIENCE FORGING MULTISECTOR PARTNERSHIPS, AND WITH EXPERTISE IN SCIENCE, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP INNOVATIVE SOLUTIONS TO THE WORLD'S MOST PRESSING HEALTH CHALLENGES. THE LARGEST INVESTMENTS IN PATH'S PROGRAMMATIC WORK IN 2022 WERE ORGANIZED INTO THREE PRIMARY PORTFOLIOS: PROGRAMS & INNOVATION, ESSENTIAL MEDICINES, AND THE AFRICA REGION.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	IN 2022, WE ALSO ACCOMPLISHED A DESIGN LOCK AND SUBSEQUENT EXECUTION OF A TECHNOLOGY TRANSFER, LICENSE, AND COMMERCIALIZATION AGREEMENT WITH LIFEASSAY DIAGNOSTICS LTD. FOR A POINT-OF-CARE RAPID DIAGNOSTIC TEST FOR PRIMARY IMMUNODEFICIENCY (PID). PID ARE A RARE CLASS OF HEREDITARY DISEASES THAT AFFECT THE IMMUNE SYSTEM, RESULTING IN INCOMPLETE IMMUNE RESPONSES THAT MAKE INDIVIDUALS MORE VULNERABLE TO DISEASES. PEOPLE WITH SOME FORMS OF PID ARE AT RISK OF PROLONGED INFECTION AND SHEDDING OF POLIOVIRUS INTO THEIR COMMUNITIES. IDENTIFYING THOSE WITH PID CAN HELP DISRUPT COMMUNITY OUTBREAKS AND DISEASE CYCLES. MEDICAL DEVICES AND HEALTH TECHNOLOGIES THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM SUPPORTS PRODUCT DEVELOPMENT AT PATH. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD. IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE MANUFACTURED IN SOUTH AFRICA AVAILABLE IN 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN BRAZIL IN 2022, BRINGING THE GLOBAL TOTAL TO 40 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE AND MARKETED. IN THE AREAS OF VACCINE AND PHARMACEUTICAL TECHNOLOGIES, WE CONVENED A THIRD GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND US DECISION-MAKERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM INCLUDING EVALUATING THE USABILITY OF CANDIDATE PRODUCTS AND THE POTENTIAL TOTAL COST TO DELIVER MEASLES AND RUBELLA VACCINE WITH A PATCH. IN ADDITION, WE ADVISED UGANDA'S MINISTRY OF HEALTH (MOH) ON THE COUNTRY-WIDE ADOPTION OF A PATH-ADVANCED VACCINE COLD CHAIN INVENTORY AND PERFORMANCE TRACKING SYSTEM. FINALLY, SCIENTISTS IN THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A NOVEL HEAT-STABLE INSULIN FORMULATION, SUITABLE FOR ORAL ADMINISTRATION. MARKET DYNAMICS PATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, CIVIL SOCIETY ORGANIZATIONS, AND PATH'S COUNTRY PROGRAMS. IN 2022, OUR LARGEST AREAS OF WORK WERE: (1) IMPROVING ACCESS TO MEDICAL OXYGEN, RESPIRATORY CARE SYSTEMS, AND CRITICAL MEDICAL DEVICES IN LMICS. AS PART OF THAT WORK, WE SUPPORTED GLOBAL AND COUNTRY EFFORTS IN RESPIRATORY CARE CAPACITY-BUILDING AND IMPLEMENTATION, STRENGTHENED ADVOCACY TO ELEVATE OXYGEN TO GLOBAL AND NATIONAL AGENDAS, AND ENHANCED RESEARCH AND MONITORING, EVALUATION, AND LEARNING ON OXYGEN WITH A GOAL TO EQUITABLY IMPROVE ACCESS TO HIGH-QUALITY OXYGEN SERVICES AT ALL LEVELS OF THE HEALTH CARE SYSTEM. IN INDIA, KENYA, SENEGAL, AND TANZANIA, WE ADVANCED ACCESS TO AFFORDABLE AND APPROPRIATE TOOLS SUCH AS PULSE OXIMETRY AND ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHMS TO HELP HEALTH CARE WORKERS IDENTIFY CRITICALLY ILL CHILDREN AND REFER THEM FOR TREATMENT WITHOUT DELAY. AS PART OF THIS WORK, WE IMPROVED ACCESS TO TOOLS AT FACILITIES, TRAINED HEALTH CARE WORKERS, AND INFORMED NATIONAL POLICY AND ADVOCACY EFFORTS TOWARD SCALING THESE CRITICAL DEVICES AT THE PRIMARY HEALTH CARE (PHC) LEVEL. (2) SUPPORTING THE INTRODUCTION AND SCALE-UP OF MALARIA HEALTH PRODUCTS WITH THE AIM OF ELIMINATING THE P. VIVAX STRAIN OF MALARIA. WITH PARTNERS, OUR WORK INCLUDED DEVELOPING APPROPRIATE STRATEGIES TO ADDRESS P. VIVAX, SHARING HIGH-QUALITY EVIDENCE TO INFORM POLICY AND DECISION-MAKING, AND SUPPORTING THE DEVELOPMENT AND AVAILABILITY OF MEDICINES AND DIAGNOSTICS TO ENSURE SAFE AND EFFECTIVE TREATMENT OF PATIENTS. EPIDEMIC PREPAREDNESS AND RESPONSE PATH'S EPIDEMIC PREPAREDNESS AND RESPONSE (EPR) GLOBAL PROGRAM EXHIBITED UNWAVERING DEDICATION TO SUPPORTING MINISTRIES OF HEALTH, AGRICULTURE, ENVIRONMENT, AND OTHER SECTORS TO PREPARE FOR THE LOOMING THREAT OF ANTIMICROBIAL RESISTANCE (AMR), CLIMATE CHANGE, AND INFECTIOUS DISEASES THROUGH A ONE HEALTH APPROACH. AMR AND CLIMATE CHANGE POSE A PRESSING CRISIS, DISRUPTING ECOSYSTEMS, INTENSIFYING NATURAL DISASTERS, AND JEOPARDIZING THE WELL-BEING OF COMMUNITIES WORLDWIDE. IN 2022, EPR STRENGTHENED ITS EFFORTS ON HUMANITARIAN RESPONSE BY PROVIDING TECHNICAL ASSISTANCE TO ENSURE THAT POPULATIONS MOST VULNERABLE TO EMERGING HEALTH THREATS RECEIVE VITAL AID AND SUPPORT. CONCURRENTLY, THE TEAM CONTINUED TO IMPLEMENT TWO USAID PROJECTS - INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) AND DISCOVERY & EXPLORATION OF EMERGING PATHOGENS, VIRAL ZOONOSES (DEEP VZN) - IN SEVERAL COUNTRIES IN AFRICA AND ASIA. WITH SUPPORT FROM THE US CDC, PATH COLLABORATED WITH THE NATIONAL GOVERNMENTS OF SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR CAPACITY TO PREPARE FOR AND RESPOND TO EPIDEMICS. PATH'S MULTIDIMENSIONAL APPROACH TO EPIDEMIC PREPAREDNESS AND RESPONSE REMAINS AN EXEMPLAR OF PROACTIVE AND COLLABORATIVE ACTION, LEVERAGING PARTNERSHIPS AND INNOVATIONS TO SAFEGUARD GLOBAL HEALTH. THANKS TO COLLABORATION WITH USAID, CDC, AND OTHER PARTNERS, PATH WORKED WITH NATIONAL LEADERS IN 17 COUNTRIES TO ENHANCE CAPACITY FOR EPR BY STRENGTHENING DISEASE SURVEILLANCE LABORATORY SYSTEMS THROUGH A MULTISECTORAL ONE HEALTH APPROACH. MALARIA AND NEGLECTED TROPICAL DISEASES PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS AROUND THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. IN 2022, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA AND INCREASED ENGAGEMENT WITH THE DRC GOVERNMENT TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA PROVIDED TECHNICAL ASSISTANCE AND EXPERTISE TO SUPPORT SUBNATIONAL TAILORING BASED ON RISK STRATIFICATION MAPS AND MODELING OF OPTIMAL INTERVENTION MIXES ACROSS ALL GEOGRAPHIES AND SUPPORTED PRIORITIZATION OF AND FUNDING FOR EVALUATION OF TARGETED CONTROL STRATEGIES ADDRESSING HIGH-RISK POPULATIONS IN SENEGAL AND ETHIOPIA. MACEPA ALSO CONDUCTED EXPLORATORY ACTIVITIES IN MALAWI AND NIGERIA (E.G., QUANTIFYING COMMUNITY CASE MANAGEMENT NEEDS AND GAPS THROUGH LANDSCAPING AND BENCHMARKING ANALYSES IN MALAWI AND FINALIZING AND DISSEMINATING RESULTS FROM SURVEILLANCE ASSESSMENTS IN NIGERIA) TO INFORM TECHNICAL ASSISTANCE NEEDS AND RECOMMENDATIONS FOR THOSE GEOGRAPHIES. THE PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO) PLUS PROJECT, FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI), PROVIDED TECHNICAL AND MATERIAL ASSISTANCE TO THE ZAMBIA MOH IN MALARIA CASE MANAGEMENT, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, DISEASE SURVEILLANCE, AND DATA MANAGEMENT AND USE. WORK IN 2022 INVOLVED MENTORING HEALTH WORKERS IN THE PROJECT'S FOUR FOCUS PROVINCES ON ADHERENCE TO MALARIA CASE MANAGEMENT STANDARDS AS WELL AS TRAINING, DEPLOYING, AND SUPPORTING COMMUNITY HEALTH WORKERS WHO TEST AND TREAT MALARIA AT THE COMMUNITY LEVEL. ADDITIONALLY, PAMO PLUS WORKED WITH THE ZAMBIA NURSING AND MIDWIFERY COUNCIL TO INTEGRATE MALARIA IN PREGNANCY TRAINING INTO THE NURSING COLLEGE CURRICULUM AND TRAINED ANTENATAL CARE PROVIDERS AND SAFE MOTHERHOOD ACTION GROUP MEMBERS ON THE MALARIA IN PREGNANCY GUIDELINES. PAMO PLUS SUPPORTED THE DEVELOPMENT OF COMMUNITY ENGAGEMENT PLANS, ORIENTED COMMUNITY CHANGE AGENTS, CONDUCTED DATA QUALITY AUDITS, AND TRAINED MOH STAFF IN DATA MANAGEMENT AND MENTORSHIP. PAMO PLUS CONTINUED IMPLEMENTING A MALARIA PRE-ELIMINATION PROGRAM, CONDUCTING RESEARCH IN LOW-BURDEN DISTRICTS OF EASTERN PROVINCE, ZAMBIA. IN 2022, PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS WITH OUR PARTNERS UNDER PMI VECTORLINK, USAID'S FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT - FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND) - WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB).
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	WE COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. UNDER THE RAPID MALARIA ASSESSMENTS TO SUPPORT APPROPRIATELY TAILORED SUBNATIONAL INTERVENTION PACKAGES IN BURKINA FASO PROJECT, FUNDED BY THE GATES FOUNDATION, PATH ALSO PROVIDED TECHNICAL SUPPORT TO THE CENTRE NATIONAL DE RECHERCHE ET DE FORMATION SUR LE PALUDISME TO EXPLORE NEW DATA SOURCES, COLLECTION METHODS, AND INDICATORS TO PROVIDE GRANULAR AND TIMELY DATA FOR DECISION-MAKING INCLUDING TO SUPPORT SUBNATIONAL PLANNING AND GLOBAL FUND GRANT ASSESSMENTS. PATH ALSO LED A USAID INITIATIVE TO SUPPORT MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN NATIONAL POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION. IN SENEGAL AND THE GAMBIA, PATH CONTINUED TO INTEGRATE MALARIA INTO THE SCOPE OF NATIONAL EMERGENCY OPERATIONS CENTERS (EOCS). IN SENEGAL, WE SUPPORTED THE MINISTRY OF HEALTH TO CREATE AND RESOURCE REGIONAL EOC-MALARIA UNITS. WITH A REGIONAL PRESENCE, THE EOC CAN MORE RAPIDLY RESPOND TO POTENTIAL PUBLIC HEALTH THREATS. IN DRC, PATH BEGAN TO SUPPORT THE RECENTLY CREATED NATIONAL PUBLIC HEALTH INSTITUTE'S EFFORTS TO SET UP A SINGLE, CENTRAL EOC TO MANAGE THE MULTIPLE HEALTH EMERGENCIES DRC HAS TO MANAGE, INCLUDING DEVELOPING AN INTEGRATED DATA PLATFORM TO SUPPORT DECISION-MAKING. PATH'S LABORATORY TEAM AT THE NATIONAL MALARIA ELIMINATION CENTER IN LUSAKA, ZAMBIA, HAS DEVELOPED A COST-EFFECTIVE AND SCALABLE ANTIMALARIAL DRUG RESISTANCE ASSAY FOR P. FALCIPARUM MALARIA UTILIZING NANOPORE SEQUENCING. IN 2022, PATH RECEIVED FUNDING FROM THE GATES FOUNDATION TO INTEGRATE NANOPORE SEQUENCING INTO ROUTINE MALARIA SURVEILLANCE IN ZAMBIA, EXPAND NANOPORE SEQUENCING TO NEW GEOGRAPHIES THROUGH COLLABORATION AND CAPACITY BUILDING, AND OPTIMIZE EXISTING AND DEVELOP NOVEL NANOPORE SEQUENCING ASSAYS FOR MALARIA MOLECULAR SURVEILLANCE. THE VIVACTION PROJECT WORKS TO CATALYZE ADOPTION AND EVENTUAL SCALE-UP OF P. VIVAX TOOLS. IN ETHIOPIA, PATH CONTINUED STUDYING WHETHER IT IS OPERATIONALLY FEASIBLE TO PROVIDE OPTIMIZED RADICAL CURE TREATMENT TO P. VIVAX PATIENTS WHO ARE ELIGIBLE BASED ON TREATMENT GUIDELINES. IN 2022, PATH FOCUSED ON DEVELOPMENT OF THE COUNTRY PROTOCOL, INCLUDING MULTIPLE SERIES OF WORKING SESSIONS WITH THE ARMAUER HANSEN RESEARCH INSTITUTE, WHICH WERE ESSENTIAL FOR ALIGNMENT ACROSS THE DIFFERENT WORKSTREAMS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE IN THE STATE OF UTTAR PRADESH, SUPPORTING THE NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAM IN DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION THROUGH CAPACITY BUILDING, OUTBREAK INVESTIGATION, AND DATA MANAGEMENT. PATH HAS SUPPORTED THE STATE IN SUSTAINING ELIMINATION LEVEL OF VISCERAL LEISHMANIASIS (VL) TRANSMISSION IN THE VL-ENDEMIC DISTRICTS, THROUGH EFFECTIVE DISEASE SURVEILLANCE AND VECTOR CONTROL MEASURES BY THE STATE HEALTH SYSTEM. PATH PROVIDED TECHNICAL SUPPORT FOR SUCCESSFUL IMPLEMENTATION OF A PHASED MASS DRUG ADMINISTRATION CAMPAIGN, AS WELL AS MORBIDITY MANAGEMENT AND DISABILITY PREVENTION SERVICES ACROSS ALL LYMPHATIC FILARIASIS-ENDEMIC DISTRICTS IN THE STATE. PATH HAS ALSO SUPPORTED THE STATE HEALTH SYSTEM IN MAINTAINING A CASE FATALITY RATIO OF <10 PERCENT FROM ACUTE ENCEPHALITIS SYNDROME IN UTTAR PRADESH. IN THE STATE OF BIHAR, PATH SUPPORTED SUCCESSFUL IMPLEMENTATION OF THE JAPANESE ENCEPHALITIS VACCINATION CAMPAIGN IN 14 NEW ENDEMIC DISTRICTS, FOLLOWED BY INTRODUCTION IN THEIR ROUTINE IMMUNIZATION PROGRAM. THE GOAL OF THE ZAMBIA DIGITAL COMMUNITY HEALTH PROJECT IS TO DEVELOP A UNIFIED PLATFORM TO COORDINATE HEALTH SERVICE DELIVERY BY COMMUNITY HEALTH WORKERS. IN 2022, THE TEAM CONTINUED TO DEVELOP A DIGITAL COMMUNITY HEALTH WORK PLATFORM THAT ADDRESSES SERVICE DELIVERY AND DECISION SUPPORT, DATA QUALITY AND MANAGEMENT, AND A DATA CULTURE THAT CONTRIBUTES TO ADDRESSING CHALLENGES IN DATA USE. IN 2022, THE USAID SURVEILLANCE FOR MALARIA ELIMINATION (S4ME) ACTIVITY SUPPORTED MALARIA ELIMINATION EFFORTS IN ETHIOPIA BY DESIGNING AND TESTING EFFECTIVE SURVEILLANCE ACTIVITIES FOR ELIMINATION AT THE WOREDA LEVEL, INCLUDING HEALTH FACILITIES AND COMMUNITY PLATFORMS; SUPPORTING THE IDENTIFICATION AND TIMELY REPORTING OF MALARIA CASES BY UTILIZING REAL-TIME DATA FROM DIGITAL SYSTEMS TO INVESTIGATE AND CLASSIFY MALARIA CASES; AND SUPPORTING THE IMPLEMENTATION OF TARGETED MALARIA ELIMINATION INTERVENTIONS. IN NOVEMBER 2022, THROUGH FUNDING FROM GIVEWELL, PATH LAUNCHED A PILOT PROJECT IN THE DRC TO DELIVER PERENNIAL MALARIA CHEMOPREVENTION (PMC) TO CHILDREN UNDER TWO YEARS OF AGE AT ROUTINE VACCINATION VISITS. PROJECT IMPLEMENTATION IS ANTICIPATED TO BEGIN IN SUMMER 2023. UNDER THE LEADERSHIP OF WHO AND WITH FUNDING FROM THE GATES FOUNDATION, PATH CONTINUED WORKING WITH NEGLECTED TROPICAL DISEASE (NTD) PROGRAMS AND OTHER STAKEHOLDERS TO DESIGN AN INTEGRATED SURVEILLANCE PLANNING TOOLKIT FOR NTDS WITH A SPECIFIC FOCUS ON ONCHOCERCIASIS AND LYMPHATIC FILARIASIS. PATH ALSO SUPPORTED IMPLEMENTATION OF PMI'S ELIMINATE MALARIA PROJECT, WHICH AIMS TO CONTRIBUTE TO ELIMINATION OF INDIGENOUS TRANSMISSION OF P. FALCIPARUM MALARIA BY 2023 AND PUT MYANMAR ON THE PATH TO ELIMINATE ALL HUMAN MALARIA BY 2030. IN 2022, THE TEAM CONTINUED TO DEVELOP AN UPDATED MALARIA INFORMATION SYSTEM AND MALARIA CASE-BASED REPORTING AND SURVEILLANCE SYSTEM TO INFORM ELIMINATION EFFORTS. EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK IN 2022, THE EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK (ECDAN), HOSTED BY PATH, CONTINUED TO ADVOCATE FOR YOUNG CHILDREN AND THEIR CAREGIVERS. THROUGH THE GLOBAL CHILDCARE CAMPAIGN ECDAN CONTINUED TO ADVANCE ITS ENGAGEMENT BY DEVELOPING TACTICAL STRATEGIES TO CONNECT MORE CLOSELY WITH COUNTRY-LEVEL ACTIVITIES. JOINT ADVOCACY EFFORTS BY ECDAN AND PARTNERS CONTRIBUTED TO THE INCLUSION OF CHILDCARE IN THE WORLD BANK INTERNATIONAL DEVELOPMENT ASSOCIATION'S (IDA) 20TH REPLENISHMENT AND THE ESTABLISHMENT OF A WORLD BANK'S INVEST IN CHILDCARE INITIATIVE BY BILATERAL GOVERNMENTS AND FOUNDATIONS THAT LEVERAGES IDA FUNDING AT THE COUNTRY LEVEL. THE GLOBAL INITIATIVE TO SUPPORT PARENTS WAS FORMALIZED AND QUICKLY MOBILIZED, TRANSLATED, AND MADE KEY RESOURCES AVAILABLE TO HUNDREDS OF LOCAL IMPLEMENTING PARTNERS RESPONDING TO BOTH THE WAR IN UKRAINE AND THE FLOODS IN PAKISTAN. REGIONAL CONVENINGS WERE ALSO HELD FOCUSED ON PARENTING IN AFRICA, ASIA, AND LATIN AMERICA. ECDAN ALSO LAUNCHED AND HOSTED A NEW FUNDERS COLLABORATIVE INITIATIVE TO DEVELOP AND SCALE UP SUCCESSFUL MODELS OF HOME-BASED CHILDCARE IN KENYA, RWANDA, AND INDIA. THE FIVE INITIAL KNOWLEDGE FELLOWS COMPLETED AND DISSEMINATED THEIR KNOWLEDGE PRODUCTS. SIX OTHER KNOWLEDGE FELLOWS (2022 COHORT) WERE SELECTED, PAIRED WITH MENTORS, AND SUPPORTED TO DESIGN KNOWLEDGE PROJECTS. ECDAN CONTINUED TO PRODUCE GLOBAL PUBLIC GOODS IN COLLABORATION WITH THE HARVARD UNIVERSITY T.H. CHAN SCHOOL OF PUBLIC HEALTH AND THE MURDOCH CHILDREN'S RESEARCH INSTITUTE, INCLUDING A SYSTEMATIC EVIDENCE REVIEW OF THE POTENTIAL APPLICATIONS OF SYSTEMS THINKING IN SCALING EFFORTS TO ENABLE EVERY CHILD TO THRIVE. PRIMARY HEALTH CARE PATH'S PRIMARY HEALTH CARE (PHC) PROGRAM EMPLOYS A COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PHC MODEL THAT ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. PHC AT PATH IS COMPOSED OF SIX TEAMS, DESCRIBED BELOW. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION TOGETHER WITH PARTNERS AROUND THE WORLD, PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) TEAM DEVELOPS, ADAPTS, AND SCALES UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AMONG MOTHERS AND CHILDREN AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. TO ENSURE OPTIMAL NEWBORN NUTRITION, PATH FOCUSES ON BREASTFEEDING PROMOTION, PROVISION OF SPECIALIZED LACTATION SUPPORT FOR MOTHERS OF SMALL AND SICK NEWBORNS, AVAILABILITY OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS, AND UPTAKE AND USE OF GLOBAL STANDARDS FOR HUMAN MILK BANKING. IN 2022, USING HUMAN-CENTERED DESIGN, WE FINALIZED A PROTOTYPE FOR A DIGITAL ADAPTATION KIT FOR DIGITIZING NEWBORN FEEDING AND LACTATION SUPPORT DATA. THIS TOOL WAS DEVELOPED IN KENYA AND IS NOW PUBLICLY AVAILABLE AS A GLOBAL GOOD FOR ALL SETTINGS. PATH CONTINUED SUPPORTING ARIADNE LABS AS A SUBJECT MATTER EXPERT AND SUPPORTED THE GLOBAL DISSEMINATION OF RESEARCH FINDINGS THROUGH MULTIPLE PEER-REVIEWED PUBLICATIONS AND AN INTERNATIONAL CONFERENCE. PATH ALSO WAS SELECTED AS THE COORDINATION BODY FOR THE WHO HUMAN MILK BANKING AND DONOR HUMAN MILK GUIDELINES. THIS INVOLVED SUPPORTING THE WHO STEERING COMMITTEE AND CREATING A GUIDELINE DEVELOPMENT GROUP.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	PATH ALSO COORDINATED THE SAMPLE COLLECTION FOR A GLOBAL DONOR MILK COMPOSITION STUDY FROM FOUR COUNTRIES' HUMAN MILK BANKS. IN GHANA, PATH IS LEADING A FOUR-YEAR EFFORT, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS SPECIFICALLY THE RIDGE HOSPITAL (ALSO KNOWN AS THE GREATER ACCRA REGIONAL HOSPITAL), TEMA GENERAL HOSPITAL, EASTERN REGIONAL HOSPITAL (KOFORIDUA), AND BONO REGIONAL HOSPITAL (SUNYANI). AS PART OF THIS INITIATIVE, THE GHANA HEALTH SERVICE (GHS) AND PATH ARE RESPONSIBLE FOR ADVOCACY, POLICY, AND PROCUREMENT OF LIFESAVING NEONATAL EQUIPMENT TO IMPROVE ADVANCED NEONATAL CARE IN ALL FOUR HOSPITALS. PATH PROCURED AND INSTALLED EQUIPMENT WITHIN THE FOUR FACILITIES AND SUPPORTED TRAININGS OF HOSPITAL STAFF ON THE PROPER USE OF THE NEONATAL EQUIPMENT. ADDITIONALLY, PATH AND GHS SUCCESSFULLY DEVELOPED A COMPREHENSIVE TRAINING MANUAL (WITH INPUT FROM KYBELE, OUR IMPLEMENTING PARTNER) TO ORIENT NURSES AT ANTENATAL AND POSTNATAL CARE DELIVERY POINTS WITHIN THE MEBCI 2.0 FACILITY CATCHMENTS. THE MANUAL WAS ALSO USED TO ORIENT FACILITY AND DISTRICT HEALTH PROMOTION OFFICERS, AS WELL AS REGIONAL NEWBORN CHAMPIONS, ON THE IMPORTANCE OF RAISING AWARENESS AND PROVIDING EDUCATION ON THE CONTINUUM OF CARE FOR SMALL AND SICK NEWBORNS, CREATING DEMAND FOR HIGH-QUALITY NEWBORN CARE. IN COLLABORATION WITH THE GHS AND WITH FUNDING FROM THE PFIZER FOUNDATION, PATH CONTINUED IMPLEMENTING THE INTEGRATED ANTENATAL CARE PROJECT IN THE BONO EAST REGION OF GHANA. THE PROJECT AIMS TO AVERT INFECTIOUS DISEASE MORTALITY AND MORBIDITY IN NEONATES AND MOTHERS BY IMPLEMENTING AN IMPROVED, COMPREHENSIVE INFECTIOUS DISEASE SCREENING PROGRAM DURING PREGNANCY. AS OF DECEMBER 31, 2022, MORE THAN 3,000 WOMEN HAVE BEEN SCREENED FOR INFECTIONS INCLUDING SEXUALLY TRANSMITTED INFECTIONS AND URINARY TRACT INFECTIONS, MORE THAN 450 HEALTH WORKERS HAVE BEEN TRAINED IN SCREENING AND MANAGEMENT OF MATERNAL INFECTIONS, AND MORE THAN 59,000 COMMUNITY MEMBERS WERE REACHED THROUGH COMMUNITY MOBILIZATION, OUTREACH, AND SENSITIZATION ACTIVITIES OR MASS MEDIA CAMPAIGNS FOR DEMAND CREATION. IN LAOS, PATH CONTINUED SERVING AS A SHORT-TERM TECHNICAL ASSISTANCE PARTNER TO JOHN SNOW INC. (JSI) ON A USAID MATERNAL, NEWBORN, AND CHILD HEALTH PROJECT OPERATING FROM SEPTEMBER 2021 TO AUGUST 2026 ACROSS FIVE PROVINCES IN THE NORTH, CENTRAL, AND SOUTH REGIONS OF THE COUNTRY. PATH'S CORE TECHNICAL RESPONSIBILITIES FOCUS ON NEWBORN AND CHILD HEALTH, NUTRITION, AND EARLY CHILDHOOD DEVELOPMENT. THE PATH SOUTHEAST ASIA REGIONAL HUB PROVIDES ADMINISTRATIVE SUPPORT, WHILE THE MNCHN TEAM PROVIDES TECHNICAL LEADERSHIP, INCLUDING TRAVEL TO LAOS TO WORK WITH THE LOCAL JSI TEAM. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. TOGETHER WITH PATH'S CLIMATE CHANGE COMMUNITY OF PRACTICE, PATH'S NUTRITION TEAM CONTINUED TO ADVOCATE FOR SUSTAINABLE CLIMATE-FRIENDLY ALTERNATIVES, SUCH AS CULTURED PROTEINS AND EDIBLE INSECTS. WHERE POLICY OR GUIDELINES SUPPORTING FORTIFIED RICE ALREADY EXISTED, PATH CONTINUED ITS WORK WITH GOVERNMENTS, PRIVATE SECTOR, WORLD FOOD PROGRAM, AND NONGOVERNMENTAL ORGANIZATIONS (NGOS) ON ROLLOUT. AS A PARTNER IN THE DEMOGRAPHIC AND HEALTH SURVEYS PROGRAM, PATH SUPPORTED BIOMARKER DATA COLLECTION INCLUDING BOTH STANDARDIZED, ROUTINE MONITORING OF KEY NUTRITION INDICATORS LIKE STUNTING AND ANEMIA AND INNOVATIONS TO EXPAND BIOMARKER MEASUREMENT IN HOUSEHOLD-BASED SURVEYS CONDUCTED AROUND THE WORLD. WE ALSO CONCLUDED WORK ON A DATA REPOSITORY TRACKING THE STATUS TO SCALE UP OF KEY MNCHN INTERVENTIONS, INCLUDING SEVERAL THAT WOULD IMPROVE NUTRITION. FINALLY, PATH CONCLUDED THE BRIDGE COLLABORATIVE TO ADDRESS HUMAN AND PLANETARY HEALTH. EARLY CHILDHOOD DEVELOPMENT IN 2022, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO SCALE UP ECD SERVICE PROVISION AS AN ESSENTIAL COMPONENT OF PRIMARY HEALTH CARE, REACHING UNPRECEDENTED BLANKET COVERAGE IN TWO LARGE SUBNATIONAL GEOGRAPHIES IN KENYA AND MOZAMBIQUE AND EXPANSION INTO ADDITIONAL SUBNATIONAL GEOGRAPHIES. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. WITH A CONSTELLATION OF PARTNERS, PATH CONTINUED TO FACILITATE COLLECTIVE ACTION AT NATIONAL AND SUBNATIONAL LEVELS TO PROMOTE ECD THROUGH ENHANCED PLANNING, COORDINATION, AND RESOURCING, WHILE ALSO TRANSITIONING KEY IMPLEMENTATION WORKSTREAMS TO GOVERNMENT OWNERSHIP. PATH ALSO COMMENCED EFFORTS TO IMPROVE THE QUALITY OF ECD SERVICE DELIVERY BY ENGAGING COMMUNITIES, SERVICE PROVIDERS, AND KEY STAKEHOLDERS TO DETERMINE SPECIFIC TOUCHPOINTS AND SOLUTIONS THAT MAXIMIZE EXPOSURE TO ECD MESSAGES AND IMPROVE ADOPTION OF KEY BEHAVIORS. HEALTH SYSTEMS THE HEALTH SYSTEMS TEAM SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS AND CONTRIBUTE TO STRONGER PRIMARY HEALTH CARE. BOTH WITHIN PATH AND IN COLLABORATION WITH EXTERNAL PARTNERS, THE TEAM LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES INTERVENTION SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2022, MAJOR ACTIVITIES INCLUDED (1) CONTINUED LEADERSHIP OF MONITORING, EVALUATION, AND LEARNING WITHIN USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PORTFOLIO ACROSS SEVERAL COUNTRIES IN AFRICA AND SOUTHEAST ASIA; (2) LAUNCHED A NEW PHASE OF THE GATES FOUNDATION-SUPPORTED MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION ASSET TRACKER; (3) SUPPORTED PATH'S SENEGAL COUNTRY PROGRAM IN STARTING UP THE USAID URBAN HEALTH SYSTEM STRENGTHENING PROJECT IN DAKAR; AND (4) CONDUCTED SEVERAL LANDSCAPING ASSESSMENTS IN PARTNERSHIP WITH OTHER PATH TEAMS, INCLUDING THE PHC POLICY TRACKER (WITH THE ADVOCACY AND PUBLIC POLICY PROGRAM), BARRIERS AND OPPORTUNITIES IN THE NCD RESPONSE AT THE PHC LEVEL IN LMICS (WITH THE NCD TEAM), AND INTEGRATED COMMUNITY CASE MANAGEMENT ASSESSMENT IN SEVERAL COUNTRIES IN AFRICA (WITH THE MACEPA TEAM). HIV, TUBERCULOSIS, AND VIRAL HEPATITIS AS COVID-19 CONTINUED TO DISRUPT ACCESS TO ESSENTIAL HEALTH SERVICES, PATH'S HIV, TB, AND VIRAL HEPATITIS TEAM FOCUSED ON ADVANCING PERSON-CENTERED HEALTH CARE ACROSS AFRICA, CENTRAL ASIA, AND SOUTHEAST ASIA FOR GENERAL, KEY, AND PRIORITY POPULATIONS. METHODS INCLUDED PROMOTING INTEGRATED SERVICE DELIVERY MODELS PARTICULARLY WITHIN PRIMARY HEALTH CARE, ACCELERATING SELF-CARE INITIATIVES, AND LEVERAGING DIGITAL HEALTH TOOLS TO ENSURE EQUITABLE AND HIGH-QUALITY ACCESS TO HEALTH SERVICES. PATH IS A PARTNER UNDER THE USAID-FUNDED MICROBICIDE RESEARCH AND DEVELOPMENT TO ADVANCE HIV PREVENTION TECHNOLOGIES THROUGH RESPONSIVE INNOVATION AND EXCELLENCE (MATRIX) CONSORTIUM, AN INVESTMENT FOCUSED ON ADVANCING THE RESEARCH AND DEVELOPMENT OF A RANGE OF ACCEPTABLE, AFFORDABLE, SCALABLE, AND DELIVERABLE HIV PREVENTION PRODUCTS TO MEET THE UNMET NEEDS OF WOMEN AT RISK OF HIV. PATH SERVES AS THE CO-LEAD FOR THE BUSINESS MARKET DYNAMICS AND COMMERCIALIZATION ACTIVITY HUB, WHICH HELPS PRODUCT DEVELOPERS UNDERSTAND MARKET DYNAMICS AND HOW TO STRUCTURE PARTNERSHIPS TO ACCELERATE EVENTUAL ACCESS TO ESSENTIAL HIV PREVENTION AND DUAL PREVENTION PRODUCTS. PATH ALSO LEADS THE TECHNOLOGY ACCELERATOR ACTIVITY HUB, WHICH PROVIDES SEED GRANTS TO FUND PROOF-OF-CONCEPT OR FEASIBILITY STUDIES FOR POTENTIAL GAME-CHANGING HIV PREVENTION OR DUAL PREVENTION PRODUCTS. IN 2022, PATH LAUNCHED SOLICITATION PROCESSES TO IDENTIFY CONCEPTS FOR SEED FUNDING, RESULTING IN AN AWARD TO THE UNIVERSITY OF THE WITWATERSRAND TO CONDUCT EARLY PRODUCT DEVELOPMENT WORK ON A DISSOLVING VAGINAL TABLET TO PROTECT AGAINST HIV AND SEXUALLY TRANSMITTED INFECTIONS. PATH, WITH FUNDING FROM UNITAID THROUGH THE STAR-III PROJECT, CONTINUED TO SCALE UP ACCESS TO HIV SELF-TESTING (HIVST) IN INDIA, INDONESIA, AND UGANDA. IN 2022, THE PROJECT CONTINUED PROVIDING DIRECT TECHNICAL SUPPORT TO IN-COUNTRY PARTNERS TO DISTRIBUTE HIVST THROUGH DIVERSIFIED DISTRIBUTION MODELS, INFORMED BY A PROJECT-LED ASSESSMENT AND CO-DESIGN PROCESS. THE PROJECT TEAM ALSO SUPPORTED WILLINGNESS-TO-PAY ASSESSMENTS TO GENERATE MARKET-SHAPING DATA TO INFORM NATIONAL GUIDELINES AND PLANS FOR SUSTAINING HIVST. IN 2022 ALONE, THE PROJECT ASSISTED WITH THE DISTRIBUTION OF MORE THAN 170,000 HIVST KITS ACROSS INDIA, UGANDA, AND INDONESIA.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	PATH ALSO WORKED TO ADVANCE SELF-TESTING FOR HEPATITIS C (HCVST)IN INDIA AND VIETNAM WITH FUNDING FROM UNITAID. 2022 ACTIVITIES INCLUDED: KICKING OFF PROCUREMENTS OF HCVST KITS AND WORKING WITH LOCAL RESEARCH PARTNERS TO SUBMIT AND ADVANCE STUDY PROTOCOLS THROUGH RESEARCH APPROVAL PROCESSES IN INDIA, COORDINATING WITH LOCAL DISTRIBUTORS AND MANUFACTURERS TO IMPORT TWO HCVST PRODUCTS (ONE BLOOD-BASED AND ONE ORAL FLUID) INTO VIETNAM, AND ENGAGING WITH STAKEHOLDERS AND COMMUNITY ENTITIES TO CREATE DEMAND-GENERATION MATERIALS FOR HCVST IN VIETNAM. AS A PARTNER ON THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH WORKED TO ESTABLISH A GLOBAL MARKET FOR DIGITAL ADHERENCE TECHNOLOGIES (DATS) AND COMPLETED A MARKET ACCESS COUNTRY STAKEHOLDER SURVEY AND AN ANALYSIS OF DAT PLATFORMS. WE COMPLETED ENROLLMENT FOR DAT RESEARCH IN FOUR REGIONS OF UKRAINE, SCALED UP THE USE OF DATS IN SIX ADDITIONAL REGIONS THROUGH SUCCESSFUL ADVOCACY WITH THE UKRAINIAN GOVERNMENT, AND INITIATED A QUALITATIVE STUDY OF HEALTH WORKER EXPERIENCE WITH DATS. IN PARTNERSHIP WITH THE TB ALLIANCE, PATH WORKED TO ADVANCE A SHORTER TREATMENT (BEDAQUILINE, PRETOMANID, AND LINEZOLID, KNOWN AS BPAL) FOR MULTIDRUG-RESISTANT TB, COMPLETING ROADMAPS TO INTRODUCE BPAL IN PERU AND UKRAINE. IN DRC, PATH CONTINUED TO ADVANCE PERSON-CENTERED APPROACHES FOR HIV AND TB PREVENTION, TESTING, TREATMENT, AND MONITORING SERVICES THROUGH THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA. IN 2022, PATH FACILITATED THE INTRODUCTION OF A SHORTER REGIMEN FOR TB PREVENTIVE THERAPY, ENABLING MORE PEOPLE TO SUCCESSFULLY COMPLETE THEIR REGIMEN. PATH ALSO INTRODUCED A HUB-AND-SPOKE NETWORKING MODEL TO EXTEND THE REACH OF VERTICAL MOTHER-TO-CHILD TRANSMISSION OF HIV PREVENTION BY TRAINING PROVIDERS AT NON-PROJECT SUPPORTED MATERNITY HOSPITALS TO OFFER HIV TESTING SERVICES AND REFERRING THOSE TESTING POSITIVE FOR TREATMENT INITIATION. THE PROJECT ALSO CONTINUED TO OPTIMIZE THE PROVISION OF VIRAL LOAD MONITORING SERVICES, INTRODUCING A MONTHLY TRACKER TO CLOSELY MONITOR VIRAL LOAD SAMPLES ACROSS VARIOUS STAGES OF THE ANALYSIS AND RESULTS RETURN PROCESS AND MORE QUICKLY DEPLOY TECHNICAL ASSISTANCE TO ADDRESS BACKLOGS DELAYING RESULTS RETURN. USE OF THIS TOOL DECREASED THE OVERALL TURNAROUND TIME FOR VIRAL LOAD RESULTS BY SEVEN DAYS WITHIN SEVEN MONTHS. IN INDIA, PATH EXPANDED OUR FOOTPRINT IN SUPPORTING THE NATIONAL AIDS CONTROL PROGRAM WITH THEIR HIV RESPONSE, BUILDING ON OUR WORK TO STRENGTHEN NATIONAL- AND STATE-LEVEL (MUMBAI AND ANDRA PRADESH) STRATEGIC INFORMATION MANAGEMENT AND DATA USE SYSTEMS TO INTEGRATE HIV PREVENTION AND TESTING PROGRAMMING FOR KEY POPULATIONS AND MIGRANTS IN THREE NORTHEAST STATES OF INDIA. THIS WORK INCLUDED INTRODUCING INNOVATIVE MODELS FOR DECENTRALIZED PREVENTION AND TESTING SERVICES, SUCH AS DEPLOYING MOBILE UNITS ON MOTORBIKES TO OFFER HIV TESTING, LINKING TO PREVENTION AND TREATMENT SERVICES IN RURAL AREAS, AND ESTABLISHING STANDALONE CENTERS THAT PROVIDE A TAILORED PACKAGE OF HIV AND PHC SERVICES FOR YOUNG PEOPLE, PEOPLE WHO INJECT DRUGS, AND TRANS PEOPLE. IN SUPPORT OF TB PROGRAMMING IN INDIA, PATH INTRODUCED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION OF TREATMENT. WITH SUPPORT FROM USAID, PATH FACILITATED A NEEDS ASSESSMENT FOR TECHNICAL SUPPORT UNITS TO FOSTER LOCAL PRIVATE-SECTOR ENGAGEMENT ACROSS FIVE INDIAN STATES. PATH ALSO SUPPORTED REVISIONS AND UPDATES TO TB CONTROL STANDARDS IN PARTNERSHIP WITH WHO AND THE NATIONAL TB PROGRAM. IN 2022 IN KENYA, PATH CONTINUED TO PROVIDE A COMPREHENSIVE PACKAGE OF HEALTH, SOCIAL, AND ECONOMIC STRENGTHENING SERVICES FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE THROUGH THE PEPFAR-FUNDED NURU YA MTOTO PROJECT SUPPORTING 327 HEALTH FACILITIES TO DELIVER: CLINICAL SERVICES TO PREVENT VERTICAL TRANSMISSION OF HIV, TB/HIV COINFECTION SERVICES, CERVICAL CANCER SCREENING AND TREATMENT, AND VIRAL LOAD MONITORING. PATH ALSO IMPLEMENTED THE CHAK A CHAKA PROJECT, WHICH STRENGTHENS ECONOMIC SKILLS AMONG YOUNG WOMEN IN KISUMU, HOMA BAY, AND MIGORI COUNTIES TO REDUCE HIV RISK AND VULNERABILITY. IN 2022, PATH HELPED 1,225 YOUNG WOMEN BUILD SAVINGS AND ENTREPRENEURIAL SKILLS THROUGH ACCESS TO BUSINESS DEVELOPMENT AND VOCATIONAL TRAININGS, BUSINESS COMMUNITY CONNECTIONS, AND INSURANCE FUNDS. PATH PROVIDED CLINICAL EXPERTISE TO CREATE AND REVISE NATIONAL GUIDELINES AND PROTOCOLS FOR DRUG-SENSITIVE AND DRUG-RESISTANT TB IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN; DEVELOPED A TEXTBOOK FOR TB HEALTH CARE PROVIDERS IN TAJIKISTAN; AND REVISED INFECTION PREVENTION AND CONTROL GUIDELINES IN UZBEKISTAN. IN TANZANIA, THE USAID-FUNDED IDDS PROJECT SUPPORTED QUALITY MANAGEMENT AT ZONAL LABORATORIES, EQUIPMENT UPGRADES, AND PREPARATION OF THE LABORATORY NETWORK FOR THE INTRODUCTION OF THE TRUENAT TB TEST. TWENTY-ONE ZONAL LABORATORY STAFF WERE TRAINED ON QUALITY MANAGEMENT SYSTEMS, 50 ROUTERS WERE INSTALLED TO IMPROVE CONNECTIVITY FOR DATA REPORTING, AND 36 PEOPLE WERE TRAINED ON TRUENAT, ACHIEVING A PRE- TO POST-TEST KNOWLEDGE ASSESSMENT INCREASE FROM 51.9 PERCENT TO 80.4 PERCENT. THROUGH IDDS IN VIETNAM, PATH SUPPORTED THE NATIONAL TB PROGRAM BY ASSESSING THE IMPLEMENTATION OF DIAGNOSTIC INTERVENTIONS INCLUDING PEDIATRIC STOOL TESTING, HANDHELD PORTABLE X-RAY INTRODUCTION, AND THE APPLICATION OF ARTIFICIAL INTELLIGENCE FOR READING CHEST X-RAYS. IN DECEMBER 2022, PATH, IN COLLABORATION WITH THE UGANDA MOH AND YOUTH LEADERS, KICKED OFF WORK TO DEVELOP DIFFERENTIATED AND INTEGRATED HIV AND FAMILY PLANNING SERVICE DELIVERY MODELS, WITH A FOCUS ON EXPANDING ACCESS TO A RANGE OF HIV PREVENTION INCLUDING PRE-EXPOSURE PROPHYLAXIS (PREP) AND CONTRACEPTIVE OPTIONS FOR ADOLESCENT GIRLS AND YOUNG WOMEN IN UGANDA. THIS PROJECT AIMS TO APPLY HUMAN-CENTERED DESIGN TO ENGAGE YOUNG WOMEN (18-24 YEARS OF AGE) AND HEALTH WORKERS TO DESIGN AND PROTOTYPE MODELS, WITH A GOAL OF DOCUMENTING AND SHARING MODELS AS WELL AS RECOMMENDATIONS FOR HOW TO OFFER THE EXPANDING RANGE OF PREP PRODUCTS THROUGH SERVICE DELIVERY POINTS WHERE ADOLESCENT GIRLS AND YOUNG WOMEN ACCESS CONTRACEPTION. IN UKRAINE, PATH COMPLETED THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCED TB, HIV, AND HEPATITIS C TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. IN 2022, SEVERAL PROJECT INTERVENTIONS WERE SUCCESSFULLY TRANSITIONED TO GOVERNMENT LEADERSHIP, INCLUDING MEDICATION-ASSISTED THERAPY, PROVISION OF PSYCHOSOCIAL AND HIV SERVICES FOR PRE-TRIAL DETAINEES, AND INDEX CASE TESTING FOR CONTACTS OF DETAINEES NEWLY DIAGNOSED WITH HIV. PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2022, STBCEU IMPLEMENTED INDEX CASE TESTING FOR PATIENTS WITH TB IN PROJECT REGIONS: AMONG 8,276 INDEX PATIENTS, 19,521 CONTACTS WERE IDENTIFIED AND OF THESE 563 STARTED ON TB TREATMENT AND 7,589 ON TB PREVENTIVE TREATMENT (TPT). THE PROJECT ALSO: PROMOTED SHORTER TPT REGIMENS LEADING TO AN INCREASE IN USE OF THE REGIMENS FROM 60 PERCENT TO 78 PERCENT; SUPPORTED QUANTIFERON-GOLD TESTING TO DIAGNOSE LATENT TB INFECTION; INTRODUCED PORTABLE X-RAY MACHINES TO SUPPORT CASE FINDING IN REMOTE AREAS; AND, SUPPORTED CONFLICT-RELATED RESPONSE INCLUDING TRANSPORTATION, EMERGENCY SUPPLY PROCUREMENT, AND INTEGRATED HEALTH SCREENINGS FOR INTERNALLY DISPLACED PERSONS. IN VIETNAM, PATH CONTINUED EFFORTS TO REDUCE NEW HIV INFECTIONS IN PURSUIT OF ENDING AIDS BY 2030 THROUGH THE USAID SUPPORT FOR TECHNICAL EXCELLENCE AND PRIVATE SECTOR SUSTAINABILITY IN VIETNAM (STEPS) PROJECT. 2022 EFFORTS WERE INTENSIVELY FOCUSED ON ENSURING ACCESS TO KEY HEALTH TOOLS FOR HIVST DURING THE COVID-19 OMICRON SURGE, SCALING UP PREP, AND DELIVERING AN INTEGRATED KEY POPULATION AND CLIENT-CENTERED PACKAGE OF SERVICES THROUGH ONE-STOP-SHOP CLINICS, BUILDING ON SYSTEMS AND APPROACHES ADVANCED BY THE USAID/PATH HEALTHY MARKETS PROJECT (20142021). IN ZAMBIA, PATH COMPLETED THE USAID-FUNDED ERADICATE TB PROJECT IN 2022. THE PROJECT SUCCESSFULLY INSTITUTIONALIZED SEVERAL TB INTERVENTIONS, INCLUDING TECHNICAL SUPPORTIVE SUPERVISION TOOLS AT HEALTH FACILITIES, AN INTEGRATED TB/HIV SPECIMEN COURIER SYSTEM IN 30 HIGH-VOLUME TB NOTIFICATION DISTRICTS, ENHANCED ACCESS TO LABORATORY TESTING FOR TB, DECENTRALIZED DRUG-RESISTANT TB SERVICES, ONE-STOP TB/HIV CLINICS, AND MOBILE CLINICS IN REGIONS WITH LIMITED ACCESS TO TB SERVICES.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE:	NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES, CARDIOVASCULAR DISEASE, AND MENTAL HEALTH IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2022, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LMICS. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT AND IMPLEMENTATION OF A FORECASTING PROGRAM FOR NCD MEDICINES AND PRODUCTS IN KENYA AND UGANDA AND BEGAN EXPANSION INTO GHANA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, MALI, MOZAMBIQUE, RWANDA, SENEGAL, TANZANIA, UGANDA, AND VIETNAM THAT BUILD STRONGER PHC SYSTEMS, GREATER ACCESS TO ESSENTIAL NCD MEDICINES AND PRODUCTS, AND DATA-DRIVEN DECISION-MAKING ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY. OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING AND IMPLEMENTATION OF THE NCD NAVIGATOR, A FIRST-OF-ITS-KIND, LOCALLY MANAGED, NCD DIGITAL INFORMATION SYSTEM FOR RESOURCE PLANNING AND ALLOCATION IN ALL OF GHANA'S 16 REGIONS. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT CONDUCTED MORE THAN 700,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN KENYA, PATH IMPLEMENTED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MINISTRY OF HEALTH BUT CONTINUED TO PROVIDE TECHNICAL ASSISTANCE. WE ALSO BEGAN IMPLEMENTING SEVERAL INNOVATIONS TO STRENGTHEN SUPPLY CHAINS SUCH AS A STOCK TRACKER, AN ELECTRONIC MEDICAL RECORDS MODULE FOR NCD FACILITY DATA, AND LAST-MILE DISTRIBUTION. ADDITIONALLY, PATH IMPLEMENTED AN HIV-HYPERTENSION INTEGRATION PROJECT IN THREE FACILITIES IN WESTERN KENYA TO INCREASE ACCESS TO CARE. OUR PRIMARY HEALTH CARE MODEL IN VIETNAM USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENING AND LINKAGES TO CARE. IN 2022, WE DISSEMINATED RESULTS FROM A SUPPLY CHAIN ASSESSMENT TO DETERMINE THE AVAILABILITY AND AFFORDABILITY OF NCD MEDICINES AT THE PHC LEVEL AND TRAINED HEALTH CARE AND SUPPLY CHAIN PERSONNEL TO SUPPORT SUPPLY MANAGEMENT. IN SENEGAL, TANZANIA, AND RWANDA, PATH IMPLEMENTED THE HEALTHY HEART AFRICA PROJECT FOCUSED ON HYPERTENSION MANAGEMENT AT THE COMMUNITY LEVEL. PATH ALSO CONTINUED TO IMPLEMENT AND EXPAND THE DIABETES CAREPAK IN KENYA, MALI, MOZAMBIQUE, TANZANIA, AND UGANDA AN INNOVATIVE BUNDLING SOLUTION OF THE COMMODITIES NEEDED FOR SAFE ADMINISTRATION OF INSULIN AND DIABETES SELF-CARE. PATH HAS ALSO CONDUCTED SEVERAL RESEARCH AND LANDSCAPING ASSESSMENT PROJECTS. WE COMPLETED AN NCD SITUATIONAL ANALYSIS AND LANDSCAPING ASSESSMENT OF CHALLENGES AND OPPORTUNITIES, SPECIFICALLY FOCUSED ON HYPERTENSION AND DIABETES. WE ALSO INITIATED A SECONDARY RESEARCH PROJECT ON THE MENTAL HEALTH LANDSCAPE OF 22 COUNTRIES TO OUTLINE THE RESEARCH, POLICIES, AND PRACTICES AROUND MENTAL HEALTH IN A VARIETY OF LOW, MIDDLE, AND HIGH-INCOME COUNTRIES. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE AND GROUNDED IN AN UNDERSTANDING OF THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF SRH THROUGHOUT THE LIFE CYCLE. WE BUILD EVIDENCE, CREATE TOOLS AND RESOURCES, AND PROVIDE SERVICES THAT ARE CO-DESIGNED WITH AND FOR WOMEN AND GIRLS TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES, REDUCE BARRIERS, AND EXPAND OPTIONS. IN 2022, PATH RENEWED ITS COMMITMENT TO FAMILY PLANNING (FP) THROUGH THE FP2030 INITIATIVE AMPLIFYING A RIGHTS-BASED APPROACH TO ADVANCING HEALTH EQUITY. WE BELIEVE ALL PEOPLE HAVE THE RIGHT TO INFORMATION, PRODUCTS, AND QUALITY FAMILY PLANNING SERVICES REGARDLESS OF WHERE THEY LIVE, THEIR AGE, THEIR MARITAL STATUS, OR THEIR WEALTH. WITH ASSISTANCE FROM PATH AND PARTNERS, COUNTRIES HAVE CONTINUED TO ACCELERATE SCALE-UP OF THE CONTRACEPTIVE INNOVATION, SELF-INJECTION WITH SUBCUTANEOUS DMPA (DMPA-SC). LED BY PATH IN PARTNERSHIP WITH JSI, THE DMPA-SC ACCESS COLLABORATIVE IN 2022 PROVIDED TECHNICAL ASSISTANCE TO 18 COUNTRIES AND COLLECTED DATA FROM 13 COUNTRIES SHOWING MORE THAN 1 MILLION CLIENT SELF-INJECTION VISITS SINCE 2018. IN UGANDA, PATH AND THE MOH CONTINUE TO IMPLEMENT GROUNDBREAKING PERSON-CENTERED PROGRAMS TO DEMONSTRATE HOW SELF-INJECTION CAN BE OFFERED AT SCALE. IN ZAMBIA, PATH COLLABORATED WITH THE MOH TO DEVELOP PERSON-CENTERED SERVICE DELIVERY MODELS FOR INTEGRATING FP SERVICES INTO CHILDHOOD IMMUNIZATION PROGRAMMING. ACROSS 40 FACILITIES IN FOUR DISTRICTS, PUBLIC-SECTOR HEALTH WORKERS REACHED POSTPARTUM WOMEN WHO WISHED TO SPACE OR LIMIT BIRTHS AND RARELY INTERACTED WITH THE HEALTH SYSTEM. PATH'S LIVING LABS TEAM FACILITATED HUMAN-CENTERED PROGRAM DESIGN WORKSHOPS WITH WOMEN, THEIR MALE PARTNERS, AND LEADERS IN PHC, FP, AND IMMUNIZATION. TOGETHER, WE REIMAGINED THE INTEGRATION OF SERVICES THROUGH NINE APPROACHES TO MEET THE NEEDS OF MOTHERS AND INFANTS MORE HOLISTICALLY. PLANS ARE UNDERWAY WITH THE MOH TO MOBILIZE SCALE-UP OF THE APPROACHES DEVELOPED AND PILOTED THROUGH THE PROJECT. PATH CONTINUES TO BE A LEADER IN THE SELF-CARE MOVEMENT, SUPPORTING INDIVIDUALS AND FAMILIES WHO CHOOSE TO MANAGE THEIR OWN HEALTH. THROUGH THE SELF-CARE PIONEERS COALITION IN SENEGAL, THE MOH, PATH, AND PARTNERS DEVELOPED AND SECURED APPROVAL OF SENEGAL'S SELF-CARE GUIDELINES IN 2022. THESE ARE AMONG THE FIRST NATIONAL SELF-CARE GUIDELINES IN THE WORLD, AND THE FIRST IN FRANCOPHONE AFRICA. PATH'S TECHNICAL EXPERTISE WAS ALSO INSTRUMENTAL IN THE DEVELOPMENT OF AND ADVOCACY FOR RECENTLY APPROVED NATIONAL REPRODUCTIVE HEALTH SELF-CARE GUIDELINES IN KENYA, WHICH AUTHORIZE SELF-INJECTION OF DMPA-SC FOR THE FIRST TIME. WE ALSO PROVIDED TECHNICAL SUPPORT AND LEADERSHIP TO DEVELOP, SCALE UP, AND MAINSTREAM EVIDENCE-DRIVEN INNOVATIONS, INCLUDING THOSE RESPONSIVE TO DIVERSE ADOLESCENT AND YOUTH POPULATIONS. MEANINGFUL ADOLESCENT AND YOUTH ENGAGEMENT UNDERPINS OUR WORK. PATH CONTINUED SERVING AS A MEMBER OF WHO'S TECHNICAL ASSISTANCE COORDINATION MECHANISM ON ADOLESCENT AND YOUTH SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (AYSRHR) HELPING TO ENSURE THAT YOUNG PEOPLE ARE ABLE TO ACCESS SRH INFORMATION AND SERVICES; THAT AYSRHR PROGRAMS ARE WELL-DESIGNED, IMPLEMENTED, MONITORED, AND DOCUMENTED; AND THAT POLITICAL PROCESSES AND STRUCTURES ARE BETTER PREPARED TO INCLUSIVELY ADDRESS THE UNIQUE SRH NEEDS OF YOUNG PEOPLE. IN 2022, PATH'S TECHNICAL ASSISTANCE INCLUDED SUPPORT TO MINISTRIES OF HEALTH TO MEANINGFULLY ENGAGE ADOLESCENTS AND YOUTH THROUGHOUT THE POLICY CYCLE. PATH ALSO CONTINUED TO PARTICIPATE IN THE GUIDELINE DEVELOPMENT GROUP TO SUPPORT UPDATED WHO GUIDELINES ON PREVENTING CHILD MARRIAGE, RESPONDING TO THE NEEDS OF MARRIED GIRLS, AND INCREASING ACCESS TO AND UPTAKE OF CONTRACEPTION AMONG ADOLESCENTS. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NGOS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FP SUPPLIES AND SERVICES.
FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE:	IN ADDITION, WE COMPLETED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS AND BEGAN DATA ANALYSIS. FINALLY, WE PARTNERED WITH LMICS ON THE PLANNING, IMPLEMENTATION, AND ONGOING MONITORING OF NATIONAL HPV VACCINATION PROGRAMS. PATH PUBLISHED SEVERAL ARTICLES ON THE ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG INFANTS IN LMICS. ADDITIONALLY, PATH UPDATED OUR RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT, WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE, AND OUR CLINICAL TRIAL TRACKER, WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS. DRUG DEVELOPMENT THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE FROM EARLY RESEARCH TO INTRODUCTION. IN 2022, WE CONTINUED DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WITH OUR COMMERCIAL MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE CONTINUED TO IMPLEMENT THE MICRONUTRIENT AND EED ASSESSMENT TOOL (MEEDAT), A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. MEEDAT WAS USED IN STUDIES OF CHILDREN IN ZAMBIA AND TANZANIA, WITH ADDITIONAL STUDIES PLANNED IN KENYA AND MALAWI. PATH ALSO EXPLORED NEW USES AND PARTNERSHIPS FOR IOWH032, A DRUG CANDIDATE WE PREVIOUSLY DEVELOPED FOR TREATMENT OF CHOLERA, WHICH ALSO HAS POTENTIAL FOR TREATING OTHER DISEASES.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	ALSO, UNDER THE MEBCI 2.0 PROJECT, PATH WORKED WITH GHS TO DEVELOP A TRAINING MANUAL FOR PROVIDERS AT THE PHC LEVEL ON THE CARE, EFFECTIVE COMMUNICATION WITH MOTHERS, AND REFERRAL PROTOCOLS FOR CRITICALLY ILL AND SMALL BABIES TO THE FOUR PROJECT HOSPITALS. AFTERWARD WE SUPPORTED THE TRAINING OF 126 HEALTH PROVIDERS FROM 24 PHC FACILITIES. WITH APPROVAL FROM GLOBAL HEALTH MEDIA, PATH ALSO TRANSLATED VIDEOS ON CARING FOR SMALL AND SICK NEWBORNS INTO TWO POPULAR LOCAL LANGUAGES FOR USE IN EDUCATION AND AWARENESS RAISING AT THE POINT OF CARE AND IN COMMUNITIES. PATH ALSO WORKED TO STRENGTHEN IMMUNIZATION PROGRAMS IN GHANA IN 2022. WITH FUNDING SUPPORT FROM OPEN PHILANTHROPY RECOMMENDED TO PATH FROM GIVEWELL, WE SUPPORTED THE EXPANSION OF THE RTS,S MALARIA VACCINE TO 51 NEW DISTRICTS IN GHANA. PATH'S OTHER AREAS OF FOCUS TO SUPPORT IMMUNIZATION PROGRAMMING INCLUDED CONTINUING TO SUPPORT THE NATIONAL RESPONSE TO COVID-19, SUPPORTING THE INTRODUCTION OF HPV VACCINATION INTO ROUTINE IMMUNIZATION PROGRAMS, EXPANDING THE USE OF GEO-ENABLED DIGITAL MICROPLANNING, AND SUPPORTING THE LAUNCH OF NATIONAL GUIDELINES FOR INTRODUCING IMMUNIZATION SERVICE DELIVERY THROUGH COMMUNITY PHARMACISTS. WITH FUNDING SUPPORT FROM ASTRAZENECA, PATH SUPPORTED NCD PROGRAMMING IN GHANA THROUGH THE HEALTHY HEART AFRICA PROGRAM. IN 2022, PATH HELPED IMPROVE THE QUALITY OF HYPERTENSION SERVICE DELIVERY IN ASHANTI AND BONO EAST REGIONS BY SUPPORTING 11 DISTRICTS AND 50 HEALTH FACILITIES WITH OVER 300 BLOOD PRESSURE DEVICES AND TRAINING OVER 200 HEALTH WORKERS ON HYPERTENSION PREVENTION AND MANAGEMENT. WE ALSO SUPPORTED THE INTEGRATION OF HYPERTENSION CARE ACROSS MULTIPLE POINTS OF CARE WITHIN FACILITIES INCLUDING CHILD WELFARE CLINICS, FAMILY PLANNING UNITS, WELLNESS CLINICS, AND NATIONAL IMMUNIZATION DAYS TO IMPROVE ACCESS TO HYPERTENSION CARE AND REDUCE MISSED OPPORTUNITIES FOR SCREENING. PATH ALSO CONDUCTED TARGETED COMMUNITY ADVOCACY CAMPAIGNS AND SCREENINGS FOR PRIORITY GROUPS. AS PART OF THESE EFFORTS, WE SUPPORTED THE DEVELOPMENT OF THE HYPERTENSION CHAMPIONS PROGRAM, WHICH LEVERAGED INFLUENTIAL COMMUNITY MEMBERS AS AGENTS FOR HYPERTENSION AWARENESS, PREVENTION, AND CONTROL. PATH WORKED WITH THE GHS NCD PROGRAM TO INTRODUCE AND SCALE THE USE OF THE NCD NAVIGATOR TOOL TO ALL 16 REGIONS OF THE COUNTRY. PATH ALSO SUPPORTED THE MULTISTAKEHOLDER HIGH-LEVEL NCD ROUNDTABLE FORUM HELD IN GHANA IN APRIL 2022 AND DELIVERED A PRESENTATION ON FINANCING NCDS ON BEHALF OF GHANA'S NCD STEERING COMMITTEE. PATH WORKED TO STRENGTHEN SUPPLY CHAIN LEADERSHIP AND GOVERNANCE WITH FUNDING FROM THE ACCESS ACCELERATED PARTNERSHIP. WE INTRODUCED A FORECASTING TOOL AND TRAINED KEY HEALTH PROVIDERS AROUND PROCUREMENT, MEDICINES AND SUPPLIES, HEALTH INFORMATION AND DATA MANAGEMENT, AND FORECASTING FOR CLINICIANS. PATH ALSO CONDUCTED A BASELINE STUDY ON INSULIN INTEGRATION INTO GHANA'S COLD CHAIN SYSTEM AND SUPPORTED AN ONGOING PILOT OF THIS INTERVENTION AT THE GA-WEST MUNICIPALITY IN THE GREATER ACCRA REGION. KENYA THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT IS A FOUR-YEAR PROJECT (JULY 2019-MARCH 2024) FUNDED BY UNITAID. THE PRIMARY GOALS ARE TO IMPROVE PHC WORKERS' ABILITY TO DIAGNOSE SEVERE DISEASE BY EQUIPPING THEM WITH PULSE OXIMETRY (POX) AND CLINICAL DECISION SUPPORT ALGORITHMS (CDSA) AND TO ACCELERATE THE DEVELOPMENT OF NONINVASIVE DEVICES THAT AUGMENT THE FEATURES OF STANDARD PULSE OXIMETERS WITH ONE OR MORE ADDITIONAL VITAL SIGN MEASUREMENTS. THE TIMCI PROJECT IMPLEMENTATION PHASE WAS ROLLED OUT IN 2022 IN THREE COUNTIES: KAKAMEGA, KITUI, AND UASIN GISHU. SIXTY HEALTH FACILITIES COLLECTED ROUTINE POX AND CDSA CASE DATA ON SICK CHILDREN, WHILE THE UNIVERSITY OF NAIROBI CONDUCTED RESEARCH ON POX AND CDSA FEASIBILITY AND COST-EFFECTIVENESS IN 19 PHC FACILITIES. ONCE THE DATA ANALYSIS IS COMPLETED, PATH AIMS TO USE THE RESULTS TO INFORM COUNTY LEADERSHIP ENGAGEMENT FOR PRIORITIZATION AND BUDGETING FOR POX, HEALTH CARE PROVIDER TRAINING AND SCALE-UP OF PULSE OXIMETRY AND CDSA, AND ENGAGEMENT OF CIVIL SOCIETY ORGANIZATIONS FOR ADVOCACY AND AWARENESS CREATION ON USE OF POX AND CDSA. PATH'S NONCOMMUNICABLE DISEASES TEAM SUPPORTED SCALE-UP OF THE AFYA KIJIJINI PRIMARY HEALTH CARE PROJECT IN MAKUENI COUNTY WITH 26 SITES AND OVER 14,000 PATIENTS LINKED TO CARE THROUGH THE ACCESS ACCELERATED PROJECT, A MULTICOUNTRY INITIATIVE IN KENYA, GHANA, AND VIETNAM. PATH ALSO SUPPORTED STRENGTHENING OF MEDICINES DATA AVAILABILITY AND END-TO-END VISIBILITY DASHBOARDS WITH THE KENYA MEDICAL SUPPLIES AUTHORITY (KEMSA) WITH THE SAME FUND. WITH INTERNATIONAL FEDERATION OF PHARMACEUTICALS MANUFACTURERS & ASSOCIATIONS AND NOVO NORDISK FUNDING, PATH SUPPORTED THE CO-CREATION OF A DIABETES SELF-CARE BUNDLE TO BE USED BY PATIENTS LIVING WITH DIABETES IN PARTNERSHIP WITH THE MOH'S DEPARTMENT ON NCDS, PATH'S LIVING LABS, AND PATIENT GROUPS. OUR WORK CONTRIBUTED TO THE DEVELOPMENT OF PROTOTYPE KITS, PATIENT MANUALS, AND TRAINING MATERIALS. ADDITIONALLY, PATH SUPPORTED A PILOT PROJECT ON HIV AND HYPERTENSION WITH RESOLVE TO SAVE LIVES (RTSL) FUNDING IN KISUMU AND NYAMIRA COUNTIES. THROUGH THE NCD PROGRAM, PATH PROVIDED TECHNICAL STAFF EMBEDDED WITHIN MOH TO SUPPORT NCD PROGRAMMING INCLUDING FOR CANCER. THE ECD PROJECT IN KENYA SUPPORTED THE DEVELOPMENT OF POLICY DOCUMENTS THAT ENTRENCH ECD AS A PRIORITY PROGRAM NATIONALLY AND SUBNATIONALLY. THE PROJECT ALSO SUCCESSFULLY ADVOCATED FOR GOVERNMENT LEADERSHIP AND INVESTMENT IN ECD THROUGH THE LAKE REGIONAL ECONOMIC BLOC, ENSURING THAT COUNTY GOVERNMENTS ALLOCATE RESOURCES IN SECTORAL BUDGETS TO PROMOTE CHILD DEVELOPMENT. UNDER THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, THE DETERMINED, RESILIENT, EMPOWERED, AIDS-FREE, MENTORED, AND SAFE (DREAMS) PROGRAM AIMS TO REDUCE NEW HIV INFECTIONS AMONG ADOLESCENT GIRLS AND YOUNG WOMEN (AGYW) BY DELIVERING HIGH-QUALITY, COMPREHENSIVE, AND YOUTH-FRIENDLY PREVENTION SERVICES TO AGYW ENROLLED IN THE PROGRAM. THE PROGRAM ALSO AIMS TO REDUCE GENDER-BASED VIOLENCE (GBV) AND IMPROVE THE HEALTH SYSTEM RESPONSE TO POST-GBV CARE FOR AGYW. THE PROJECT ENROLLED AND HAS AN ACTIVE AGYW BASE OF 37,575 AND AN 87 PERCENT ACHIEVEMENT AGAINST TARGETS. THE ORPHANS AND VULNERABLE CHILDREN (OVC) INTERVENTION AIMS TO SAFEGUARD THE HEALTH, RIGHTS, AND WELFARE OF CHILDREN AND ADOLESCENTS, WORKING WITH COUNTY GOVERNMENTS, STAKEHOLDERS, AND LOCAL IMPLEMENTING PARTNERS. WE DELIVER HIGH-QUALITY HEALTH AND SOCIAL SERVICES TO OVC AND HOUSEHOLDS AFFECTED BY HIV AND HELP STRENGTHEN CHILD PROTECTION SYSTEMS AND SERVICE DELIVERY IN CLOSE COLLABORATION WITH THE DEPARTMENT OF CHILDREN SERVICES AND MOH. THE PROJECT ADMINISTERED CASE PLAN ACHIEVEMENT READINESS ASSESSMENTS (CPARAS) FOR 27,863 HOUSEHOLDS AND DEVELOPED CASE PLANS FOR 64,675 OVC, WHICH IS A 100 PERCENT ACHIEVEMENT FOR HHS WITH CASE PLANS. PATH'S MARKET DYNAMICS TEAM BEGAN IMPLEMENTING TWO PROJECTS IN KENYA DURING 2022 THAT WILL RUN THROUGH 2025: STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) AND SCALING ACCESS TO LIFESAVING EQUIPMENT (SCALE). PATH HAS CONDUCTED COUNTIES' NEEDS ASSESSMENTS IN THE SEVEN IMPLEMENTATION COUNTIES IN KENYA. WE CONDUCTED WORKSHOPS ON FINANCIAL PLANNING, PROCUREMENT TRAINING, AND BUDGETING TO SUPPORT EQUIPMENT AND INFRASTRUCTURE RELATED TO MEDICAL OXYGEN PRODUCTION, STORAGE, AND DISTRIBUTION. PATH ALSO SUPPORTED CAPACITY-BUILDING EFFORTS FOR COUNTY BIOMEDICAL ENGINEERS AND CLINICIANS ON DETERMINATION OF OXYGEN NEEDS AND ON RATIONAL USE OF OXYGEN. PATH LED ADVOCACY TRAINING WITH THE GOAL OF INCREASING DOMESTIC FINANCING TO ENSURE A SUSTAINABLE AND RESILIENT SUPPLY CHAIN FOR EQUIPMENT, SPARE PARTS, AND EQUIPMENT CONSUMABLES. UNDER THE SOURCE PROJECT WE HAVE SUPPORTED THE MOH IN THE DEVELOPMENT OF GUIDELINES ON PRODUCTION, DELIVERY, AND MANAGEMENT OF MEDICAL OXYGEN AND DEVELOPMENT OF OXYGEN INDICATORS TO BE INCORPORATED INTO THE NATIONAL HEALTH INFORMATION SYSTEM. UNDER THE SCALE PROJECT, PATH FOCUSED ON INCREASING ACCESS TO MNCH/PHC DEVICES, VIRAL LOAD TESTING, AND COLD CHAIN EQUIPMENT. PATH CONTINUED SUPPORTING THE EXPANSION OF IMMUNIZATION SERVICES IN KENYA. DISTRIBUTION OF THE RTS,S MALARIA VACCINE EXPANDED TO AN ADDITIONAL 26 HIGH-RISK SUBCOUNTIES IN 2022, MAKING A TOTAL OF 52 SUBCOUNTIES PROVIDING THE RTS,S VACCINE AS PART OF THE COUNTRY'S ROUTINE IMMUNIZATION. THROUGH GAVI TCA AND COVID-19 DELIVERY SUPPORT FUND, PATH HAS BEEN ABLE TO PROVIDE TECHNICAL SUPPORT AT NATIONAL AND SUBNATIONAL LEVELS ON COVID-19 VACCINATION. THROUGH USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PROJECT, PATH SUPPORTED THE COUNTRY IN REDUCING THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNIZED CHILDREN.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	WITH FINANCIAL SUPPORT FROM THE GATES FOUNDATION, PATH'S LIVING LABS PROJECT PARTNERED WITH HEALTH CARE WORKERS USING A HUMAN-CENTERED DESIGN APPROACH TO CO-CREATE SOLUTIONS FOR IMPROVING HEALTH WORKER MOTIVATION AND INCREASING VACCINE COVERAGE. PATH LIVING LABS ALSO COLLABORATED WITH ADOLESCENT GIRLS AND YOUNG WOMEN AND PREP SERVICE PROVIDERS IN HOMA BAY COUNTY TO JOINTLY DEVELOP FIVE SOLUTIONS AIMED AT ENHANCING AGYW ADHERENCE TO PREP. PATH LIVING LABS HAS, THROUGH USER ENGAGEMENT, ESTABLISHED THE SIGNIFICANCE OF THE MOTHER-CHILD HEALTH BOOKLET IN PROMOTING NURTURING CARE FOR EARLY CHILDHOOD DEVELOPMENT (NCFECD). IN 2022, WE CONTINUED TO FOCUS ON THE DEVELOPMENT OF TRAINING GUIDES AND OPERATING PROCEDURES AIMED AT EMPOWERING HEALTH CARE WORKERS AND COMMUNITY HEALTH VOLUNTEERS TO EFFECTIVELY INTEGRATE NCFECD AT FACILITY AND COMMUNITY LEVELS AND ENSURE HIGH-QUALITY IMPLEMENTATION. OUR LIVING LABS AND M-RITE TEAMS COLLABORATED TO REVIEW AND EVALUATE THE M-RITE CRISTA FRAMEWORK, WHICH FOCUSES ON ASSESSING THE TRANSFERABILITY OF COVID-19 DIGITAL SYSTEMS TO ROUTINE IMMUNIZATION. THIS FRAMEWORK PROVIDES A SYSTEMATIC PROCESS FOR COLLECTING EVIDENCE AND GENERATING RECOMMENDATIONS TO SUPPORT THE TRANSFER OF DIGITAL SYSTEMS FROM COVID-19 TO ROUTINE IMMUNIZATION PROGRAMS. TO ASSESS THE TOOL, THE LIVING LABS TEAM CONDUCTED EXPERT INTERVIEWS AND DESK REVIEWS AND PROVIDED VALUABLE FEEDBACK ON THE USABILITY AND EFFECTIVENESS OF THE TOOL, AIMING TO ENHANCE ITS OVERALL FUNCTIONALITY. IN COLLABORATION WITH THE NATIONAL VACCINES AND IMMUNIZATION PROGRAM (NVIP) TEAM, WE UNDERTOOK THE TASK OF REDESIGNING HPV MATERIALS WITH CONSIDERATION OF THE FEEDBACK RECEIVED FROM 16 COUNTIES WITH LOW PERFORMANCE IN HPV VACCINATION. THE GOAL WAS TO IMPROVE THE EFFECTIVENESS AND RELEVANCE OF THE MATERIALS, ENSURING THEY ADDRESS THE SPECIFIC CHALLENGES FACED BY THESE COUNTIES. BY INCORPORATING THE VALUABLE INSIGHTS GATHERED FROM A WORKSHOP WITH REPRESENTATIVES FROM LOW-PERFORMING COUNTIES, WE AIMED TO CREATE REDESIGNED HPV MATERIALS THAT ARE BETTER SUITED TO MEET THE NEEDS AND OVERCOME THE BARRIERS ENCOUNTERED IN PROMOTING HPV VACCINATION. PATH LIVING LABS, IN COLLABORATION WITH THE DIGITAL SQUARE TEAM, WAS INVOLVED IN ENHANCING THE MOH'S CHANJO KE PORTAL FOR COVID-19 VACCINATION SERVICES. AS PART OF THIS INITIATIVE, WE CONDUCTED AN ASSESSMENT OF CHANJO KE UTILIZATION IN KAJIADO AND NAKURU COUNTIES. THE ASSESSMENT YIELDED VALUABLE INSIGHTS THAT WILL GUIDE THE ENHANCEMENT PROCESS. ADDITIONALLY, WE FACILITATED A WORKSHOP INVOLVING KEY STAKEHOLDERS SUCH AS THE NVIP, MOH DIGITAL HEALTH TEAMS, COUNTY HEALTH MANAGEMENT TEAMS (CHMT), AND HEALTH CARE WORKERS. THIS COLLABORATIVE WORKSHOP WAS HOSTED TO REVIEW THE UTILIZATION FINDINGS, DEFINE WHAT NEEDS TO BE ENHANCED, AND CO-CREATE AND REFINE SYSTEM FEATURES FOR ENHANCEMENT. LIVING LABS ALSO PARTNERED WITH OTHER PATH TEAMS TO DESIGN A NEWBORN NUTRITION DIGITAL ADAPTION KIT (NNDAK) THAT PROVIDES DATA-INFORMED GUIDANCE TO OPTIMIZE CRITICAL FEEDING ACCORDING TO CLINICAL CARE GUIDELINES. THE NNDAK HAS THE POTENTIAL TO REDUCE HOSPITAL STAYS, IMPROVE NEWBORN NUTRITION, AND REDUCE MORBIDITY AND MORTALITY ASSOCIATED WITH LACK OF OPTIMAL NUTRITION EARLY IN LIFE. MALAWI IN 2022, PATH WORKED CLOSELY WITH THE HEALTH EDUCATION SERVICES (HES) IN THE MINISTRY OF HEALTH TO DEVELOP THE COMMUNICATION STRATEGY; MESSAGES; AND INFORMATION, EDUCATION, AND COMMUNICATION MATERIALS FOR THE INTRODUCTION OF THE RTS,S MALARIA VACCINE IN MALAWI. AS PART OF THE ADVOCACY, COMMUNICATION AND SOCIAL MOBILIZATION SUBCOMMITTEE, PATH ALSO WORKED WITH HES AND OTHER PARTNERS IN GETTING THE MESSAGES TO COMMUNITIES THROUGH POSTERS, LEAFLETS, FLYERS, COMMUNITY MEETINGS, AND VOLUNTEERS. WITH FUNDING FROM OPEN PHILANTHROPY, PATH SUPPORTED THE EXPANSION OF RTS,S FROM THE INITIAL 147 PILOT FACILITIES TO 281 HEALTH FACILITIES. WE ALSO WORKED WITH PARTNERS IN DEVELOPING AND DISTRIBUTING MESSAGES AND MATERIALS FOR THE INTRODUCTION OF THE TYPHOID CONJUGATE VACCINE. THROUGH THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) GLOBAL PROJECT, PATH SUPPORTED THE MOH IN IMPROVING ACCESS TO MEDICAL OXYGEN THROUGH THE IMPLEMENTATION OF THE MEDICAL OXYGEN ECOSYSTEM ROADMAP. WORKING WITH THE MOH, WE PROVIDED TECHNICAL ASSISTANCE IN THE DEVELOPMENT OF OXYGEN INDICATORS AND OXYGEN USAGE GUIDELINES AND CONTINUED TO SUPPORT A PILOT TESTING THEIR EFFECTIVENESS PRIOR TO NATIONAL SCALE-UP. PATH CONDUCTED MALAWI'S FIRST NATIONAL-SCALE MEDICAL EQUIPMENT INVENTORY ASSESSMENT, WHICH INCLUDED EVALUATING THE STATE OF AVAILABLE MEDICAL EQUIPMENT, QUANTIFYING THE GAPS IN AVAILABILITY AND FUNCTIONALITY OF MEDICAL EQUIPMENT, AND SUPPORTING THE DEVELOPMENT OF AN ESSENTIAL SPARE PARTS LIST FOR RESPIRATORY CARE EQUIPMENT (RCE) IN MALAWI TO SUPPORT THE MOH IN PLANNING BULK PROCUREMENT FOR RCE SPARE PARTS. OUR MARKET DYNAMICS TEAM ALSO LAUNCHED A MARKET LANDSCAPE SURVEY TO UNDERSTAND THE AVAILABILITY OF RCE SPARE PARTS ON THE LOCAL MARKET AND HOW TO BEST SUPPORT MARKET STIMULATION. MOZAMBIQUE 2022 MARKED PATH'S TENTH ANNIVERSARY IN MOZAMBIQUE. OVER THE LAST DECADE, THE CONRAD N. HILTON FOUNDATION HAS FUNDED PATH'S TECHNICAL ASSISTANCE TO INTEGRATE EARLY CHILDHOOD DEVELOPMENT (ECD) INTO THE HEALTH SYSTEM IN MOZAMBIQUE. AS PART OF THE HILTON PHASE IV ECD GRANT, PATH CONTINUED ITS LONG-TERM ADVOCACY AND SOCIAL MOBILIZATION EFFORTS TO ELEVATE NURTURING CARE FOR ECD IN THE GOVERNMENT'S AGENDA AT NATIONAL AND SUBNATIONAL LEVELS, WHICH RESULTED IN THE DEVELOPMENT OF GOVERNMENT-OWNED ECD ACTION PLANS IN NAMPULA AND MAPUTO PROVINCES; ENGAGEMENT OF SPOUSES OF GOVERNORS AND SECRETARIES OF STATE AS ECD CHAMPIONS IN THOSE TWO PROVINCES; AND INTEGRATION OF ECD INTO SEVERAL MNCHN POLICIES, GUIDELINES, AND TOOLS FOR INCREASED REACH OF NURTURING CARE INTERVENTIONS THROUGH INTEGRATED PHC SERVICE DELIVERY FOR THE YOUNGEST CHILDREN IN MOZAMBIQUE. PATH COLLABORATED WITH THE WORLD FOOD PROGRAMME (WFP) IN MOZAMBIQUE TO STRENGTHEN THE INTEGRATION OF NURTURING CARE, INCLUDING NUTRITION, EARLY LEARNING, AND RESPONSIVE CAREGIVING INTERVENTIONS INTO WFP'S EMERGENCY RECOVERY NUTRITION-SENSITIVE PROGRAMMING IN BUZI DISTRICT, SOFALA PROVINCE. THE NINE-MONTH PROJECT, IMPLEMENTED FROM OCTOBER 2021 TO JUNE 2022, RESULTED IN INCREASED CAPACITY OF 64 COMMUNITY HEALTH ACTORS TO IMPLEMENT THE MOH'S PACKAGE OF NUTRITION INTERVENTIONS (PIN); INCREASED QUALITY OF PIN SERVICE DELIVERY; AND INCREASED KNOWLEDGE OF OPTIMAL EARLY LEARNING AND RESPONSIVE CAREGIVING BEHAVIORS AMONG APPROXIMATELY 4,125 CAREGIVERS OF CHILDREN 0-24 MONTHS OF AGE, REACHED WITH NURTURING CARE FOR ECD BEHAVIOR CHANGE INTERVENTIONS. IN 2022, THE PATH TEAM IN MOZAMBIQUE LAUNCHED THE DIABETES CAREPAK PROJECT, A MULTICOUNTRY PROJECT FUNDED BY THE HELMSLEY CHARITABLE TRUST AND PHASE III OF THE PMI-FUNDED DIGITAL COMMUNITY HEALTH INITIATIVE (DCHI), IMPLEMENTED THROUGH DIGITAL SQUARE IN SEVERAL COUNTRIES. AS PART OF PHASE III OF THE DCHI, THE MOZAMBIQUE MOH SELECTED ONE PRIORITY AREA FOR STRENGTHENING THE COMMUNITY DIGITAL HEALTH ECOSYSTEM AMONG THE VARIOUS NEEDS IDENTIFIED THROUGH AN ASSESSMENT CONDUCTED IN PREVIOUS PHASES OF THE PROJECT. TO STRENGTHEN GOVERNANCE OF COMMUNITY DIGITAL HEALTH PLATFORMS, PATH SECONDED A COMMUNITY DIGITAL HEALTH ADVISOR TO THE PHC DEPARTMENT OF THE MOH TO DEVELOP A STRATEGIC PLAN FOR THE IMPLEMENTATION OF A COMMUNITY HEALTH INFORMATION SUBSYSTEM AND TO STRENGTHEN COORDINATION AMONG VARIOUS COMMUNITY DIGITAL HEALTH STAKEHOLDERS. SENEGAL IN 2022, PATH WAS SELECTED TO LEAD USAID'S INVESTMENT IN URBAN HEALTH PROJECT TO STRENGTHEN LOCAL URBAN HEALTH SYSTEMS AND IMPROVE HEALTH EQUITY IN DAKAR IN THREE HEALTH DISTRICTS: GUDIAWAYE, YEUMBEUL, AND KEUR MASSAR. PATH LEADS A CONSORTIUM OF PARTNERS IN THIS PROJECT, INCLUDING OPEN DEVELOPMENT, ACTION ET DEVELOPPEMENT (ACDEV), ALLIANCE DU SECTEUR PRIVE DE LA SANTE DU SENEGAL (ASPS), AND ENDA SANTE. PATH SUPPORTED USAID'S ENGAGEMENT WITH SEVERAL NATIONAL, REGIONAL, AND DISTRICT LEVEL STAKEHOLDERS, INCLUDING THE DAKAR REGIONAL MEDICAL OFFICER (RMO), THE DISTRICT HEALTH OFFICES (DHOS), THE DIRECTION GENERALE DE LA SANTE PUBLIQUE (DGSP), THE DIRECTION OF MATERNAL AND CHILD HEALTH (DSME), THE COORDINATOR OF THE TUBERCULOSIS PROGRAM, THE DIRECTION OF PLANIFICATION AND RESEARCH (DPRS), AND THE DIRECTION OF PRIVATE-SECTOR HEALTH FACILITIES. PATH ISSUED PRE-AWARD CONTRACTS TO PARTNERS IN OCTOBER 2022 TO KICK OFF THE INCEPTION PHASE ACTIVITIES. TO FACILITATE COORDINATION AND PLANNING, A TECHNICAL WORKING GROUP WAS ESTABLISHED, AND EACH PARTNER DEVELOPED A YEAR-ONE ACTION PLAN TO PROVIDE TECHNICAL SUPPORT TO THE DISTRICTS AND RMOS. UNDER THIS PLAN, PATH AND OPEN DEVELOPMENT CONDUCTED A FINANCIAL AND MANAGERIAL RISK ASSESSMENT TO EVALUATE THE CAPACITY OF DHOS AND RMOS TO RECEIVE AND ADEQUATELY MANAGE EXTERNAL FUNDING.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	PATH CONTINUED SUPPORTING THE SENEGALESE GOVERNMENT IN CONDUCTING TWO BIOMEDICAL EQUIPMENT INVENTORIES IN HEALTH FACILITIES AND COVID-19 TREATMENT CENTERS TO COLLECT DATA ON EXISTING MEDICAL EQUIPMENT, INCLUDING OXYGEN DEVICES, AND IDENTIFY GAPS IN OXYGEN ACCESS AND UTILIZATION. PATH DONATED THROUGH THE ACCESS TO COVID-19 TOOLS ACCELERATOR INITIATIVE OXYGEN DEVICES WORTH $1 MILLION TO SUPPORT THE MOH IN COVID-19 RESPONSE. WE ALSO SUPPORTED THE ASSESSMENT OF THE ONLINE MAINTENANCE MANAGEMENT SYSTEM TO IDENTIFY CHALLENGES THAT MAY DETER FUTURE SCALE-UP OF ACCESS AND UTILIZATION OF OXYGEN DEVICES AND DEVELOPED A VALUE-BASED PROCUREMENT GUIDE TO SUPPORT THE PROCUREMENT OF MEDICAL EQUIPMENT. PATH ALSO CONTRIBUTED TO THE DEVELOPMENT OF A MANUAL OF STANDARD OPERATING PROCEDURES TO SUPPORT PROCUREMENT AND MANAGEMENT OF NTD DRUGS TO RATIONALIZE RESOURCES DURING MASS DRUG ADMINISTRATION IN SENEGAL. PATH, THROUGH ITS MACEPA PROGRAM, CONTINUED SUPPORTING SENEGAL'S NATIONAL MALARIA CONTROL PROGRAM (NMCP) DURING 2022 IN THE IMPLEMENTATION OF MALARIA SURVEILLANCE AND ELIMINATION ACTIVITIES IN ELIGIBLE AREAS. THE MACEPA TEAM SUPPORTED SENEGAL'S HEALTH CARE SYSTEM IN THE TIMELY DETECTION, DOCUMENTATION, AND TREATMENT OF MALARIA CASES. PATH ALSO SUPPORTED DATA QUALITY AUDITS AND SUPERVISIONS OF THE DHIS2 TRACKER TO IMPROVE DATA QUALITY AND STRENGTHEN THE CAPACITY OF PROIVIDERS TO USE OF THE TOOL TO CAPTURE MALARIA CASE INVESTIGATION DATA. IN 2022 UNDER THE MACEPA IV PROJECT, PATH'S SENEGAL STAFF ALSO PROVIDED TECHNICAL AND FINANCIAL SUPPORT TO NMCP FOR THE INTRODUCTION OF CASE-BASED MALARIA SURVEILLANCE IN THE NORTH BANK REGIONS OF THE GAMBIA. KEY ACCOMPLISHMENTS INCLUDE THE DEVELOPMENT AND VALIDATION OF CASE-BASED MALARIA SURVEILLANCE GUIDELINES, STANDARD OPERATING PROCEDURES, AND DATA COLLECTION TOOLS. EIGHTY-TWO HEALTH CARE WORKERS WERE TRAINED ON CASE-BASED MALARIA SURVEILLANCE AND 31 HEALTH CARE WORKERS ON THE DHIS2 TRACKER. FIELD TESTING OF THE DHIS2 TRACKER WAS CONDUCTED TO ASCERTAIN THE EFFECTIVE FUNCTIONING OF THE APP. AS PART OF CROSS-BORDER COLLABORATION BETWEEN SENEGAL AND THE GAMBIA, PATH SUPPORTED A JOINT WORKSHOP WHERE A COMMON DATA VISUALIZATION PLATFORM WAS SET UP FOR THE SYNCHRONIZED MASS LONG-LASTING INSECTICIDAL NETS (LLIN) CAMPAIGN CONDUCTED IN 2022 FOR THE TWO COUNTRIES. IN PARTNERSHIP WITH RESOLVE TO SAVE LIVES, PATH SUPPORTED ESTABLISHMENT OF THE PUBLIC HEALTH EMERGENCY OPERATION CENTRE (PHEOC) THROUGH THE DEVELOPMENT OF THE LEGAL FRAMEWORK; SUPPORTED PROVISION OF INFORMATION AND COMMUNICATION TECHNOLOGY EQUIPMENT TO SUPPORT WATCH, ALERT, AND RESPONSE FUNCTIONS; AND SUBSEQUENTLY SUPPORTED THE RESPONSE TO ACUTE KIDNEY INJURY OUTBREAK (JULOCT 2022). WE FACILITATED MONTHLY COLLABORATION CALLS BETWEEN SENEGAL AND THE GAMBIA PHEOC FOR CROSS-BORDER LEARNING AND PUBLISHED MONTHLY EXPANDED PROGRAMME ON IMMUNIZATION (EPI) BULLETINS USING THE DHIS2 DASHBOARD. FOLLOWING SUCCESSFUL INTRODUCTION OF THE HPV VACCINE IN THE GAMBIA, PATH SIGNED A SERVICE AGREEMENT WITH GAVI FOR THE VACCINE VISIBILITY SYSTEM AND ONGOING HPV VACCINE TECHNICAL ASSISTANCE AND IMPLEMENTATION (TO BEGIN IN 2023). THE DIGITAL SQUARE TEAM CARRIED OUT VARIOUS ACTIVITIES AS PART OF THE GLOBAL VAX INITIATIVE IN SENEGAL. THESE INCLUDED THE DEVELOPMENT AND VALIDATION OF THE WORK PLAN AND BUDGET, AS WELL AS PARTICIPATION IN COORDINATION BODIES FOR COVID-19 CONTROL AND ROUTINE IMMUNIZATION. THE MAIN OBJECTIVE WAS TO SUPPORT THE AVAILABILITY OF QUALITY DATA FOR BETTER IMMUNIZATION MANAGEMENT. DIGITAL SQUARE PARTICIPATED IN COORDINATION MEETINGS WITH USAID PARTNERS AND THE KAFFRINE MEDICAL REGION TO DISCUSS THE RESULTS-BASED FINANCING INITIATIVE. IN ADDITION, A VIRTUAL MEETING WAS HELD WITH USAID IMPLEMENTING PARTNERS, THE PERMANENT SECRETARIAT OF ONE HEALTH SENEGAL, AND GOVERNORS TO OFFICIALLY LAUNCH COVID-19 IMMUNIZATION SCALE-UP ACTIVITIES AT THE REGIONAL LEVEL. A KEY FOCUS OF THIS WORK WAS THE RETROSPECTIVE ENTRY OF COVID-19 VACCINATION DATA INTO THE NATIONAL DHIS2 PLATFORM. DIGITAL SQUARE ORGANIZED WORKSHOPS TO ELIMINATE DATA ENTRY DELAYS IN 20 HEALTH DISTRICTS SPREAD ACROSS 10 MEDICAL REGIONS. ADDITIONALLY, DIGITAL SQUARE PROVIDED SUPPORT TO THE MINISTRY OF HEALTH THROUGH ITS EPI WITH THE ACQUISITION OF 624 SMARTPHONES FOR HEALTH FACILITY WORKERS IN SIX MEDICAL REGIONS. THESE SMARTPHONES WERE USED TO FACILITATE THE MANAGEMENT OF COVID-19 DATA AND STOCKS IN THE DHIS2 AND LOGISTIMO SYSTEMS. IN ADDITION, WE CONDUCTED INTERVIEWS TO ANALYZE THE ROOT CAUSES OF DATA ENTRY DELAYS IN SIX HEALTH FACILITIES IN THE KDOUGOU MEDICAL REGION. PATH CONTINUED WORKING WITH THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT IN SENEGAL. THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN IN 2022 WITH IMPLEMENTATION OF PULSE OXIMETRY AND CLINICAL DECISION SUPPORT ALGORITHMS (CDSA) AT 60 INTERVENTION SITES. SERVING AS THE LEAD PARTNER ON THE TIMCI PROJECT, PATH SUPPORTED THE MOH REVISION OF THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS. THROUGH THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT, PATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE THIRD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE TECHNICAL GUIDELINES, A KEY TOOL DEVELOPED BY THE WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR AFRICA (WHO AFRO) FOR THE IDENTIFICATION, MANAGEMENT, AND MITIGATI0N OF INFECTIOUS DISEASE OUTBREAKS. PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE. PATH ALSO WORKED WITH THE DIRECTORATE OF LABORATORIES IN DECENTRALIZING BACTERIOLOGY TESTING CAPACITIES BY INCLUDING SEVEN TIER 1 DIAGNOSTIC FACILITIES INTO THE NETWORK. PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF PRIVATE HEALTH FACILITIES IN INCORPORATING 12 PRIVATE CLINICS INTO THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM. THE ORGANIZATION COMPLETED THE EXPANSION OF THE COMMUNITY-BASED SURVEILLANCE OF PRIORITY HUMAN AND ZOONOTIC DISEASES IN THE TAMBACOUNDA REGION. WE ALSO PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF PREVENTION IN UPGRADING THE EARLY WARNING SYSTEM BY INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS. PATH'S DIGITAL SQUARE PROGRAM CONTINUED SUPPORTING SENEGAL'S MINISTRY OF HEALTH AND SOCIAL ACTION (MSAS) THROUGH USAID'S DIGITAL HEALTH COMMUNITY INITIATIVE (DCHI). IN 2022, DIGITAL SQUARE SUPPORTED THE MSAS IN DEVELOPING A COMMON VISION FOR COMMUNITY HEALTH DIGITIZATION USING THE COUNTRY PROFILE FINDINGS, THE DIGITAL HEALTH STRATEGIC PLAN, NMCP NATIONAL STRATEGIC PLAN, AND THE NATIONAL STRATEGIC COMMUNITY HEALTH PLAN. DIGITAL SQUARE ALSO SUPPORTED A HUMAN-CENTERED APPROACH TO DESIGNING THE DIGITAL COMMUNITY HEALTH TOOL BY CONDUCTING A USER NEEDS ASSESSMENT, A COLLABORATIVE REQUIREMENTS DEVELOPMENT METHODOLOGY (CRDM) WORKSHOP WITH KEY MSAS STAKEHOLDERS TO IDENTIFY 13 BUSINESS PROCESSES AND WORKFLOWS FOR COMMUNITY HEALTH AND 213 SYSTEM FUNCTIONAL REQUIREMENTS TO DEVELOP OR ADAPT THE DIGITAL TOOL. DIGITAL SQUARE SUPPORTED THE MSAS TO SELECT AN APPROPRIATE DIGITAL TOOL TO BE ADAPTED FOR COMMUNITY HEALTH DIGITIZATION IN A COLLABORATIVE WAY, INCLUDING THE HEALTH MANAGEMENT INFORMATION SYSTEMS (HMIS) EXPERTS FROM THE MSAS. THE DIGITAL SQUARE TEAM ALSO CONDUCTED A TWO-DAY WORKSHOP WITH A HEALTH ENTERPRISE ARCHITECTURE (HEA) EXPERT TO INTRODUCE THE CONCEPT OF HEA TO THE MSAS. NINE DIGITAL HEALTH EXPERTS FROM THE MSAS WERE SELECTED FOR THE OPEN GROUP ARCHITECTURE FRAMEWORK (TOGAF) TRAINING TO SUPPORT THE FUTURE DEVELOPMENT OF HEA IN SENEGAL. DIGITAL SQUARE'S SENEGAL TEAM ALSO WORKED TO STRENGTHEN THE USE OF COVAX DHIS2 AND IMPROVE THE MANAGEMENT OF COVID-19 VACCINATION DATA IN MALI. WE HOSTED ESSENTIAL TRAINING COURSES ON USE OF THE DHIS2 COVAX PACKAGE IN VARIOUS MEDICAL REGIONS, INCLUDING KAYES, SIKASSO, MOPTI, AND SGOU, AS WELL AS IN THE BAMAKO HEALTH DISTRICT. A TOTAL OF 104 HEALTH WORKERS, INCLUDING DATA MANAGERS AND COVID-19, VACCINATION, AND SURVEILLANCE FOCAL POINTS, WERE TRAINED IN THE COLLECTION AND MANAGEMENT OF DATA RELATING TO COVID-19 VACCINATION. PATH ALSO ORGANIZED DATA REVIEW MEETINGS IN THE MEDICAL REGIONS OF KAYES, SIKASSO, MOPTI, AND SGOU. THESE MEETINGS, WHICH USED DHIS2 AS A DATA VISUALIZATION AND ANALYSIS TOOL, WERE ATTENDED BY 188 REGIONAL AND DISTRICT STAFF. THEY PROVIDED AN OPPORTUNITY TO REVIEW IMMUNIZATION DATA IN DETAIL AND MONITOR PROGRESS IN EACH REGION. SUPERVISING VISITS WERE MADE TO THE KAYES AND KOULIKORO REGIONS TO PROVIDE PERSONALIZED SUPPORT TO 14 PEOPLE WHO HAD ALREADY BEEN TRAINED IN USE OF THE DHIS2 COVID-19 MODULE AND TO GUARANTEE THE QUALITY OF THE DATA COLLECTED AND ENTERED.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	TO FACILITATE RAPID AND SECURE DATA TRANSMISSION, DIGITAL SQUARE PROVIDED 180 INTERNET CONNECTIVITY KITS (KNOWN AS FLYBOXES) WITH 6-MONTH INTERNET PACKAGES TO THE MOH TO SUPPORT THE NATIONAL IMMUNIZATION CENTER AND HEALTH DISTRICTS IN SIX MEDICAL REGIONS (BAMAKO, KAYES, SIKASSO, KOULIKORO, SGOU, AND MOPTI) RESPONSIBLE FOR COVID-19 VACCINATION DATA COLLECTION. DIGITAL SQUARE ALSO HELPED UPDATE DHIS2 FORMS, ENSURING THEIR RELEVANCE AND ALIGNMENT WITH THE SPECIFIC NEEDS OF COVID-19 IMMUNIZATION DATA COLLECTION. THE TEAM DEVELOPED A USER GUIDE FOR THE COVAX DHIS2 PACKAGE, AS WELL AS A SPECIFIC GUIDE FOR DATA ANALYSIS. THESE GUIDES PROVIDE DETAILED INSTRUCTIONS ON HOW TO USE THE COVAX DHIS2 AND INTERPRET VACCINATION DATA. SOUTH AFRICA IN 2022 PATH ESTABLISHED A TECHNICAL ASSISTANCE PARTNERSHIP WITH THE PRIVATE OFFICE OF THE PRESIDENT (POP) IN SOUTH AFRICA, WHICH GREW FROM OUR SUPPORT TO THE PRESIDENT IN HIS LEADERSHIP ROLE WITH THE AFRICAN UNION (AU) COVID-19 COMMISSION. WE ADVISED THE PRESIDENT ON GLOBAL AND REGIONAL POLICY PROCESSES AIMED AT INCREASING ACCESS TO HEALTH TECHNOLOGIES, ESPECIALLY SUSTAINABLE MANUFACTURING. FOR EXAMPLE, WE DRAFTED A CONCEPT NOTE FOR POSITIONING SOUTH AFRICA AS HOST FOR A REGIONAL CENTRE OF REGULATORY EXCELLENCE (RCORE), A PARTNERSHIP BETWEEN THE POP AND THE SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY (SAHPRA). WE ALSO ADVOCATED THROUGH THE AU COVID-19 COMMISSION, TARGETING MULTILATERAL PROCUREMENT AGENCIES SUCH AS GAVI AND UNICEF TO PURCHASE AT LEAST 30 PERCENT OF VACCINES FROM AFRICAN MANUFACTURERS. ADDITIONALLY, ALONG THE SIDELINES OF THE WORLD HEALTH SUMMIT, PATH CO-CONVENED A SESSION IN PARTNERSHIP WITH THE POP THAT BROUGHT TOGETHER HIGH-PROFILE DELEGATES, INCLUDING THE SOUTH AFRICA DEPUTY MINISTER OF HEALTH, REPRESENTATIVES FROM GAVI, AND THE PRESIDENT OF THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) TO DELIBERATE ON MATTERS AFFECTING SUSTAINABLE MANUFACTURING SUCH AS POOLED PROCUREMENT OF AFRICAN-MANUFACTURED MEDICAL PRODUCTS, OFFSET GUARANTEES, AND MECHANISMS FOR EFFECTIVE TECHNOLOGY TRANSFER. STEMMING FROM PATH'S RELATIONSHIP WITH THE POP IN SOUTH AFRICA AS WELL AS PATH'S MEMORANDUM OF UNDERSTANDING WITH THE AFRICA CDC, PATH DRAFTED A PROPOSAL FOR THE HARMONISED ENTITY OF AFRICAN LEADERS IN TECHNOLOGIES FOR HEALTH (HEALTH), WHICH WILL BE HOUSED BY THE AFRICA CDC AND THE AU COVID-19 COMMISSION WITH A MANDATE TO ENSURE COORDINATED EFFORTS ON SUSTAINABLE PHARMACEUTICAL MANUFACTURING IN AFRICA AND REDUCE IMPORTATION OF BIOTECHNOLOGY AND HEALTH TECHNOLOGY. AS PART OF OUR PRIORITY TO ADVANCE MANUFACTURING POLICIES AND INCREASE DEMAND FOR LOCAL PRODUCTS, PATH SECURED A SEAT ON THE SOUTH AFRICA HEALTH PRODUCTS MASTER PLAN WORKING GROUP. THIS GROUP ENABLES PATH TO DIRECTLY INFLUENCE AND PROVIDE SUPPORT TO SOUTH AFRICA'S PLANS, THEREFORE SUPPORTING SKILLS TRANSFER AND STRENGTHENING THE RESEARCH AND DEVELOPMENT (R&D) POLICY ENVIRONMENT. WE ALSO PARTICIPATED IN THE SAMRC SUB-SAHARAN AFRICA FUNDERS FORUM WHERE WE DISSEMINATED RESEARCH AND REFLECTIONS FROM PATH'S DIAGNOSTICS AND CENTER FOR VACCINES INNOVATION AND ACCESS TEAMS TO INFORM THIS GROUP'S PRIORITIES. WE CONTINUED TO ADVOCATE ON THE AFRICAN MEDICINES AGENCY (AMA) RATIFICATION. IN SOUTH AFRICA, WE SAW THE CABINET APPROVE THE AMA TREATY AND INITIATE THE PROCESS OF SUBMITTING DOCUMENTS TO PARLIAMENT FOR RATIFICATION. TO ACHIEVE THIS MILESTONE, PATH PROVIDED TECHNICAL ASSISTANCE TO THE SOUTH AFRICAN NATIONAL DEPARTMENT OF HEALTH'S DIRECTORATE OF INTERNATIONAL HEALTH, INCLUDING PREPARING TECHNICAL BRIEFS AND TALKING POINTS. PATH HAS WORKED OVER THE PAST SEVERAL YEARS WITH SAHPRA TO IMPROVE ITS REGULATORY CAPACITY AND TO IMPROVE TRANSPARENCY AND COMMUNICATIONS. TO SUSTAIN VIBRANT R&D ADVOCACY AT COUNTRY AND REGIONAL LEVEL, PATH CONTINUED TO PROVIDE TECHNICAL ASSISTANCE AND CAPACITY STRENGTHENING TO A LOCAL COALITION, THE SOUTH AFRICA HEALTH TECHNOLOGIES ADVOCACY COALITION. TANZANIA IN 2022, THE DATA USE PARTNERSHIP PROJECT AN INITIATIVE LED BY THE GOVERNMENT OF TANZANIA WITH SUPPORT FROM THE GATES FOUNDATION THROUGH PATH FINALIZED THE RENOVATION OF THE CENTER OF DIGITAL HEALTH PREMISES, PAVING THE WAY FOR GOVERNMENT AND PARTNERS TO COLLABORATE AND COORDINATE DIGITAL HEALTH IMPLEMENTATION IN THE COUNTRY. PATH ALSO SUPPORTED THE DEVELOPMENT AND REVIEW OF THE DATA USE TOOL KIT AND DIGITIZATION OF THE TANZANIA HEALTH ENTERPRISE ARCHITECTURE (TZHEA) COMPLIANCE ASSESSMENT TOOL. THROUGH THE PEPFAR-CDC FUNDED HEALTH INFORMATION SYSTEM STRENGTHENING INITIATIVE FOR HIV AND TB PROJECT, PATH SUPPORTED INTEGRATION OF THE ELECTRONIC SAMPLE REFERRAL SYSTEM WITH THE SAMPLE TRANSPORTATION ON THE COURIER LOGISTIC SYSTEM (POSTA KIGANJANI) TO IMPROVE THE SAMPLE TRACKING MECHANISM FROM THE POINT OF COLLECTION TO TESTING. FURTHERMORE, WE ALSO SUPPORTED DEVELOPMENT OF THE ZANZIBAR LABORATORY INFORMATION SYSTEM AND UPGRADED THE TANZANIA HIV/AIDS CARE AND TREATMENT PATIENT RECORD SYSTEM TO INCLUDE BIOMETRIC FINGERPRINT. THE PATH-LED DIGITAL SQUARE PROJECT IN TANZANIA FACILITATED HEALTH INFORMATION MEDIATORS, DEVELOPED THE ZANZIBAR HEALTH INTEROPERABILITY LAYER FOR DATA EXCHANGE, AND SUPPORTED MOH HEALTH PROMOTION SERVICES IN IDENTIFYING, RELOCATING, AND MANAGING COMMUNITY-BASED WORKFORCES. PATH'S IDDS PROJECT TEAM SUPPORTED THE MOH IN REVIEWING THE AMR NATIONAL ACTION PLAN 2017-2022, ENHANCING TB DIAGNOSTIC CONNECTIVITY THROUGH SERVER INTEGRATION, DATA MIGRATION, AND GX-ALERT UPGRADES. PATH WITH SUPPORT FROM ASTRAZENECA SUCCESSFULLY LAUNCHED THE HEALTHY HEART AFRICA PROJECT IN DODOMA WITH STRONG INVOLVEMENT AND ATTENDANCE OF HIGH-LEVEL GOVERNMENT OFFICIALS. THROUGH THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) PROJECT, PATH SUPPORTED THE NATIONAL MEDICAL OXYGEN SCALE-UP PLAN, CORRECTIVE MAINTENANCE OF BIOMEDICAL EQUIPMENT, AND ROLLOUT OF MEDICAL EQUIPMENT AND INFRASTRUCTURE MANAGEMENT INFORMATION SYSTEM (MEIMIS)IN SEVEN REGIONS. UGANDA THROUGH THE USAID-FUNDED AND ICF-LED IDDS PROJECT, PATH SUPPORTED THE MINISTRY OF AGRICULTURE, ANIMAL INDUSTRIES, AND FISHERIES (MAAIF) TO IMPROVE DIAGNOSTIC CAPACITY IN THE ANIMAL HEALTH SECTOR BY IMPLEMENTING LABORATORY QUALITY MANAGEMENT SYSTEMS BASED ON THE INTERNATIONAL ORGANIZATION FOR STANDARDIZATION (ISO) 17025:2017 STANDARD AT FOUR ANIMAL HEALTH REGIONAL LABORATORIES. THIS WAS UNDERTAKEN AS PART OF THE PROCESS TO SUPPORT THE FIRST LABORATORY IN THE ANIMAL HEALTH SECTOR TO ACHIEVE ISO 17025 ACCREDITATION. PATH SUPPORTED THE NATIONAL ANIMAL DISEASES DIAGNOSTICS AND EPIDEMIOLOGY CENTER AND THE ANIMAL HEALTH NATIONAL REFERENCE LABORATORY WITHIN MAAIF TO DEVELOP AND ROLL OUT A MACRO-ENABLED EXCEL-BASED DATA ENTRY AND ANALYSIS TOOL TO ALL DISTRICTS AS A MEANS TO IMPROVE DATA ENTRY, QUALITY, ANALYSIS, AND REPORTING FOR ANIMAL HEALTH SURVEILLANCE SITES, WHICH HAD PREVIOUSLY BEEN USING A PAPER-BASED SYSTEM. THE IDDS PROJECT ALSO STRENGTHENED TB DIAGNOSIS CAPACITY OF THE LABORATORY NETWORK THROUGH THE PROCUREMENT AND INSTALLATION OF 38 TRUENAT TRUELAB MOLECULAR MACHINES WITH PORTABLE, BATTERY-OPERATED DEVICES THAT CAN RUN TESTS FOR RAPID TB DIAGNOSIS. THESE WERE INSTALLED AT 38 HIGH-VOLUME HEALTH FACILITIES TO IMPROVE PATIENT ACCESS TO TB AND RIFAMPICIN-RESISTANT DETECTION. PATH ALSO SUPPORTED THE DEVELOPMENT OF STANDARD OPERATING PROCEDURES AND WASTE MANAGEMENT GUIDELINES FOR COVID-19 VACCINATION ROLLOUT AND PROVIDED REGULATORY SUPPORT TO THE MOH TO EXPEDITE COVID-19 VACCINE AUTHORIZATION AND SHIPMENT INTO THE COUNTRY. THROUGH THE UNITAID-FUNDED HIV STAR III INITIATIVE, UGANDA HAS ACHIEVED SIGNIFICANT SCALE-UP IN HIV SELF-TESTING (HIVST) SERVICES. THE COUNTRY IS SET TO DISTRIBUTE 3.5 MILLION HIVST KITS ANNUALLY, MAKING IT THE LARGEST HIVST MARKET GLOBALLY. IN 2022, PATH DEVELOPED THE POST-MARKET SURVEILLANCE NATIONAL PLAN AND STANDARD OPERATING PROCEDURES FOR HIVST AND INTRODUCED THREE WHO-PREQUALIFIED BLOOD-BASED KITS INTO THE COUNTRY TO EXPAND CHOICE AND ACCESS. THESE CHANGES HAVE BEEN INTEGRATED INTO THE SUPPLY CHAIN AND OTHER SYSTEMS, LEADING TO THE GOVERNMENT'S REVIEW AND ADOPTION OF HIVST TRAINING MATERIALS FOR HEALTH CARE WORKERS AND DEVELOPMENT OF TRAINING MATERIALS FOR PEER HIVST DISTRIBUTORS. IN 2022 PATH ALSO PILOTED FOUR HIVST SERVICE DELIVERY MODELS IDENTIFIED THROUGH A USER-CENTERED APPROACH, TWO OF WHICH HAVE BEEN ADOPTED BY UGANDA'S MOH WITH SUPPORT FROM THE GLOBAL FUND. IN ADDITION, PATH HAS SUPPORTED THE BUNDLING OF SELF-CARE PRODUCTS BY PARTNERING WITH SOCIAL MARKETING ORGANIZATIONS, WHICH RESULTED IN INCREASED DEMAND FOR HIVST IN PRIVATE AND PUBLIC SECTOR.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	THE UGANDA SELF-INJECTION (SI) SCALE-UP PROJECT MADE SIGNIFICANT PROGRESS IN COLLABORATION WITH THE MOH AND PARTNERS TO SCALE UP SELF-INJECTION NATIONWIDE, WITH SELF-INJECTION AVAILABLE IN 85 PERCENT OF PUBLIC-SECTOR FACILITIES. PATH ADDRESSED GAPS IN SI SCALE-UP TRAINING, SUPERVISION, AND MONITORING, AND DISTRIBUTED TOOLS AND GUIDELINES IN 20 DISTRICTS THAT LACKED PARTNER SUPPORT. PATH ALSO SUPPORTED INTEGRATION OF DMPA-SC AND SI INTO THE NATIONAL PRE-SERVICE TRAINING CURRICULUM IN UGANDA AND ORIENTED 197 INSTRUCTORS ON THE CONTENT, WHO THEN TRAINED OVER 3,000 HEALTH WORKERS. IN PARTNERSHIP WITH INSUPPLY KENYA, PATH CONDUCTED A DMPA-SC SUPPLY CHAIN ANALYSIS AS PART OF THE REGIONAL TECHNICAL ASSISTANCE MECHANISM. THIS LED TO THE DEVELOPMENT OF AN ACTION PLAN TO ADDRESS KEY GAPS AND RECOMMENDATIONS WITH THE MOH AND PARTNERS, WHICH ARE PART OF THE UPDATED 20222024 NATIONAL DMPA-SC SELF-INJECTION SCALE-UP PLAN. PATH ACTIVELY PARTICIPATED IN THE DEVELOPMENT AND PILOTING OF THE SELF-CARE GUIDELINES USING SELF-INJECTION AS A SPRINGBOARD TO OTHER SELF-CARE INTERVENTIONS. THROUGH THE ADVOCACY AND PUBLIC POLICY PROGRAM, PATH SUPPORTED THE MOH, ALONGSIDE WHO AND UNICEF, TO DRAFT AND COST THE NATIONAL IMMUNIZATION STRATEGY (NIS) 2022-2026. IN 2022, PATH FACILITATED REESTABLISHMENT OF THE UGANDA PARLIAMENTARY FORUM ON IMMUNIZATION (UPFI) AND SUPPORTED DEVELOPMENT OF A FIVE-YEAR STRATEGIC PLAN INCLUDING A SET OF KEY PERFORMANCE INDICATORS TO GUIDE THEIR WORK. PATH ALSO TRAINED AND MENTORED 25 LOCAL IMMUNIZATION PARTNERS AND FACILITATED OPPORTUNITIES FOR THEM TO INPUT INTO KEY POLICY PROCESSES, SUCH AS THE NIS. ADDITIONALLY, WE SUCCESSFULLY LED THE ADVOCACY EFFORTS FOR THE GOVERNMENT TO FULFILL ITS CO-FINANCING OBLIGATIONS TO GAVI. PATH SUPPORTED THE COUNTRYWIDE ROLLOUT OF COLD CHAIN INFORMATION SYSTEM (CCIS), AN ODK-X BASED TOOL, TO DIGITIZE THE COLD CHAIN EQUIPMENT (CCE) INVENTORY AND GENERATE ACTIONABLE DATA FOR THE MAINTENANCE, MANAGEMENT, AND REPAIR OF CCE ASSETS. PATH ALSO SUCCESSFULLY TRAINED OVER 150 DISTRICT COLD CHAIN TECHNICIANS FROM 136 DISTRICTS AND 25 NATIONAL-LEVEL TECHNICIANS/SUPER USERS, EQUIPPED THEM WITH MOBILE DEVICES WITH THE APP INSTALLED, AND FACILITATED THEM TO CONDUCT CCE INVENTORY UPDATES. THROUGH THE COVID-19 DELIVERY SUPPORT PROJECT, PATH SECONDED TWO TECHNICAL OFFICERS TO THE MOH IMMUNIZATION PROGRAM TO FILL THE HUMAN RESOURCES CAPACITY GAP DUE TO THE COVID-19 PANDEMIC. AS PART OF THE HILTON-FUNDED AQUA STREAM PROJECT, PATH CONDUCTED JOINT MONITORING VISITS WITH THE MOH TO OBSERVE THE FUNCTIONALITY OF THE AQUA STREAM ONSITE CHLORINE DEVICES AND THE BENEFITS THAT THE DEVICES OFFERED TO THE TEN PILOT HEALTH FACILITIES. NUMEROUS STRONG USER TESTIMONIES ON HOW THE AQUA STREAM HAS CONTRIBUTED TO INFECTION PREVENTION AND CONTROL AT THE TEN PILOT HEALTH FACILITIES WERE OBTAINED. WITH RECOMMENDATION FROM THE HEALTH POLICY ADVISORY COMMITTEE AFTER A PRESENTATION OF AQUA STREAM PILOT PROJECT RESULTS, PATH CONDUCTED A JOINT EVALUATION VISIT WITH THE NATIONAL ADVISORY COMMITTEE ON MEDICAL EQUIPMENT TO HEALTH FACILITIES WHERE THE AQUA STREAM WAS DEPLOYED AND DETERMINED THAT THE AQUA STREAM CHLORINE WAS FOUND TO BE NON-CORROSIVE TO MEDICAL INSTRUMENTS AND FURNITURE. IN NOVEMBER 2022, PATH WORKED WITH THE MOH'S CLINICAL SERVICE DEPARTMENT ON THE DEPLOYMENT OF TWO AQUA STREAM DISINFECTANT GENERATORS TO SUPPORT THE NATIONAL EBOLA VIRUS DISEASE RESPONSE EFFORTS. ZAMBIA IN 2022, PATH CONTINUED TO COLLABORATE WITH ZAMBIA'S MOH. TO ACCELERATE ZAMBIA'S JOURNEY TO ELIMINATION, PATH'S MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA SUPPORTED THE MOH, THROUGH THE NATIONAL MALARIA ELIMINATION PROGRAMME, TO LAUNCH MALARIA CASE INVESTIGATION (MCI) AS PART OF ITS ONGOING EFFORTS TO END LOCAL TRANSMISSION OF MALARIA. MCI BUILDS ON A CENTRAL PLANK OF THE COUNTRY'S NATIONAL STRATEGY: TRAINING COMMUNITY HEALTH WORKERS (CHWS) TO TEST, TREAT, AND TRACK MALARIA IN THEIR HOME COMMUNITIES. PATH AND THE MOH CONTINUED TRAINING HEALTH FACILITY STAFF AND CHWS ON THE INTERVENTION AND HOW TO STRENGTHEN THEIR SKILLS IN THE FIELD AS PART OF THE MCI INTRODUCTION IN THE CHIKANKATA AND MAZABUKA DISTRICTS THAT BEGAN IN SEPTEMBER 2021. NEARLY 900 CASES OF MALARIA HAVE BEEN IDENTIFIED SINCE MCI BEGAN IN LATE 2021, WITH A MAJORITY OF THOSE INFECTIONS IN PEOPLE WHO HAD TRAVELED FROM OUTSIDE OF THE PROVINCE. PATH CO-FACILITATED A RELIGIOUS LEADER ORIENTATION FOR MUCHINGA, CENTRAL, AND COPPERBELT PROVINCES WITH FAITH LEADER ADVOCACY FOR MALARIA ELIMINATION (FLAME). FLAME CONDUCTED SUBNATIONAL ORIENTATIONS TO ESTABLISH FLAME CHAPTERS IN EACH OF THE COUNTRY'S TEN PROVINCES. PATH'S MACEPA TEAM PARTNERED WITH FLAME TO HOST ORIENTATIONS IN CENTRAL, COPPERBELT, AND MUCHINGA PROVINCES, SUCCESSFULLY ORIENTING ABOUT 250 RELIGIOUS LEADERS TO THE LOCAL MALARIA SITUATION, THE NATIONAL STRATEGY, KEY MALARIA MESSAGES, AND THEIR ROLE IN ZAMBIA'S PUSH TO END MALARIA. FAITH LEADERS ARE WELL POSITIONED TO DISSEMINATE MALARIA MESSAGES AND SUPPORT THE DEVELOPMENT OF COORDINATED NETWORKS AND STRATEGIC PARTNERSHIPS TO PRIORITIZE MALARIA AND STRENGTHEN HEALTH SYSTEMS AMONG INTERFAITH COMMUNITIES WITHIN THEIR PROVINCES. THE PAMO PLUS PROJECT IN ZAMBIA SUPPORTED THE NATIONAL MALARIA ELIMINATION PROGRAM (NMEP) TO TRAIN 1,723 CHWS AND 139 CHW SUPERVISORS IN MALARIA CASE MANAGEMENT AT THE COMMUNITY LEVEL IN THE FOUR SUPPORTED PROVINCES OF EASTERN, LUAPULA, MUCHINGA, AND NORTHERN. THE AIM IS TO TAKE MALARIA SERVICES CLOSER TO THE PEOPLE BY REDUCING TRAVEL TIME TO THE POINT OF CARE THEREBY ENCOURAGE EARLY CARE SEEKING. ADDITIONALLY, 2,423 COMMUNITY CHANGE AGENTS AND 400 FAITH LEADERS WERE TRAINED TO INFLUENCE BEHAVIOR CHANGE IN THEIR COMMUNITIES FOR INCREASED UPTAKE AND USE OF PROVEN MALARIA INTERVENTIONS. TO INCREASE UPTAKE OF SULFADOXINE-PYRIMETHAMINE (SP) AND INSECTICIDE-TREATED NETS, PAMO PLUS ORIENTED 1,405 SAFE MOTHERHOOD ACTION GROUPS THAT ENCOURAGE WOMEN TO GO FOR EARLY ANTENATAL CARE (ANC) BOOKING AND ADHERE TO RECOMMENDED SUBSEQUENT ANC VISITS. PAMO PLUS CONTINUED CONDUCTING A QUALITATIVE ASSESSMENT FOR THE PROACTIVE COMMUNITY CASE MANAGEMENT FOR MALARIA IN ZAMBIA (PROACT) STUDY TO DESCRIBE THE FEASIBILITY, CHALLENGES, AND BENEFITS OF PROACTIVE COMMUNITY CASE MANAGEMENT FROM THE PERSPECTIVE OF HEALTH FACILITY STAFF, CHWS, AND COMMUNITY MEMBERS. THE STUDY ALSO AIMS TO DESCRIBE COMMUNITY PERCEPTIONS OF THE DESIRABILITY, BENEFITS, AND EXPERIENCES OF THE CARE OFFERED THROUGH PROACTIVE CASE DETECTION. THE PROACT STUDY IS A THREE-YEAR RANDOMIZED CONTROL TRIAL (2021-2023) WITH THE GOAL OF COMPARING PASSIVE MALARIA CASE MANAGEMENT TO PROACTIVE MALARIA CASE MANAGEMENT TO DETERMINE WHICH OF THE TWO APPROACHES CAN REDUCE MALARIA INCIDENCE AND DEATHS QUICKER. THE PROACT STUDY ALSO CONDUCTED A BARRIER ANALYSIS TO EXPLORE BEHAVIORAL BARRIERS AND FACILITATING FACTORS AMONG SEGMENTED POPULATION GROUPS FOR THE ADOPTION, USE, AND MAINTENANCE OF PRIORITY BEHAVIORS. THE RESEARCH COMPRISED A QUALITATIVE COMPONENT THAT INCLUDED 160 INTERVIEWS (KEY INFORMANT INTERVIEWS AND FOCUS GROUP DISCUSSIONS WITH RELEVANT TARGET GROUPS). THE STRENGTHENING OXYGEN UTILIZATION AND RESPIRATORY CARE ECOSYSTEM (SOURCE) PROJECT SUPPORTED DEVELOPMENT OF THE NATIONAL MEDICAL OXYGEN STRATEGIC PLAN 20222026. THE MOH COMPLETED DEVELOPMENT IN NOVEMBER 2022 AND IS EXPECTED TO LAUNCH THE PLAN IN MAY 2023. DMPA-SC ACCESS COLLABORATIVE (AC) CONTINUED SUPPORTING THE FAMILY PLANNING TECHNICAL WORKING GROUP (FPTWG), INCLUDING HOSTING MEETINGS AND LEADING ON ADVOCACY FOR REPRODUCTIVE HEALTH POLICY. THE AC SUCCESSFULLY SUPPORTED THE SCALE-UP AND INTRODUCTION OF DMPA-SC AND SELF-INJECTION IN PRIVATE PHARMACIES IN ZAMBIA. THE PROJECT BUILT QUALITY ASSURANCE AND EVALUATION ACTIVITIES INTO THE INITIAL PRIVATE PHARMACY INTRODUCTION TO INFORM ADVOCACY FOR FUTURE SCALE-UP. THE AC ALSO WORKED WITH THE PHARMACEUTICAL SOCIETY OF ZAMBIA AND OTHER PARTNERS TO TRAIN 136 PHARMACIES AND 156 PHARMACISTS TO PROVIDE DMPA-SC AND TO TRAIN WOMEN TO SELF-INJECT. THROUGH THE CATALYTIC OPPORTUNITY FUND, PATH SUPPORTED TWO SUPERVISION AND MENTORING VISITS TO 136 PHARMACIES IN FOUR PROVINCES OF ZAMBIA. WITH FUNDING FROM THE HEWLETT FOUNDATION, PATH COMPLETED THE FP/IMMUNIZATION INTEGRATION PROJECT IN FOUR DISTRICTS OF SOUTHERN PROVINCE USING A HUMAN-CENTERED DESIGN (HCD) APPROACH. THE ZAMBIA DIGITAL COMMUNITY HEALTH PROJECT COMPLETED REQUIREMENTS GATHERING FOR THE COMMUNITY HEALTH INFORMATION PLATFORM AND CONTRACTED TWO TECHNICAL PARTNERS TO DEVELOP IT. THE PROJECT SUPPORTED THE MOH TO REVISE REPORTING INDICATORS FOR THE NATIONAL COMMUNITY HEALTH MANAGEMENT INFORMATION SYSTEM WHICH IS CURRENTLY PAPER BASED.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE:	FUNDED BY THE BAYER FOUNDATION, THE SUPPORT FOR COVID-19 VACCINE PREPAREDNESS, ROLLOUT, AND SURVEILLANCE PROJECT IN ZAMBIA INITIATED THE ENGAGEMENT OF TRADITIONAL LEADERSHIP WITH SUPPORT FROM THE SPECIAL ADVISOR TO THE PRESIDENT. PATH ORIENTED 57 HEADMEN (INDUNAS) AND 5 CHIEFS TO THE PROJECT. PATH ALSO HELPED DEVELOP A WASTEWATER SURVEILLANCE PROTOCOL (APPROVED BY RELEVANT RESEARCH AUTHORITIES), PROCURED A NOVEL TESTING METHOD, AND TRAINED KEY PERSONNEL ON ENVIRONMENTAL SURVEILLANCE FOR SARS-COV-2 AND OTHER PATHOGENS SAMPLING. IN 2022, QUALITATIVE INSIGHTS FROM LIVING LABS WERE AMPLIFIED WITH QUANTITATIVE ANALYSIS AND DATA VISUALIZATION TO DESCRIBE 26 ROOT CAUSES OF DEMOTIVATION AMONG FRONTLINE IMMUNIZATION PROVIDERS AND ANALYZE COMMONALITIES IN HCD-DERIVED THEORIES OF CHANGE. PATH CREATED THE INSIGHTS EXPLORER TOOL, AN INTERACTIVE DASHBOARD TO FACILITATE THE EXPLORATION OF THESE ROOT CAUSES, AND PUBLISHED IT ONLINE WITH PUBLIC ACCESS. THIS WEB-BASED INTERACTIVE COMMUNICATION PLATFORM DOCUMENTS LIVING LABS' HCD PROCESSES AND OUTPUTS IN KENYA AND ZAMBIA IN A FORMAT THAT FACILITATES EXPLORATION AND UNDERSTANDING OF KEY PROJECT QUALITATIVE INSIGHTS. THE GOAL IS TO ADVANCE PREVIOUS EFFORTS IN HCD GLOBAL HEALTH PROJECTS BY INCREASING TRANSPARENCY OF THE CONTINUUM OF CONTEXTUAL CHALLENGE THROUGH TO THE PROCESS OF GENERATING PROTOTYPES WITH END USERS. PATH'S LIVING LABS SUPPORTED THE DEVELOPMENT OF THE RELI DELIVERY SYSTEM, A LOW-COST, HYBRID PNEUMATIC-ELECTRIC INFUSION PUMP DESIGNED TO ADDRESS CHALLENGES FOUND IN RESOURCE-CONSTRAINED HEALTH SYSTEMS. IT IS A LOW-COST, RELIABLE, STURDY, AND EASY-TO-USE ALTERNATIVE TO CONVENTIONAL ELECTRIC INFUSION PUMPS. THE LIVING LABS TEAM SUPPORTED THE DESIGN OF THE RELI'S ELECTRONIC SUBSYSTEMS AND CONDUCTED A USER ASSESSMENT IN ZAMBIA TO UNDERSTAND THE CONTEXT OF USE AND USER PERCEPTIONS OF THE RELI, WHICH IS ESSENTIAL TO ACHIEVE OPTIMAL DESIGN OF THE SYSTEM. THE ASSESSMENT AIMED TO: (1) PROVIDE PROSPECTIVE USERS WITH AN OPPORTUNITY TO CONDUCT A SIMULATION OF AN INFUSION USING A PROTOTYPE OF THE RELI DELIVERY SYSTEM AND TO ASSESS USER EXPERIENCES OF THE USABILITY OF THE VARIOUS COMPONENTS OF THE DEVICE. (2) GATHER USER INPUT ON THE ACCEPTABILITY AND EASE OF USE OF THE RELI DELIVERY SYSTEM INCLUDING SETTING UP THE SYSTEM, ACTIVATING THE SYSTEM, AND COMPLETING A SIMULATION USING THE RELI DELIVERY SYSTEM. PATH AND FIND PARTNERED TO IMPROVE DATA COLLECTION AND MITIGATE CURRENT PAIN POINTS ASSOCIATED WITH COVID-19 DIAGNOSTIC TESTING IN LOW- AND MIDDLE-INCOME SETTINGS. THE TEAMS WORKED TO DEVELOP STANDARDS AND ENHANCE THE INTEROPERABILITY OF PATIENT AND DIAGNOSTIC DATA COLLECTION PLATFORMS WHILE INCORPORATING THEM INTO MOBILE HEALTH TOOLS. LIVING LABS IN ZAMBIA AND SENEGAL ENGAGED END USERS TO IDENTIFY AND VALIDATE NEEDS AND PRIORITIES AND WORKED WITH APPLICATION DEVELOPERS TO ITERATIVELY TEST AND REFINE THE DIGITAL HEALTH SOLUTION, USING OPERATIONAL RESEARCH AT COMMUNITY HEALTH FACILITIES.
FORM 990, PART VI, SECTION B, LINE 11B	THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM.
FORM 990, PART VI, SECTION B, LINE 12C	PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING.
FORM 990, PART VI, SECTION B, LINE 15	THE BOARD ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO AND DIVISION CHIEFS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD IN 2022. AT THE REQUEST OF THE BOARD, PATH ENGAGED FUTURE SENSE (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND DIVISION CHIEFS. FUTURE SENSE USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD REVIEWED THE FUTURE SENSE REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE DIVISION CHIEFS. ADDITIONALLY, FUTURE SENSE REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE.
FORM 990, PART VI, SECTION C, LINE 19	PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE.

For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.

Cat. No. 51056K

Schedule O (Form 990) 2021

Additional Data

Software ID:
Software Version:

- TIN:

SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBullet

Attach to Form 990.
MediumBullet

Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2021

Open to Public Inspection

Name of the organization

PATH

Employer identification number

91-1157127

Part I

Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.

(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity

Part II

Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	Yes	No
(1)FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	SZ	501(C)(3)		PATH	Yes
(2)PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA ACS PLAZA 4TH FL LENANA RD PO BOX NAIROBI KE	EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH	KE	501(C)(3)		PATH	Yes

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Cat. No. 50135Y

Schedule R (Form 990) 2021

Page 2

Part III

Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Part IV

Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity?
(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	Yes	No

Schedule R (Form 990) 2021

Page 3

Part V

Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.

Yes

1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?

a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................

b Gift, grant, or capital contribution to related organization(s) ............................

Yes

c Gift, grant, or capital contribution from related organization(s) ............................

Yes

d Loans or loan guarantees to or for related organization(s) ............................

e Loans or loan guarantees by related organization(s) ............................

f Dividends from related organization(s) ............................

g Sale of assets to related organization(s) ............................

h Purchase of assets from related organization(s) ............................

i Exchange of assets with related organization(s) ............................

j Lease of facilities, equipment, or other assets to related organization(s) .......................

k Lease of facilities, equipment, or other assets from related organization(s) ......................

l Performance of services or membership or fundraising solicitations for related organization(s) .....................

m Performance of services or membership or fundraising solicitations by related organization(s) .................

n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................

o Sharing of paid employees with related organization(s) ............................

p Reimbursement paid to related organization(s) for expenses ............................

q Reimbursement paid by related organization(s) for expenses ............................

r Other transfer of cash or property to related organization(s) ............................

s Other transfer of cash or property from related organization(s) ............................

If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.

(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1) PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA	C	3,713,487	FMV
(2) FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND	B	5,631,350	FMV
(3) PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA	B	9,001,439	FMV
(4) FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND	C	3,544,561	FMV

Schedule R (Form 990) 2021

Page 4

Part VI

Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(e) Are all partners section 501(c)(3) organizations?		(f) Share of total income	(g) Share of end-of-year assets	(h) Disproprtionate allocations?		(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
(a) Name, address, and EIN of entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	Yes	No	(f) Share of total income	(g) Share of end-of-year assets	Yes	No	(i) Code V-UBI amount in box 20 of Schedule K-1 (Form 1065)	Yes	No	(k) Percentage ownership

Schedule R (Form 990) 2021

Page 5

Part VII

Supplemental Information

Provide additional information for responses to questions on Schedule R. See instructions.

Return Reference	Explanation

Schedule R (Form 990) 2021

Additional Data

Software ID:
Software Version:

		Prior Year	Current Year
8	Contributions and grants (Part VIII, line 1h) .........	333,068,959	347,720,581
9	Program service revenue (Part VIII, line 2g) .........	0	0
10	Investment income (Part VIII, column (A), lines 3, 4, and 7d ) ....	9,205,357	4,226,978
11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	843,270	869,980
12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	343,117,586	352,817,539
13	Grants and similar amounts paid (Part IX, column (A), lines 1–3 )...	75,961,955	90,575,790
14	Benefits paid to or for members (Part IX, column (A), line 4).....	0	0
15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	135,407,327	138,417,115
16a	Professional fundraising fees (Part IX, column (A), line 11e) .....	0	0
b	Total fundraising expenses (Part IX, column (D), line 25) 2,510,590
17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e)....	123,975,347	117,640,612
18	Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25)	335,344,629	346,633,517
19	Revenue less expenses. Subtract line 18 from line 12.......	7,772,957	6,184,022
		Beginning of Current Year	End of Year
20	Total assets (Part X, line 16).............	307,073,332	335,091,155
21	Total liabilities (Part X, line 26).............	253,115,813	282,616,412
22	Net assets or fund balances. Subtract line 21 from line 20.....	53,957,519	52,474,743

Sign Here

	Signature of officer	Date

	Type or print name and title


4a	(Code: ) (Expenses $ 129,569,809 including grants of $ 38,931,915 ) (Revenue $ )
	THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION AND DATA USE, PRIMARY HEALTH CARE, DIAGNOSTICS, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, MALARIA AND NEGLECTED TROPICAL DISEASES, AND MORE.(CONTINUED ON SCHEDULE O)CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2022, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED COUNTRY-LED DIGITAL HEALTH TRANSFORMATION IN NUMEROUS WAYS. WORK CONTINUED ON THE DATA USE PARTNERSHIP, A PROJECT FUNDED BY THE BILL & MELINDA GATES FOUNDATION THROUGH WHICH PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS AND USE OF DATA. WITH SUPPORT FROM THIS PROJECT, THE GOVERNMENT PUBLISHED A REFRESHED DIGITAL HEALTH INVESTMENT ROADMAP, AN IMPORTANT STEP TO ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE PROJECT LAUNCHED AN IMPROVED HUMAN RESOURCES FOR HEALTH INFORMATION SYSTEM TO BETTER TRACK CREDENTIALS AND ALLOCATE HEALTH WORKERS ACROSS THE COUNTRY. THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - AND DEVELOPED A MODEL FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE FINDINGS AND RECOMMENDATIONS WERE PUBLISHED IN A REPORT AND A SERIES OF COMMUNICATIONS MATERIALS AND WERE SHARED AT EVENTS INCLUDING THE WORLD HEALTH SUMMIT.DIGITAL SQUARE, A PATH-LED INITIATIVE BACKED BY A UNITED STATES AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO $170 MILLION THROUGH 2026, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES. HIGHLIGHTS FROM 2022 INCLUDED UPDATING THE DIGITAL SQUARE GLOBAL GOODS GUIDEBOOK, LAUNCHING A NEW DIGITAL HEALTH TECHNOLOGIES FUNDING CALL (NOTICE G), AND RELEASING A NEW TOTAL COST OF OWNERSHIP TOOL. IN 2022, DIGITAL SQUARE ALSO ANNOUNCED THE DIGITAL RESULTS IMPROVE VACCINE EQUITY AND DEMAND (DRIVE DEMAND) PROJECT, A TWO-YEAR, $5 MILLION PARTNERSHIP WITH THE ROCKEFELLER FOUNDATION TO DEPLOY AND EXPAND THE USE OF DIGITAL HEALTH TOOLS IN FIVE COUNTRIES.PATH, WITH US CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING OVERALL HEALTH INFORMATION SYSTEM (HIS) SUPPORT ACTIVITIES AS PART OF THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM (TAP), WHICH PARTNERS WITH COUNTRIES TO BUILD LASTING DIGITAL HEALTH CAPACITY. IN 2022, THE TEAM BEGAN IMPLEMENTING THE THIRD YEAR OF THE PROJECT, WITH A FOCUS ON NATIONAL HEALTH DATA POLICIES AND GOVERNANCE, HEALTH INFORMATION SYSTEM STANDARDS, AND HEALTH INFORMATION SYSTEM WORKFORCE STRENGTHENING. THROUGH TAP, PATH WORKED TO STRENGTHEN HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN BOTSWANA, COTE D'IVOIRE, DEMOCRATIC REPUBLIC OF THE CONGO (DRC), ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, UGANDA, VIETNAM, AND ZAMBIA.IN 2022, PATH LAUNCHED THE DIGITAL HEALTH ECOSYSTEM (DHE) PROJECT IN PARTNERSHIP WITH MEDIC AND FUNDED BY THE BAYER FOUNDATION. THIS PROJECT SUPPORTS SUSTAINABILITY AND EXPANSION OF DIGITAL TOOLS FOR HEALTH BY HELPING LOCAL ENTREPRENEURS MORE EASILY ACCESS FINANCING, TECHNICAL RESOURCES, AND OPPORTUNITIES FOR SCALE. IN 2022, DHE LAUNCHED ITS FIRST ACCELERATOR PROGRAM AND IDENTIFIED AND FUNDED FOUR AFRICAN DIGITAL HEALTH ORGANIZATIONS TO EXPAND ACCESS TO TOOLS FOR COMMUNITY HEALTH. PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS, INCLUDING: TRANSFORM HEALTH; THE WORKING GROUP FOR RECOMMENDATIONS FOR G20 LEADERS; THE DIGITAL CONNECTED CARE COALITION; THE DIGITAL PUBLIC GOODS ALLIANCE, OF WHICH PATH BECAME A MEMBER IN MAY 2022; AND THE DIGITAL PUBLIC GOODS CHARTER CAMPAIGN.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.IN 2022, PATH SUPPORTED THE ADVANCEMENT OF AFFORDABLE, RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES; CONDUCTED PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATED A G6PD (GLUCOSE-6-PHOSPHATE DEHYDROGENASE) OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHED NINE PEER-REVIEWED ARTICLES. WE CONTINUED TO CONTRIBUTE TO THE AVAILABILITY OF COST-EFFECTIVE AND DEPENDABLE DIAGNOSTIC SOLUTIONS IN LOW-RESOURCE SETTINGS, ENSURING THAT COMMUNITIES IN NEED HAVE ACCESS TO TOOLS FOR AN ACCURATE AND TIMELY DIAGNOSIS.IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS). THIS INCLUDED DESIGNING AND PRODUCING 100 COVID-19 BENCHMARKING PANELS AND FACILITATING INDEPENDENT EVALUATION OF COVID-19 DIAGNOSTICS FOR THE WORLD HEALTH ORGANIZATION'S (WHO) EMERGENCY USE LISTING (EUL); COLLABORATING TO DEVELOP A PUBLICLY AVAILABLE INTERACTIVE DASHBOARD THAT STREAMLINED INFORMATION ON TECHNICAL SPECIFICATIONS, REGULATORY STATUS, AND SUPPLY OF COVID-19 TESTS, AIDING PROCUREMENT DECISIONS; SUPPORTING NATIONAL RESPONSES IN MULTIPLE COUNTRIES,INCLUDING QUANTIFYING SARS-COV-2 IN WASTEWATER AND ASSESSING COST-EFFECTIVENESS; COLLABORATING WITH MULTIPLE DIAGNOSTICS DEVELOPERS TO DEVELOP BLINDED PANELS TO TEST MOLECULAR DIAGNOSTIC ASSAYS AND ASSESS THE BEST-IN-CLASS CANDIDATES VIA IN-HOUSE STUDIES TO ENSURE UNBIASED PERFORMANCE EVALUATION; AND, CONDUCTING FEASIBILITY STUDIES IN BRAZIL TO EVALUATE THE EFFECTIVENESS OF CONTACT TRACING WITH SERIAL SELF-TESTING AND GENERATING EVIDENCE AND RESOURCES FOR IMPLEMENTATION. WE ALSO LAUNCHED THE DIAGNOSTIC IMAGE REPOSITORY, OFFERING OVER 35,000 OPEN-SOURCE IMAGES OF COVID-19 RAPID DIAGNOSTIC TESTS TO SUPPORT DEVELOPMENT OF ARTIFICIAL INTELLIGENCE-BASED SMART READERS, AND ESTABLISHED PARTNERSHIPS TO IMPROVE THE OPERATIONAL ASPECTS OF WHO'S EUL PROCESSES.WE CONDUCTED A CLINICAL TRIAL FOR ASSESSING PRESUMPTIVE TUBERCULOSIS (TB) CASES IN A LOW HIV PREVALENCE REGION (HANOI, VIETNAM) FOR THE PRESENCE OF A TB BIOMARKER, LIPOARABINOMANNAN, IN URINE. THIS WAS THE LARGEST COHORT OF ITS TYPE TO DATE (N=780) AND PATH WAS ABLE TO ASSESS THE PERFORMANCE OF TWO HIGHLY SENSITIVE IMMUNOASSAYS ON THESE SAMPLES. URINE SAMPLES WERE COLLECTED UNDER FULL ETHICAL APPROVAL AND WERE MADE AVAILABLE FOR USE BY OTHER DIAGNOSTIC DEVELOPERS WHO AIM TO IMPROVE OR DEVELOP NEW PRODUCTS.TO ENHANCE THE SECURITY OF LOCAL DIAGNOSTIC SUPPLY CHAINS IN LMICS, PATH CONDUCTED A COMPREHENSIVE LANDSCAPE ANALYSIS TO DETERMINE KEY MARKET FAILURES AND IDENTIFIED MARKET-SHAPING INTERVENTIONS NEEDED TO EXPAND ACCESS TO HIGH-QUALITY DIAGNOSTICS. THIS INCLUDED THE DEVELOPMENT OF AN INTERACTIVE DASHBOARD THAT CONSOLIDATED PUBLICLY AVAILABLE DATA ON DIAGNOSTIC COMPANIES WITH A MANUFACTURING PRESENCE IN AFRICA, LATIN AMERICA, AND SOUTHEAST ASIA. THE DASHBOARD INCREASED THE VISIBILITY AND AWARENESS OF THESE COMPANIES WITHIN EACH REGION WHILE PROVIDING AN OVERVIEW OF THEIR PRODUCT PORTFOLIOS AND QUALITY SYSTEMS.TO INCREASE ACCESS TO G6PD TESTING, ESSENTIAL FOR TREATING PLASMODIUM (P.) VIVAX MALARIA PATIENTS, WE BROKERED A VOLUME GUARANTEE FOR THE SD BIOSENSOR STANDARD G6PD TEST, THE SOLE QUANTITATIVE POINT-OF-CARE DIAGNOSTIC FOR THIS TYPE OF MALARIA. THIS GUARANTEE, PROVIDED BY MEDACCESS, SUPPORTS SD BIOSENSOR IN REDUCING THE PRICE OF THEIR POINT-OF-CARE G6PD DEVICE AND TESTING STRIPS FOR LMICS AND MORE IMPORTANTLY ENSURES SUPPLY SECURITY OF THE TEST THROUGH COMMITMENTS FROM THE SOLE MANUFACTURER.IN COLLABORATION WITH THE UK NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 29 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT THE DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW COST, SEROTYPE SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.

4b	(Code: ) (Expenses $ 94,042,875 including grants of $ 36,699,439 ) (Revenue $ )
	ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.IN 2022, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY PROVIDING EXPERTISE TO THE COVID-19 VACCINES GLOBAL ACCESS (COVAX) FACILITY, SUPPORTING VACCINE SUPPLY CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE MANUFACTURERS, STRENGTHENING COUNTRY DELIVERY READINESS, AND TRAINING PHARMACISTS IN GHANA AS VACCINATORS. WE ALSO COORDINATED GRANTS TO RESEARCH GROUPS CONDUCTING TRIALS OF COVID-19 VACCINES AT FRACTIONAL DOSES IN LOW-RESOURCE SETTINGS. WE SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL, THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, WE SUPPORTED STUDIES IN AUSTRALIA, BRAZIL, INDONESIA, MONGOLIA, AND PAKISTAN. IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED LMIC VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL MANUFACTURERS PREPARING FOR WHO PREQUALIFICATION SUBMISSION OR INSPECTION; SUPPORTED MANUFACTURERS IN CLINICAL TRIAL DESIGN AND REGULATORY FILINGS; BEGAN MAPPING THE CURRENT VACCINE MANUFACTURING CAPACITY IN AFRICA; AND SUPPORTED CLINICAL ASSAY DEVELOPMENT AND TECHNOLOGY TRANSFERS, AMONG OTHER ACTIVITIES. PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. IN 2022, PATH DISSEMINATED COLLABORATIVE STUDY RESULTS ON UNIVERSAL REAGENTS FOR SABIN INACTIVATED POLIO VACCINES. THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH CONTINUED STUDIES ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. PATH WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING AND SUBMITTED AN APPLICATION FOR JE VACCINE INTRODUCTION TO GAVI, THE VACCINE ALLIANCE, IN SEPTEMBER 2022. INTRODUCTION OF JE VACCINE IN BANGLADESH IS ANTICIPATED IN 2025.ALSO IN 2022, WE COMPLETED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE (MMCV). THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTINUED TO CONTRIBUTE TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE ROLLOUT OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP. PATH ALSO SERVED AS A COORDINATOR BETWEEN WHO, GAVI, AND GLOBAL PARTNERS TO IDENTIFY PATHWAYS TO ACCELERATE MMCV INTRODUCTION ONCE THE VACCINE IS MADE AVAILABLE. PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN JULY 2022, WHO PREQUALIFIED THE RTS,S MALARIA VACCINE, HAVING RECOMMENDED IT FOR BROADER USE IN 2021 TO CURB P. FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. IN NOVEMBER 2022, MALAWI BECAME THE FIRST OF THE THREE COUNTRIES TO EXPAND VACCINATION INTO THE SO-CALLED "COMPARATOR" AREAS OF THE PILOT PROGRAM. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO CONTINUED TO RESEARCH USE OF THE VACCINE ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION TO AVERT MALARIA IN HIGHLY SEASONAL SETTINGS.THE DEFEAT DIARRHEAL DISEASE INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2022 WAS THE NEED TO CONTINUE TO STRENGTHEN ROUTINE IMMUNIZATION COVERAGE DURING COVID-19 RECOVERY, USING ROTAVIRUS VACCINE AS AN EXAMPLE OF THE CHALLENGES AND OPPORTUNITIES.TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE THROUGH A PHASE III EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO CONTINUED A PHASE II STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL. PATH CONTINUED TO SUPPORT RESEARCH RELATED TO VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST SHIGELLA, ONE OF THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS, FOR WHICH THERE IS NO LICENSED VACCINE. WE CONDUCTED PRECLINICAL RESEARCH ON THE NOVEL, ORALLY ADMINISTERED, INACTIVATED WHOLE CELL SHIGELLA TRUNCATED MUTANT VACCINE CANDIDATE. WE ALSO INITIATED A CLINICAL TRIAL TO TEST TWO EXPERIMENTAL CHALLENGE STRAINS OF SHIGELLA TO INFORM THE FUTURE DEVELOPMENT OF SHIGELLA VACCINES. FINALLY, WE COMPLETED A SERIES OF STUDIES TO BETTER UNDERSTAND THE PUBLIC HEALTH VALUE OF POTENTIAL SHIGELLA VACCINES AND HELP INFORM DECISIONS BY INTERNATIONAL AGENCIES, FUNDERS, VACCINE DEVELOPERS, AND NATIONAL POLICYMAKERS.WE ALSO HOSTED THE 2022 VACCINES AGAINST SHIGELLA AND ENTEROTOXIGENIC ESCHERICHIA COLI CONFERENCE IN WASHINGTON, DC. THIS THREE-DAY INTERNATIONAL MEETING BROUGHT TOGETHER 270 ATTENDEES FROM 29 COUNTRIES TO SHARE RESEARCH RELATED TO THE DEVELOPMENT OF VACCINES AGAINST NEGLECTED DIARRHEAL PATHOGENS.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRISE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS. WE ALSO INITIATED WORK ON A PROJECT TO EVALUATE TWO DIFFERENT MEASLES AND RUBELLA MICROARRAY PATCHES. CLINICAL STUDY PREPARATIONS WERE UNDERWAY THROUGHOUT 2022. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WE PROVIDED SUPPORT TO THE GOVERNMENT OF NEPAL TO INTRODUCE TCV IN APRIL 2022 AND TO MAKE THE TRANSITION TO HAVE TCV IN ROUTINE IMMUNIZATION; WE CONTINUED TO SUPPORT THE GOVERNMENT OF MALAWI TO PLAN FOR TCV INTRODUCTION; AND PATH WORKED WITH NATIONAL DECISION-MAKERS TO ADVANCE APPLICATIONS FOR TCV INTRODUCTION. THE GOVERNMENT OF BANGLADESH, WITH PATH SUPPORT, SUBMITTED AN APPLICATION IN SEPTEMBER 2022. BURKINA FASO HAD A NEAR-FINAL APPLICATION IN 2022. IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES. TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HUMAN PAPILLOMAVIRUS (HPV) VACCINATION TO WHO AND OTHER STAKEHOLDERS. BASED ON THIS EVIDENCE, IN 2022, WHO ENDORSED A SINGLE-DOSE HPV VACCINATION SCHEDULE TO HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE III STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES. WE ALSO PUBLISHED AN HPV VACCINE PRODUCT CHOICE CALCULATOR FOR ASSESSING AND COMPARING COSTS OF HPV VACCINATION PROGRAMS.

4c	(Code: ) (Expenses $ 42,564,478 including grants of $ 7,016,849 ) (Revenue $ )
	AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA (DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA) WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR OFFICES INCLUDE:(CONTINUED ON SCHEDULE O)DRCIN 2022, PATH WORKED CLOSELY WITH THE MINISTRY OF HEALTH UNDER THE MASHAKO PLAN TO ADVANCE IMMUNIZATION COVERAGE AND COMBAT EPIDEMICS, PARTICULARLY POLIO. DEVELOPED BY THE MOH, THE PRIMARY AIM OF THE MASHAKO PLAN IS TO REDUCE THE NUMBER OF ZERO-DOSE CHILDREN THOSE WHO HAVE NOT RECEIVED ANY SCHEDULED VACCINES BY 35 PERCENT BY THE END OF 2025 AND TO INCREASE VACCINE COVERAGE THROUGH AN INITIAL PHASE OF VACCINATION CAMPAIGNS IN HAUT KATANGA, HAUT LOMAMI, ITURI, KASAI, KINSHASA, KWILU, MONGALA, TANGANYIKA, AND TSHUAPA PROVINCES. THESE NINE PROVINCES ARE MOST AFFECTED BY THE MEASLES AND POLIO EPIDEMICS AND ARE HOME TO HALF OF ALL CONGOLESE ZERO-DOSE CHILDREN. TO DATE, THE MASHAKO PLAN HAS BEEN GRADUALLY EXPANDED BETWEEN 2020 AND 2022 TO COVER ALL OF THE COUNTRY'S PROVINCES, GENERATING A 50 PERCENT INCREASE IN THE NUMBER OF VACCINATION SESSIONS COMPARED WITH 2018, RESULTING IN FULL VACCINATION COVERAGE RISING FROM 35 PERCENT TO 50 PERCENT BETWEEN 2018 AND 2020. IN 2022, PATH ALSO SUPPORTED THE MINISTRY OF PUBLIC HEALTH, HYGIENE, AND PREVENTION AND THE NATIONAL UNIVERSAL HEALTH COVERAGE COUNCIL IN THE FORMAL ADOPTION AND APPROPRIATION OF THE COSTED DIGITAL HEALTH INVESTMENT ROADMAP, WHICH AIMS TO ACCELERATE DIGITAL HEALTH TRANSFORMATION IN THE DRC. THE ROADMAP, SUPPORTED BY USAID AND DIGITAL SQUARE AT PATH AND ADOPTED FOLLOWING A ROUNDTABLE DISCUSSION THAT INCLUDED MORE THAN 90 PARTICIPANTS FROM THE DRC GOVERNMENT, DONOR ORGANIZATIONS, AND THE PRIVATE SECTOR WILL HELP TO PLOT A COURSE FOR STANDARDIZING THE DRC'S DIFFERENT DIGITAL PLATFORMS, TRAINING THOUSANDS OF HEALTH WORKERS, AND COMPUTERIZING THOUSANDS OF HEALTH CENTERS BY 2024.ETHIOPIAIN APRIL 2022, USAID-FUNDED SURVEILLANCE FOR MALARIA ELIMINATION (S4ME) PROJECT WAS LAUNCHED IN ETHIOPIA TO STRENGTHEN THE CAPACITY OF NATIONAL AND SUBNATIONAL MALARIA ELIMINATION EFFORTS. PATH PARTNERS WITH ADDIS CONTINENTAL INSTITUTE OF PUBLIC HEALTH IN THE IMPLEMENTATION OF THE S4ME PROJECT. THE S4ME TEAM ESTABLISHED THREE CLUSTER OFFICES IN HARAR, DEBREBERHAN, AND SHASHEMENE, OPERATING WITHIN THE HEALTH BUREAUS TO BRING SUPPORT CLOSER TO END USERS, FOSTER COLLABORATION WITH REGIONAL HEALTH BUREAUS AND ZONAL HEALTH DEPARTMENTS, AND ENSURE THE SUSTAINABILITY OF THE PROJECT. TO ASSESS THE IMPLEMENTATION STATUS OF THE NATIONAL MALARIA ELIMINATION PROGRAM (NMEP), PATH CONDUCTED A BASELINE SURVEY ACROSS 57 SUPPORTED WOREDAS (DISTRICTS) IN SEVEN REGIONAL STATES. SURVEY FINDINGS OF STRENGTHS AND GAPS IN THE NMEP WERE USED IN DESIGNING TARGETED AND TAILORED SUPPORT FOR MALARIA SURVEILLANCE AND ELIMINATION EFFORTS. AFTER USAID RECEIVED A REQUEST FOR SUPPORT FROM THE MOH AND THE GLOBAL FUND COUNTRY COORDINATING MECHANISM, UNDER THE S4ME PROJECT, PATH ALSO MANAGED THE HIRING PROCESS FOR TWO CONSULTANTS, BOTH INTERNATIONAL AND LOCAL, TO PROVIDE EXPERTISE THAT WILL STRENGTHEN ETHIOPIA'S APPLICATION FOR FUNDING FROM THE GLOBAL FUND. PATH CONTINUED RUNNING THE MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM IN ETHIOPIA. IN 2022, THE MACEPA TEAM CUSTOMIZED THE PUBLIC HEALTH EMERGENCY MANAGEMENT DISTRICT HEALTH INFORMATION SYSTEM-2 (DHIS2) TO MONITOR WEEKLY AND IMMEDIATELY REPORTABLE DISEASES (ENHANCING THE CAPACITY FOR DISEASE SURVEILLANCE), AND CREATED USER ACCOUNTS FOR 40,000 HEALTH FACILITIES. IN PARTNERSHIP WITH THE ETHIOPIAN PUBLIC HEALTH INSTITUTE, THE PROJECT INTRODUCED A DIGITAL SOLUTION USING THE DHIS2 TRACKER SYSTEM TO CAPTURE TRAVELERS' VACCINATION STATUS, FACILITATING THE RECORDING OF ADMINISTERED VACCINES AND ADVERSE REACTIONS. MOREOVER, THE MACEPA TEAM PLAYED A KEY ROLE IN MALARIA RISK STRATIFICATION FOR TARGETED INTERVENTIONS AND RESOURCE ALLOCATION. COLLABORATING WITH THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO, THE FEDERAL MINISTRY OF HEALTH (FMOH), THE ARMAUER HANSEN RESEARCH INSTITUTE, AND THE AMHARA PUBLIC HEALTH INSTITUTE, THE PROJECT CONDUCTED STUDIES TO UNDERSTAND MALARIA TRANSMISSION DYNAMICS IN HIGH-RISK POPULATIONS.PATH ALSO SUPPORTED THE GATES FOUNDATION'S HPV COST OF DELIVERY STUDY PROJECT. IN 2022, PATH CONDUCTED A COMPREHENSIVE HPV VACCINE COST OF DELIVERY STUDY IN ETHIOPIA, PROVIDING INSIGHTS INTO THE OPERATIONAL AND CONTEXTUAL FACTORS, AND THE OVERALL COSTS, OF THE HPV VACCINATION PROGRAM AMONG 14-YEAR-OLD GIRLS. RECOMMENDATIONS WERE MADE TO IMPROVE PROGRAM EFFICIENCY AND EXPAND VACCINATION TO MULTI-AGE COHORTS, TARGETING GIRLS AGED 9 TO 14 YEARS. UNDER USAID'S TARGETED AND TAILORED COVID-19 MASS VACCINATION PROJECT, PATH WORKED WITH THE ETHIOPIAN GOVERNMENT TO MITIGATE THE COVID-19 PANDEMIC BY PROVIDING SUPPORT IN COORDINATION AND PLANNING, CAPACITY BUILDING, SERVICE DELIVERY, DEMAND GENERATION, AND MONITORING AND EVALUATION OF VACCINATION CAMPAIGNS. THE PROJECT PLAYED AN ACTIVE ROLE IN FACILITATING THE INTEGRATION OF COVID-19 VACCINATION INTO THE ROUTINE IMMUNIZATION PROGRAM AND PROVIDED CAPACITY BUILDING, SUPPORTIVE SUPERVISION, AND DATA MANAGEMENT SUPPORT TO SIX REGIONS. THE PROJECT TEAM ACTIVELY CONTRIBUTED TO THE DEVELOPMENT OF GUIDELINES FOR COVID-19 VACCINATION INTEGRATION INTO THE EXISTING ROUTINE IMMUNIZATION SYSTEM WITH THE AIM TO INCREASE UPTAKE AND IMPROVE ACCESS TO THE COVID-19 VACCINE. PATH ALSO WORKED WITH THE GATES FOUNDATION'S COVID-19 VACCINE HESITANCY PROJECT IN ETHIOPIA TO ADDRESS COVID-19 VACCINE HESITANCY THROUGH DATA-DRIVEN, TAILORED, CULTURALLY SENSITIVE, AND INCLUSIVE COMMUNICATION INTERVENTIONS IN ADDIS ABABA AND BAHIR DAR CITY ADMINISTRATIONS. PATH CONTINUED WORKING AS PART OF GAVI'S TARGETED COUNTRY ASSISTANCE (TCA) PROJECT TO SUPPORT THE FMOH AND THE AFAR AND SOMALI REGIONS IN ACHIEVING INCREASED AND EQUITABLE IMMUNIZATION COVERAGE WITH A FOCUS ON IDENTIFYING, MAPPING, AND REACHING ZERO-DOSE CHILDREN, UNDER-IMMUNIZED CHILDREN, AND MISSED COMMUNITIES. THE PROJECT TEAM DEVELOPED A PLAN TO SUSTAIN HEALTH FACILITIES WHILE PREPARING TO EXIT FROM THE FOUR SUPPORTED WOREDAS IN THE AFAR AND SOMALI REGIONS. PATH'S ETHIOPIA SENIOR MANAGEMENT TEAM VISITED FACILITIES IN THE AFAR AND SOMALI REGIONS TO ASSESS THE IMPACT OF THE GAVI TCA PROJECT IN THE FACE OF PROLONGED CONFLICT IN NORTHERN ETHIOPIA. WE ALSO PROVIDED TECHNICAL SUPPORT ON LEADERSHIP, MANAGEMENT, AND GOOD GOVERNANCE TO THE NATIONAL AND REGIONAL EXPANDED PROGRAM ON IMMUNIZATION TEAMS UNDER GAVI'S COVID-19 VACCINE DELIVERY SUPPORT LEADERSHIP MANAGEMENT COORDINATION PROJECT. PATH CONTINUED IMPLEMENTING USAID'S BRUEH TESFA DEMONSTRATING PATHWAYS TO SCALE FOR NURTURING CARE THROUGH ENGAGEMENT, LEADERSHIP, AND SYSTEMS STRENGTHENING PROJECT, WORKING TO INTEGRATE ETHIOPIA'S EARLY CHILDHOOD DEVELOPMENT POLICY FRAMEWORK INTO MATERNAL AND CHILD HEALTH PROGRAMS AND PROMOTING MULTISECTORAL COLLABORATION.GHANAIN 2022, PATH WORKED IN COLLABORATION WITH THE GHANA HEALTH SERVICE (GHS) TO EXPAND THE ONSITE CHLORINE GENERATION PROJECT TO THREE ADDITIONAL REGIONS WITH 40 AQUA RESEARCH STREAM CHLORINE GENERATORS INSTALLED IN 24 HEALTH CARE FACILITIES. WE ALSO SUPPORTED REFRESHER TRAINING FOR OVER 200 HEALTH WORKERS IN INFECTION PREVENTION AND CONTROL PRACTICES AS PART OF THIS PROJECT.WITH FUNDING FROM THE UK FOREIGN, COMMONWEALTH, AND DEVELOPMENT OFFICE, PATH SUPPORTED THE INTRODUCTION OF THE ELLAVI UTERINE BALLOON TAMPONADE (UBT) INTO THE POSTPARTUM HEMORRHAGE MANAGEMENT AND SAFE MOTHERHOOD PROTOCOLS IN GHANA. PATH COLLABORATED WITH THE MANUFACTURER SINAPI BIOMEDICAL IN SOUTH AFRICA TO IDENTIFY A LOCAL DISTRIBUTER AND REGISTERED THE ELLAVI UBT IN GHANA. WE ALSO SHARED A POLICY BRIEF WITH THE GHS POLICY, PLANNING, MONITORING, AND EVALUATION DIVISION FOR COUNTRY SCALE-UP AND INCLUSION OF THE DEVICE IN THE ESSENTIAL COMMODITIES FOR MATERNAL HEALTH AND SUBSEQUENT ADDITION IN THE ESSENTIAL MEDICINES LIST AND NATIONAL HEALTH INSURANCE MEDICINES LIST.PATH DEVELOPED TRAINING MANUALS FOR INFECTION CONTROL AND MANAGEMENT AND SOCIAL BEHAVIOR CHANGE MATERIALS TO SUPPORT IMPLEMENTATION OF THE MATERNAL INFECTIOUS DISEASES CONTROL PROJECT AT ANTENATAL CARE SERVICES IN BONO EAST REGION.WITH FUNDING SUPPORT FROM THE CHILDREN'S INVESTMENT FUND FOUNDATION AND IN COLLABORATION WITH KYBELE INC. AND AFRICA HEALTH SUPPLIES THROUGH IMPLEMENTATION OF THE MEBCI 2.0 PROJECT, PATH EQUIPPED FOUR REGIONAL HOSPITALS' NEONATAL INTENSIVE CARE UNITS WITH NEWBORN EQUIPMENT. WE ALSO SUPPORTED TRAININGS ON THE CORRECT USE AND MAINTENANCE OF EQUIPMENT PER MANUFACTURER STANDARDS FOR MORE THAN 250 CLINICAL ENGINEERS, DOCTORS, AND NURSES WHO OFFER NEONATAL SERVICES FROM ALL FOUR FACILITIES.

	(Code: ) (Expenses $ 45,172,884 including grants of $ 7,927,587 ) (Revenue $ )
	ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN COUNTRIES IN AFRICA (SUCH AS THE DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS. PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2022, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE AND RECOVERY EFFORT FOR THE COVID-19 PANDEMIC.ASIA, MIDDLE EAST, AND EUROPE REGIONPATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR GLOBAL EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM, THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION AND PROGRAM DELIVERY. HIGHLIGHTS INCLUDE:IN 2022, PATH CONTINUED FORGING LOCAL PARTNERSHIPS TO ADVANCE INNOVATIVE, AGILE HEALTH SYSTEMS IN BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT THE PANDEMIC RESPONSE AND TEACHING IN EASTERN EUROPE AND SOUTH ASIA REGIONS. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE MOTHER-TO-CHILD TRANSMISSION OF VIRAL HEPATITIS B AND IMPLEMENT FACTORY-BASED PANDEMIC PREPAREDNESS PROGRAMS IN SOUTHEAST ASIA. THANKS TO OUR CONTINUOUS WORK IN IMPROVING LIVES WITH SCIENCE AND TECHNOLOGY, PATH WAS ABLE TO STRENGTHEN THE DEVELOPMENT OF COVID-19, POLIO, HPV, YELLOW FEVER, AND MEASLES, MUMPS, AND RUBELLA VACCINES IN CHINA; DEVELOP HIGH-IMPACT PUBLIC HEALTH PROGRAMS SUCH AS RICE FORTIFICATION, DIAGNOSTIC & SURVEILLANCE, AND DIGITAL HEALTH IN INDIA; AND SUPPORT MEDICATION-ASSISTED TREATMENT FOR TB, HIV, AND HEPATITIS C PATIENTS IN UKRAINE. THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING PRIMARY HEALTH SYSTEM SERVICES, CAPACITY, AND RESILIENCE USING COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO THE MOST VULNERABLE COMMUNITIES. FOR INSTANCE, IN INDIA, WE LAUNCHED A CLIMATE CHANGE STRATEGY THAT FOCUSES ON GENERATING EVIDENCE, BUILDING PARTNERSHIPS, AND ADVOCATING TO SUPPORT CLIMATE-RESILIENT HEALTH SYSTEMS IN THE COUNTRY.PATH IN THE AMEE REGION INTRODUCED ITS WORK AT THE HIGHEST POLITICAL LEVELS DURING THE COMMONWEALTH HEADS OF GOVERNMENT MEETING IN KIGALI, SUPPORTED INDIA IN ITS G20 HEALTH TRACK MEETINGS, AND BEGAN PREPARING TO PARTICIPATE IN THE 28TH MEETING OF THE CONFERENCE OF PARTIES AT THE UN CLIMATE CHANGE CONFERENCE IN THE UNITED ARAB EMIRATES TO HIGHLIGHT THE NEED FOR URGENT ACTION IN CLIMATE CHANGE AND HEALTH.PATH CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND HIV; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL.

4d	Other program services (Describe in Schedule O.)
	(Expenses $ 45,172,884 including grants of $ 7,927,587 ) (Revenue $ )
4e	Total program service expenses311,350,046

1b	Sub-Total................
c	Total from continuation sheets to Part VII, Section A....
d	Total (add lines 1b and 1c)...........	4,758,666	309,656	766,797

1a	Federated campaigns..		1a
b	Membership dues..		1b
c	Fundraising events..		1c
d	Related organizations		1d	7,258,047
e	Government grants (contributions)		1e	124,001,387

f	All other contributions, gifts, grants, and similar amounts not included above		1f	216,461,147

g	Noncash contributions included in lines 1a - 1f:$		1g	817,716

h Total. Add lines 1a-1f.......		347,720,581

1	Briefly describe the organization’s mission or most significant activities: SEE PART III, LINE 1.
2	Check this box
3	Number of voting members of the governing body (Part VI, line 1a) ........	3	15
4	Number of independent voting members of the governing body (Part VI, line 1b) .....	4	15
5	Total number of individuals employed in calendar year 2021 (Part V, line 2a) ......	5	667
6	Total number of volunteers (estimate if necessary) .............	6	0
7a	Total unrelated business revenue from Part VIII, column (C), line 12 ........	7a	0
b	Net unrelated business taxable income from Form 990-T, Part I, line 11 .........	7b	0

		Business Code
2a
b
c
d
e
f	All other program service revenue.
g	Total. Add lines 2a–2f .....

3 Investment income (including dividends, interest, and othersimilar amounts) ......			4,050,778			4,050,778
4 Income from investment of tax-exempt bond proceeds
5 Royalties...........
		(ii) Personal	(i) Real
6a	Gross rents			6a
b	Less: rental expenses			6b
c	Rental income or (loss)			6c
d	Net rental income or (loss).......
		(ii) Other	(i) Securities
7a	Gross amount from sales of assets other than inventory	57,996	37,269,962	7a
b	Less: cost or other basis and sales expenses	49,745	37,102,013	7b
c	Gain or (loss)	8,251	167,949	7c
d	Net gain or (loss).........			176,200			176,200
8a	Gross income from fundraising events (not including $ of contributions reported on line 1c). See Part IV, line 18 ....
			8a
b	Less: direct expenses ...		8b
c	Net income or (loss) from fundraising events..
9a	Gross income from gaming activities. See Part IV, line 19 ...
			9a
b	Less: direct expenses ...		9b
c	Net income or (loss) from gaming activities..
10a	Gross sales of inventory, less returns and allowances ..
			10a
b	Less: cost of goods sold ..		10b
c	Net income or (loss) from sales of inventory..
Business Code			Miscellaneous Revenue
11a	OTHER		900099	833,517			833,517
b	REIMBURSEMENTS		900099	36,463			36,463
c
d	All other revenue ....
e	Total. Add lines 11a–11d ......			869,980
12	Total revenue. See instructions.....			352,817,539	0	0	5,096,958

1	Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 ....	30,451,668	30,451,668
2	Grants and other assistance to domestic individuals. See Part IV, line 22 ...........
3	Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. .............	60,124,122	60,124,122
4	Benefits paid to or for members .......
5	Compensation of current officers, directors, trustees, and key employees ...........	3,462,838	1,396,390	2,043,594	22,854
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) .........
7	Other salaries and wages........	99,251,909	84,875,846	13,719,320	656,743
8	Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) ....	11,368,301	9,492,195	1,801,126	74,980
9	Other employee benefits .......	16,517,455	14,759,917	1,687,296	70,242
10	Payroll taxes ...........	7,816,612	6,551,104	1,214,931	50,577
11	Fees for services (non-employees):
a	Management ......
b	Legal .........	1,290,110	560,192	728,347	1,571
c	Accounting ...........	771,284	171,127	600,157
d	Lobbying ...........
e	Professional fundraising services. See Part IV, line 17
f	Investment management fees ......	328,905		328,905
g	Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O)	18,835,671	15,126,015	3,634,561	75,095
12	Advertising and promotion ....	74,754	69,009	4,078	1,667
13	Office expenses .......	6,500,259	6,264,483	178,126	57,650
14	Information technology ......	7,354,699	5,692,257	1,619,420	43,022
15	Royalties ..	239,103	239,103
16	Occupancy ...........	11,558,732	-377,084	11,940,032	-4,216
17	Travel ............	14,531,024	13,757,357	771,898	1,769
18	Payments of travel or entertainment expenses for any federal, state, or local public officials .
19	Conferences, conventions, and meetings ....	13,325,667	13,037,359	256,127	32,181
20	Interest ...........	4		4
21	Payments to affiliates .......
22	Depreciation, depletion, and amortization ..	1,934,824		1,934,824
23	Insurance ...	922,241	243,761	678,480
24	Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a	SUBCONTRACTORS	27,441,134	27,434,942	6,192
b	EQUIP RENT & MAINT	5,321,856	5,334,266	-12,410
c	FACILITIES ALLOC	3,632,712	13,928,149	-10,510,003	214,566
d	DIRECT AID TO BENEF.	1,870,822	1,870,822
e	All other expenses	1,706,811	347,046	147,876	1,211,889
25	Total functional expenses. Add lines 1 through 24e	346,633,517	311,350,046	32,772,881	2,510,590
26	Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here if following SOP 98-2 (ASC 958-720).

1	Cash–non-interest-bearing ........			12,911,863	1	12,287,583
2	Savings and temporary cash investments .........			10,006,728	2	39,962,314
3	Pledges and grants receivable, net ......			38,296,068	3	37,140,905
4	Accounts receivable, net .............			555,337	4	303,620
5	Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
					5
6	Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
					6
7	Notes and loans receivable, net ...........				7
8	Inventories for sale or use ............				8
9	Prepaid expenses and deferred charges ......			7,454,031	9	7,299,862
10a	Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D	10a	37,198,207
b	Less: accumulated depreciation	10b	30,625,474	7,119,705	10c	6,572,733
11	Investments—publicly traded securities .			230,729,600	11	198,170,250
12	Investments—other securities. See Part IV, line 11 .....				12
13	Investments—program-related. See Part IV, line 11 ..				13
14	Intangible assets ...............				14
15	Other assets. See Part IV, line 11 ...........			0	15	33,353,888
16	Total assets. Add lines 1 through 15 (must equal line 33)...			307,073,332	16	335,091,155

17	Accounts payable and accrued expenses .....	253,115,813	17	240,270,829
18	Grants payable ...		18
19	Deferred revenue .........		19
20	Tax-exempt bond liabilities .........		20
21	Escrow or custodial account liability. Complete Part IV of Schedule D		21
22	Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
			22
23	Secured mortgages and notes payable to unrelated third parties ..		23
24	Unsecured notes and loans payable to unrelated third parties ..		24
25	Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D	0	25	42,345,583
26	Total liabilities. Add lines 17 through 25..	253,115,813	26	282,616,412

	Organizations that follow FASB ASC 958, check here and complete lines 27, 28, 32, and 33.
27	Net assets without donor restrictions ..........	20,653,709	27	23,389,854
28	Net assets with donor restrictions ...........	33,303,810	28	29,084,889
	Organizations that do not follow FASB ASC 958, check here and complete lines 29 through 33.
29	Capital stock or trust principal, or current funds .....		29
30	Paid-in or capital surplus, or land, building or equipment fund ...		30
31	Retained earnings, endowment, accumulated income, or other funds		31
32	Total net assets or fund balances ...........	53,957,519	32	52,474,743
33	Total liabilities and net assets/fund balances ........	307,073,332	33	335,091,155

1	Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
2	Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
3	Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
4	Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .	Yes	No
5	Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No
6	Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .	Yes	No